¤ł¤ł ¤Ť¤é ˝ü¤¤ ĽŃĽÁĽóĽł


áu’ÉŠÇ—@`ŽĄ—ĂƒKƒCƒhƒ‰ƒCƒ“

ƒKƒCƒhƒ‰ƒCƒ“•ś’†‚Ě•śŒŁ”ԍ†‚Š‚çCŠY“–‚ˇ‚éŽQl•śŒŁˆę——‚đŽQĆ‚ˇ‚é‚ą‚Ć‚Ş‚Ĺ‚Ť‚Ü‚ˇ

–ÚŽŸF


Ž‘ —ż

1DěŹ‰ß’ö

‚PD2010 ”N”Ĺ‚ĚěŹ‰ß’ö

–{ƒKƒCƒhƒ‰ƒCƒ“‚́C“ú–{ŠÉ˜aˆă—ĂŠw‰ď‚́uŠÉ˜aˆă—ĂƒKƒCƒhƒ‰ƒCƒ“ěŹˆĎˆő‰ď@‚Ş‚ńáu’ɃKƒCƒhƒ‰ƒCƒ“ě‹Ć•”‰ďviˆČ‰şCˆĎˆő‰ďj‚ށC2001 ”N‚É”­s‚ł‚ę‚˝uf—ĂƒKƒCƒhƒ‰ƒCƒ“‚̍쐬‚ĚŽč‡vi•ŸˆäŽŸ–îE’OŒăr˜Yj‚ɏ€‚ś‚č쐬‚ľ‚˝BƒGƒrƒfƒ“ƒXƒŒƒxƒ‹‚Ɛ„§‚Ě‹­‚ł‚ÉŠÖ‚ľ‚ẮCŠÉ˜aƒPƒA‚̐ŤŽż‚âƒKƒCƒhƒ‰ƒCƒ“‚ĚŒ¤‹†‚ÉŠÖ‚ˇ‚éŒťó‚đl—ś‚ľC‘Oq‚̂悤‚É’č‚ß‚˝iⅠ-3 „§‚Ě‹­‚ł‚ĆƒGƒrƒfƒ“ƒXƒŒƒxƒ‹‚̍€ŽQĆjB

ěŹŒăCAGREE •]‰ż–@i2001j‚É‚ć‚é•]‰ż‚đs‚Á‚˝B

❶ ŠT@—v

“ú–{ŠÉ˜aˆă—ĂŠw‰ď‚É‚¨‚˘‚ÄˆĎˆő‰ď‚đ‘gD‚ľCƒKƒCƒhƒ‰ƒCƒ“‚̍쐬‚Ě‚˝‚ß‚ĚŽč‡‚đěŹ‚ľ‚˝BŽŸ‚ɁCŠeˆĎˆő‚Š‚ç—Տ°‹^–âˆÄ‚đŽűW‚ľCˆĎˆő‰ď‚É‚¨‚˘‚Ä—Ő°‹^–â‚đěŹ‚ľ‚˝B‘ą‚˘‚āCˆĎˆő‚Ş•Ş’S‚ľ‚āCŒn““I•śŒŁŒŸő‚đs‚˘ŠY“–•śŒŁ‚đŽűW‚ľCŠî€‚đ–ž‚˝‚ˇ˜_•ś‚đ’Šo‚ľC—Տ°‹^–â‚ɑ΂ˇ‚錴ˆÄ‚đěŹ‚ľ‚˝BŒ´ˆÄ‚́Cƒfƒ‹ƒtƒ@ƒC–@‚ɏ]‚Á‚č‡ˆÓ‚Ş“ž‚ç‚ę‚é‚Ü‚ĹCł‚ľ‚˝B‚ł‚ç‚ɁCŠO•”ˆĎˆő‚Ě•]‰ż‚đ“ž‚˝‚ ‚ƂɁCÄ‚Ńƒfƒ‹ƒtƒ@ƒC–@‚đs‚˘ĹI”Ĺ‚đěŹ‚ľ‚˝B

❷ —Տ°‹^–â‚̐ݒč

ŽűW‚ľ‚˝—Տ°‹^–âˆÄ‚đPECO Œ`ŽŽiPFŠłŽŇCEF–\˜ICCF”äŠrCOFŒ‹‰Ęj‚ɒ莎‰ť‚ľ‚˝B’莎‰ť‚ł‚ę‚˝—Տ°‹^–â‚đ‰đŒˆ‚Ĺ‚Ť‚é—Տ°Œ¤‹†‚Ş‘śÝ‚ľ‚Č‚Š‚Á‚˝ę‡‚ɂ́C‚ć‚č•ďŠ‡“I‚Č—Ő°‹^–â‚đěŹ‚ľ‚˝B‡Œv65 ‚Ě—Ő°‹^–â‚đ‚¨‚˘‚˝B

❸ Œn““I•śŒŁŒŸő

—Տ°‹^–₲‚Ć‚És‚Á‚˝B•śŒŁ‚Ěƒ\[ƒX‚́C①PUBMED ‚đ—p‚˘‚˝Œn““I•śŒŁŒŸőiÚ×‚́CⅣ-2 •śŒŁ‚ĚŒŸőŽŽ‚̍€ŽQĆj‚Ć‚ť‚Ěrelated articlesC②2000 ”N1 ŒŽ1 “ú`2008”N7 ŒŽ31 “ú‚Ü‚Ĺ‚ĚJournal of Pain and Symptom Management‚¨‚ć‚ŃPalliative Medicine ‚Ěhand searchC③Cochrane database ‚ĚPaPaS categoryiCochrane PainCPalliative and Supportive Carej‚ĚŠY“–€–ځC④ˆĎˆő‰ď‚ĹŽQlŽ‘—ż‚Ć‚ľ‚Ä‘I‘đ‚ľ‚˝ƒKƒCƒhƒ‰ƒCƒ“‚Ć‹ł‰Č‘‚Ɉř—p‚ł‚ę‚Ä‚˘‚é•śŒŁC‚¨‚ć‚э쐬ˆĎˆő‚Ěƒf[ƒ^ƒx[ƒX‚Ć‚ť‚ę‚ç‚Ěˆř—p•śŒŁ‚Ć‚ľ‚˝B‚ą‚ę‚ç‚Š‚çC’S“–ŽŇ‚Ş“KŠiŠî€i•\1j‚É–ž‚˝‚ˇ‚ŕ‚Ě‚đ‚ˇ‚×‚Ä‘I‘đ‚ľ‚˝Bť–ň‰ďŽĐ‚Č‚Ç‚Š‚ç‚ĚŽ‘‹ŕ’ń‹Ÿ‚đŽó‚Ż‚Ä‚˘‚é•śŒŁ‚Í‚í‚Š‚é‚悤‚É“Ż’č‚ľ‚˝BŒ´‘Ľ‚Ć‚ľ‚āCŠî€‚ÉŠY“–‚ľ‚Č‚˘Œ¤‹†‚ÍŽQl•śŒŁ‚Ć‚ľ‚˝B•śŒŁŒŸő‚Ě‘ÎŰ‚Ć‚ľ‚˝ŠúŠÔ‚ɂ‚˘‚ẮCŠe€–Ú‚˛‚Ƃɐݒ肾‚˝iⅣ-2 •śŒŁ‚ĚŒŸőŽŽŽQĆjB

•\1@•śŒŁ‚Ě“KŠiŠî€
  • Źl‚đ‘ÎŰ‚Ć‚ľ‚Ä‚˘‚é
  • “ú–{Œę‚Ü‚˝‚͉pŒę‚Ĺ‹LÚ‚ł‚ę‚Ä‚˘‚é
  • Žĺ‚Č‘ÎŰŠłŽŇ‚Í‚Ş‚ńŠłŽŇ‚Ĺ‚ ‚遌
  • ‘“ŕ‚Ĺ—˜—p‚Ĺ‚Ť‚é•ű–@E–ň•¨‚Ĺ‚ ‚é
  • Œn““IƒŒƒrƒ…[Aƒƒ^ƒAƒiƒŠƒVƒXA–łěˆ×‰ť”äŠrŽŽŒąA‚Ü‚˝‚Í‘OŒü‚Ť‚ĚŠĎŽ@“IŒ¤‹†E‘OŒă”äŠrŒ¤‹†‚Ĺ‚ ‚é
  • R‚Ş‚ńŽĄ—ÁiŠO‰ČŽĄ—ÁA‰ťŠw—Ă–@A•úŽËüŽĄ—Áj‚ĚŒř‰Ę‚Ć‚ľ‚Ä‚Ě’É‚Ý‚đ‚Ý‚Ä‚˘‚é‚ŕ‚́A‚¨‚ć‚сAˆ’u‚É”ş‚¤’É‚Ý‚đ‚Ý‚Ä‚˘‚é‚ŕ‚Ě‚ÍœŠO‚ˇ‚éB

ŚŠY“–˜_•ś‚Ş‚Ů‚Ć‚ń‚Ç‚Č‚˘_ŒoáŠQŤáu’É‚â‚š‚ń–Ď‚Č‚Ç‚Ě€–ڂɂ‚˘‚Ä‚Í”ń‚Ş‚ńŠłŽŇ‚đ‘ÎŰ‚Ć‚ľ‚˝Œ¤‹†‚ŕŠÜ‚ß‚ÄŒŸ“˘‚ľ‚˝‚ށA‘Ώ۩łŽŇ‚Í‚Ş‚ńŠłŽŇ‚Ĺ‚ ‚é‚ŠA”ń‚Ş‚ńŠłŽŇ‚Ĺ‚ ‚é‚Š‚đ‹ć•Ę‚ľ‚Ä‹Lq‚ľ‚˝B

❹ ƒKƒCƒhƒ‰ƒCƒ“‚Ć‹ł‰Č‘

ŽQlŽ‘—ż‚Ć‚ľ‚āCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Ć‹ł‰Č‘‚ÍˆČ‰ş‚Ě‚ŕ‚Ě‚đ‘I‘đ‚ľ‚˝B

1jƒKƒCƒhƒ‰ƒCƒ“
  • EAPC ƒKƒCƒhƒ‰ƒCƒ“i2001aj
    Hanks GW, de Conno F, Cherny N, et alGExpert Working Group of the Research Network of the European Association for Palliative Care. Morphine and alternative opioids in cancer painFthe EAPC recommendations. Br J Cancer 2001G84F587-93
  • EAPC ƒKƒCƒhƒ‰ƒCƒ“i2001bj
    Cherny N, Ripamonti C, Pereira J, et alGExpert Working Group of the European Association of Palliative Care Network. Strategies to manage the adverse effects of oral morphineFAn evidence-based report. J Clin Oncol 2001G19F 2542-54
  • EAPC ƒKƒCƒhƒ‰ƒCƒ“i2002j
    Mercadante S, Radbruch L, Caraceni A, et alGSteering Committee of the European Association for Palliative CareiEAPCjResearch Network. EpisodicibreakthroughjpainFconsensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002G94F832-9
  • NCCN ƒKƒCƒhƒ‰ƒCƒ“i2008j
    National Comprehensive Cancer NetworkFNCCN Clinical Practice Guidelines in Oncology, Adult cancer pain.
  • ESMO ƒKƒCƒhƒ‰ƒCƒ“i2007j
    ESMO Guidelines Working Group, Jost L. Management of cancer painFESMO clinical recommendations. Ann Oncol 2007G18iSuppl 2jFii92-4
  • ACCP ƒKƒCƒhƒ‰ƒCƒ“i2007j
    Kvale Pa, Selecky PA, Prakash UBGAmerican College of Chest Physicians. Palliative care in lung cancerFACCP evidence-based clinical practice guidelinesi2nd editionj. Chest 2007G132iSuppl 3jFS368-403
2j‹ł‰Č‘
  • Loeser JD. eds; Butler SH, Chapman CR, Turk DC. associate eds. Bonica's Management of Pain, 3rd ed, Lippincott Williams & Wilkins, 2001
  • Berger AM, Shuster JL, Von Roenn JH eds. Principles and Practice of Palliative Care and Supportive Oncology, 3rd ed, Lippincott Williams & Wilkins, a Wolters Kluwer business, 2007
  • Doyle D, Hanks GWC, Cherny NI, Calman K eds. Oxford Textbook of Palliative Medicine, 3rd ed, Oxford University Press, 2005
  • McMahon SB, Koltzenburg M eds. Wall and Melzack's Textbook of Pain, 5th ed, Elsevier Churchill Livingstone, 2006
  • Walsh D. eds. Palliative Medicine, Saunders Elsevier, 2009
  • Bruera E, Higginson IJ, Ripamonti C, von Gunten C eds. Textbook of Palliative Medicine, Hodder Arnold, 2006
❺ ‘Ă“–Ť‚ĚŒŸŘ

i1jƒfƒ‹ƒtƒ@ƒC–@‘O‚ĚŒŸ“˘

”wŒi’mŽŻC„§‘S‘Ě‚É‚í‚˝‚éƒKƒCƒhƒ‰ƒCƒ“‘S‘Ě‚đ130 €–Ú‚É•Ş‚ŻC‚ť‚ę‚ź‚ę‚ɂ‚˘‚āC‚í‚Š‚č‚₡‚łC‘Ă“–Ť‚đ3 Œ–@‚Ĺ•]‰ż‚đ‹‚ß‚˝B€–Ú‚˛‚Ƃɉń“š‚Ě•Ş•z‚đŠeˆĎˆő‚ÉŒöŠJ‚ľC16 ŽžŠÔ‚̉ď‹c‚É‚ć‚Á‚Ä‘Šˆá“_‚đ‹c˜_‚ľ‚˝B

i2j1 ‰ń–Ú‚Ěƒfƒ‹ƒtƒ@ƒC–@

u”wŒivCu„§v‚Ě185 €–Ú‚ť‚ę‚ź‚ę‚ɂ‚˘‚Ä‘Ă“–Ť‚đ1i“KŘ‚Ĺ‚Č‚˘j‚Š‚ç9i“KŘ‚Ĺ‚ ‚éj‚Ě9 Œ–@‚Ĺ•]‰ż‚đ‹‚ß‚˝B‚ť‚ĚŒ‹‰ĘC’†‰›’l8 ˆČă‚̍€–Ú‚Ş162 €–ځiĹŹ‚ĆĹ‘ĺ‚̍ˇ‚Ş6 ˆČăF96 €–ځjC’†‰›’l‚Ş7 ˆČă8 –˘–ž‚̍€–Ú‚Ş14 €–Ú‚Ĺ‚ ‚čC’†‰›’l‚Ş7 –˘–ž‚̍€–Ú‚Ş9 €–Ú‚Ĺ‚ ‚Á‚˝B€–Ú‚˛‚Ć‚É’†‰›’lCĹŹ’lCĹ‘ĺ’l‚đŠeˆĎˆő‚ÉŒöŠJ‚ľC‰ď‹c‚É‚ć‚Á‚Ä‘Šˆá“_‚đ‹c˜_‚ľ‚˝B‹c˜_‚Ě‹cŽ–˜^‚đˆĎˆő‚É”z•z‚ľCŒ´e‚̏Cł‚đs‚Á‚˝B

i3j2 ‰ń–Ú‚Ěƒfƒ‹ƒtƒ@ƒC–@

u”wŒivCu„§v‚Ě184 €–Ú‚ť‚ę‚ź‚ę‚ɂ‚˘‚Ä‘Ă“–Ť‚đ1i“KŘ‚Ĺ‚Č‚˘j‚Š‚ç9i“KŘ‚Ĺ‚ ‚éj‚Ě9 Œ–@‚Ĺ•]‰ż‚đ‹‚ß‚˝B‚ť‚ĚŒ‹‰ĘC’†‰›’l8 ˆČă‚̍€–Ú‚Ş177 €–ځiĹŹ‚ĆĹ‘ĺ‚̍ˇ‚Ş6 ˆČăF43 €–ځjC’†‰›’l‚Ş7 ˆČă8 –˘–ž‚̍€–Ú‚Ş5 €–Ú‚Ĺ‚ ‚čC’†‰›’l‚Ş7 –˘–ž‚̍€–Ú‚Ş2 €–Ú‚Ĺ‚ ‚Á‚˝B1 ‰ń–Ú‚Ěƒfƒ‹ƒtƒ@ƒC–@‚É”äŠr‚ľ‚ăRƒ“ƒZƒ“ƒTƒX‚Ş“ž‚ç‚ę‚Ä‚˘‚é‚ƍl‚Ś‚ç‚ęC‘S‘Ě‚Ć‚ľ‚Ä‘ĺ‚Ť‚ČˆÓŒŠ‚Ě‘Šˆá‚đ”F‚ß‚Č‚˘‚ƍl‚Ś‚ç‚ę‚˝B€–Ú‚˛‚Ć‚É’†‰›’lCĹŹ’lCĹ‘ĺ’l‚đŠeˆĎˆő‚ÉŒöŠJ‚ľC‰ď‹c‚É‚ć‚Á‚Ä‘Šˆá“_‚đ‹c˜_‚ľ‚˝B‘Šˆá“_‚̏Cł‚đŠÜ‚߂āC‘S‘Ě‚Ě“ˆę‚đ‚Ć‚é‚˝‚߂ɁC3 –ź‚Š‚ç‚Č‚éƒ^ƒXƒNƒtƒH[ƒXiŽR–{@—şCVé‘ń–çCX“c’B–çj‚É‚ć‚ču„§v‚đ“ŕ—e‚đ•ĎX‚ľ‚Č‚˘Œ`‚ĹˆęŠŃ‚ľ‚ĉÁ•MCł‚ľ‚˝BCł‚ľ‚˝Œ´e‚đˆĎˆő‰ď‚ĚŽb’če‚Ć‚ľ‚˝B

i4j3 ‰ń–Ú‚Ěƒfƒ‹ƒtƒ@ƒC–@‚Ć•]‰żˆĎˆő‚É‚ć‚é•]‰ż

ˆĎˆő‰ď‚ĚŽb’če‚ɑ΂ľ‚āC•]‰żˆĎˆői–{ƒKƒCƒhƒ‰ƒCƒ“‚̍쐬‚ÉŠÖ—^‚ľ‚Ä‚˘‚Č‚Š‚Á‚˝ˆăŽt‚ĆŠĹŒěŽtj12 –ź‚É•]‰ż‚đ‹‚ß‚˝B‚ ‚í‚š‚āCÄ‚сCu”wŒivCu„§v‚Ě180 €–Ú‚ť‚ę‚ź‚ę‚ɂ‚˘‚Ä‘Ă“–Ť‚đ1i“KŘ‚Ĺ‚Č‚˘j‚Š‚ç9i“KŘ‚Ĺ‚ ‚éj‚Ě9 Œ–@‚Ĺ•]‰ż‚đ‹‚ß‚˝B‚ť‚ĚŒ‹‰ĘC’†‰›’l8 ˆČă‚̍€–Ú‚Ş178 €–ځi‚ť‚Ě‚¤‚żĹŹ‚ĆĹ‘ĺ‚̍ˇ‚Ş6F14 €–ځG7F1 €–ځjC’†‰›’l‚Ş7 ˆČă8 –˘–ž‚̍€–Ú‚Ş2 €–Ú‚Ĺ‚ ‚Á‚˝B’†‰›’l‚Ş8 –˘–ž‚Ě2 ‚Â‚Ě€–ڂɂ‚˘‚Ä‚Í–{•ś‚Š‚çíœ‚ľ‚˝BˆČă‚ĚŒ‹‰ĘC‘ĺ‚Ť‚ČˆÓŒŠ‚Ě‘Šˆá‚đ”F‚ß‚¸Cˆę’v‚Ş‚Ý‚ç‚ę‚˝‚ƍl‚Ś‚ç‚ę‚˝B

i5jˆĎˆő‰ď‚É‚ć‚éCł

•]‰żˆĎˆő‚Ě•]‰ż‚Ćƒfƒ‹ƒtƒ@ƒC–@‚ĚŒ‹‰Ę‚đ‚ŕ‚ƂɁCěŹˆĎˆő‚É‚ć‚é2 “úŠÔ‚̉ď‹c‚đs‚˘CCł‚đ‰Á‚Ś‚˝‚ŕ‚Ě‚đˆĎˆő‰ď‚ŏł”F‚ľ‚˝BĹIŒ´e‚đCěŹˆĎˆő6 –źiŽu^‘וvCVé‘ń–çC×–î”ü‹IC“IęŒłOCX“c’B–çCŽR–{@—şj‚ŏŹCł‚đ‰Á‚ŚC“IęŒłO‚ޏW–ń‚ľ‚˝B

i6j”wŒi‚ĚŠÖ˜AŠw‰ď‚Ě‹LÚ

”wŒi’mŽŻ‚Ě‚¤‚żC–ň•¨—Ă–@ˆČŠO‚Ě’É‚ÝŽĄ—Ă–@‚ÉŠÖ‚ľ‚ẮCu•úŽËüŽĄ—ÁvCuŒo”ç“I’Ĺ‘ĚŒ`ŹpiœƒZƒƒ“ƒgjv‚đC‚ť‚ę‚ź‚ęC“ú–{•úŽËüŽîᇊw‰ďC“ú–{ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒiƒ‹ƒ‰ƒWƒIƒƒW[Šw‰ď‚Ɉ˗Š‚ľ‚˝B

i7j AGREE ƒKƒCƒhƒ‰ƒCƒ“‚É‚ć‚é•]‰ż

ĹIŒ´e‚ɂ‚˘‚āCŹŽR@OCŽl•ű@“N‚É‚ć‚čCAGREE ƒKƒCƒhƒ‰ƒCƒ“i2001j‚É‚ć‚é•]‰ż‚đs‚Á‚˝kAGREE ‹¤“ŻŒv‰ćƒKƒCƒhƒ‰ƒCƒ“‚ĚŒ¤‹†E•]‰ż—pƒ`ƒFƒbƒNƒŠƒXƒgAppraisal of Guidelines for Research & EvaluationiAGREEjinstrumentC2001 ”N9 ŒŽClBAGREE ‚ÉŠî‚Ă‚ŤƒKƒCƒhƒ‰ƒCƒ“‚đ•]‰ż‚ľ‚˝‚Ć‚ą‚ëCěŹ‰ß’ö‚ÍŒľ–§‚Ĺ‚ ‚é‚ƍl‚Ś‚ç‚ęC•ŇW‚Ě“Ć—§Ť‚ŕ\•Ş‚Ĺ‚ ‚é‚ƍl‚Ś‚ç‚ę‚˝Bˆę•űC“K—p‰Â”\Ťiapplicabilityj‚ɂ‚˘‚Ä‚Ě‹LÚ‚Í•s\•Ş‚Ĺ‚ ‚čC“Á‚ÉŽŸ‰ń‰ü’ůŽž‚ɂ́CƒKƒCƒhƒ‰ƒCƒ“…Žç‚đƒ‚ƒjƒ^ƒŠƒ“ƒO‚ˇ‚é•ű–@‚ÉŠÖ‚ˇ‚é’ńˆÄ‚Ş‚Č‚ł‚ę‚é‚ą‚Ć‚Ş–]‚Ü‚ę‚é‚Ć•]‰ż‚ł‚ę‚˝B

❻ ŠÉ˜aˆă—ĂŠw‰ď‚̏ł”F

“ú–{ŠÉ˜aˆă—ĂŠw‰ď‚É‚¨‚˘‚ďł”F‚ľ‚˝B

❼ ƒKƒCƒhƒ‰ƒCƒ“ěŹŽŇ
mŠÉ˜aˆă—ĂƒKƒCƒhƒ‰ƒCƒ“ěŹˆĎˆő‰ďn

yˆĎˆő’ˇz

Žu^ ‘וv

’}”gƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[•a‰@ŠÉ˜aˆă—ÉČ

y’S“–ˆĎˆőz

ŒË’Ji×–îj”ü‹I

‘—§‚Ş‚ńŒ¤‹†ƒZƒ“ƒ^[’†‰›•a‰@ŠĹŒě•”

“Ię ŒłO

‘—§‚Ş‚ńŒ¤‹†ƒZƒ“ƒ^[’†‰›•a‰@ŠÉ˜aˆă—ÉȁE¸_ŽîᇉČ

X“c ’B–ç

š—ęŽO•űŒ´•a‰@ŠÉ˜aŽxŽŽĄ—ÉČ
m‚Ş‚ńáu’ɃKƒCƒhƒ‰ƒCƒ“ě‹Ć•”‰ďn

y•”‰ď’ˇz

Žu^ ‘וv

’}”gƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[•a‰@ŠÉ˜aˆă—ÉČ

y•›•”‰ď’ˇz

ŒË’Ji×–îj”ü‹I

‘—§‚Ş‚ńŒ¤‹†ƒZƒ“ƒ^[’†‰›•a‰@ŠĹŒě•”

“Ię ŒłO

‘—§‚Ş‚ńŒ¤‹†ƒZƒ“ƒ^[’†‰›•a‰@ŠÉ˜aˆă—ÉȁE¸_ŽîᇉČ

X“c ’B–ç

š—ęŽO•űŒ´•a‰@ŠÉ˜aŽxŽŽĄ—ÉČ

yˆĎ ˆőz

Ô–Ř  “O

‘—§‚Ş‚ńŒ¤‹†ƒZƒ“ƒ^[’†‰›•a‰@–ňÜ•”

rˆä •Ű–ž

‘—§‚Ş‚ńŒ¤‹†ƒZƒ“ƒ^[’†‰›•a‰@•úŽËüf’f‰ČC
“ú–{ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒiƒ‹ƒ‰ƒWƒIƒƒW[Šw‰ďkŠO•”ˆĎˆől

V”Ś ’qŽq

Œcœä‹`m‘ĺŠwŠĹŒěˆă—ĂŠw•”

—L‰ę ‰xŽq

’é‹ž‘ĺŠwˆăŠw•”“ŕ‰ČŠwuŔŠÉ˜aˆă—ÉȁC
’é‹ž‚Ş‚ńƒZƒ“ƒ^[/ˆă—Ïî•ńƒVƒXƒeƒ€Œ¤‹†ƒZƒ“ƒ^[

’r‰i š”V

—„ěƒLƒŠƒXƒg‹ł•a‰@ƒzƒXƒsƒX

ˆä‘ň ’mŽq

‹ž“s‘ĺŠwˆăŠw•”•‘Ž•a‰@ŠĹŒě•”

ˆÉ¨ —Y–ç

“ú–{ˆă‰Č‘ĺŠw•t‘Ž•a‰@–ňÜ•”

ˆäŠÖ ‰ëŽq

‡“V“°‘ĺŠwˆăŠw•”–ƒŒ‰ČEƒyƒCƒ“ƒNƒŠƒjƒbƒN

ˆÉ“Œ r‰ë

“Œ‹ž—Žqˆă‰Č‘ĺŠw•a‰@–ňÜ•”

ŽËę “TŽq

NPO –@lŒ’N‚Ć•a‚˘‚ĚŒę‚čƒfƒBƒyƒbƒNƒXEƒWƒƒƒpƒ“

Ąˆä Œ˜Œá

—„ěƒLƒŠƒXƒg‹ł•a‰@ƒzƒXƒsƒX

ă‰€ •Űm

‘—§‚Ş‚ńŒ¤‹†ƒZƒ“ƒ^[Œ¤‹†Š‚Ş‚ńŠłŽŇ•a‘Ԑś—Œ¤‹†•”

ă“c ŒhŽq

Œb—C‰ďŽD–y•a‰@ŠÉ˜aƒPƒA‰Č

”~“c  Œb

Š”ŽŽ‰ďŽĐŠÉ˜aƒPƒAƒp[ƒgƒi[ƒY

‘ĺâ  ŠŢ

Ă‰ŞŒ§—§Ă‰Ş‚Ş‚ńƒZƒ“ƒ^[ŠÉ˜aˆă—ÉČ

‘ĺŕV ‹§O

Ż–ň‰Č‘ĺŠw–ň•¨ŽĄ—ĂŠw‹łŽş

‘唨 ”ü—˘

š˜H‰Á‘Ű•a‰@ŠĹŒě•”

ŹŠ}Œ´—˜Ž}

‰Ą•lŽs—§‚Ý‚Č‚ĆÔ\Žš•a‰@ŠĹŒě•”

‰Ş–{ ’őW

‘ĺă‘ĺŠw‘ĺŠw‰@–ňŠwŒ¤‹†‰ČŽŔ‘H–ňŠw‹łˆçŒ¤‹†ƒZƒ“ƒ^[•a‰@–ňŠw‹łˆçŒ¤‹†•”

‰œ’Ă ‹P’j

Ă‰ŞŒ§—§Ă‰Ş‚Ş‚ńƒZƒ“ƒ^[ŠÉ˜aˆă—ÉČ

‰œo—LŽq

‡“V“°‘ĺŠwˆăŠw•”•‘Ž‡“V“°ˆă‰@ŠĹŒě•”

‰Á‰ę’J ”Ł

Ďś‰ď‰Ą•lŽs“ě•”•a‰@–ňÜ•”

•—ŠÔ ˆčŽq

‘Űˆă—Ă•ŸŽƒ‘ĺŠwŽO“c•a‰@ŠĹŒě•”

•ĐŽR Žu˜Y

“ú–{ˆă‰Č‘ĺŠw•t‘Ž•a‰@–ňÜ•”

‰Á“Ą  Œb

•‘ –ěÔ\Žš•a‰@ŠĹŒě•”

ě’n“ŢŽq

ŠŕŒ¤‹†‰ď—L–ž•a‰@ŠĹŒě•”

ě‘şŽOŠóŽq

–kŠC“šˆă—Ă‘ĺŠwŠĹŒě•ŸŽƒŠw•”

–؉ş Š°–ç

‘—§‚Ş‚ńŒ¤‹†ƒZƒ“ƒ^[“Œ•a‰@ŠÉ˜aˆă—ÉȁE¸_ŽîᇉČ

Š‹ŠŞ ’źŽq

Ż–ň‰Č‘ĺŠw–ň•i“ŐŤŠw‹łŽş

H“Ą ŽŽq

‘—§‚Ş‚ńŒ¤‹†ƒZƒ“ƒ^[Œ¤‹†Š

‘•Ş G–ç

–k—˘‘ĺŠw•a‰@–ňÜ•”

Ź“‡ Œ\Žq

“Œ‹žŽœŒb‰ďˆă‰Č‘ĺŠw•‘Ž•a‰@–ƒŒ‰Č

ŹŒ´ O”V

Œ§—§L“‡•a‰@ŠÉ˜aƒPƒA‰Č

Ź‹{ KŽq

‰Ą•lŽs—§‘ĺŠw•‘Ž•a‰@–ňÜ•”

ŹŽR  O

‘—§•a‰@‹@\‹ž“sˆă—ĂƒZƒ“ƒ^[‹łˆçŒ¤C•”’ˇkŠO•”ˆĎˆől

ŹŽR•x”üŽq

‹ß‹E‘ĺŠwˆăŠw•”•‘Ž•a‰@‚Ş‚ńƒZƒ“ƒ^[ŠĹŒě•”

‹Ť  “O–ç

’ˇč‘ĺŠwˆăŠw•”–ƒŒŠw‹łŽş

âŒł “ÖŽq

ˆÇ—Ń‘ĺŠwˆăŠw•”•t‘Ž•a‰@ŠĹŒě•”

â–{ ‰ëŽ÷

–źŒĂ‰ŽŽs—§‘ĺŠw•a‰@ŠÉ˜aƒPƒA•”

˛X–Ř‘”ü

‚Ý‚Ç‚č“ŕ‰ČƒNƒŠƒjƒbƒN

˛–ě Œł•F

é‹Ęˆă‰Č‘ĺŠw‘‡ˆă—ĂƒZƒ“ƒ^[–ňÜ•”

‰–ě  –ž

š˜H‰Á‘Ű•a‰@–ňÜ•”

Žl•ű  “N

‘hś‰ď‘‡•a‰@ŠO‰ČkŠO•”ˆĎˆől

ŽłŒË ‰pŽ÷

ŽłŒË“ŕ‰Čˆă‰@

ŽÂ  “šO

Ă‰ŞŒ§—§Ă‰Ş‚Ş‚ńƒZƒ“ƒ^[–ňÜ•”

ŽÂŒ´ –žŽq

’é‹ž‘ĺŠwˆăŠw•”•‘Ž•a‰@ŠÉ˜aˆă—ÉČ

´…‚í‚ŠŽq

ŒN’Ă’†‰›•a‰@•úŽËüŽĄ—ÉȁC“ú–{•úŽËüŽîᇊw‰ď

”’•E  –L

”’•E“ŕ‰Čˆă‰@

VŠL•v–íŽq

ˆ¤’mŒ§‚Ş‚ńƒZƒ“ƒ^[’†‰›•a‰@ŠĹŒě•”

Vé ‘ń–ç

ŽĐ‰ď•ŰŒŻ_ŒË’†‰›•a‰@ŠÉ˜aƒPƒA•a“

{‰ę ş•F

Ă‰ŞĎś‰ď‘‡•a‰@ŠÉ˜aˆă—ÉČ

—é–Ř  •×

Ż–ň‰Č‘ĺŠw–ň•i“ŐŤŠw‹łŽş

‚Ł ‹vŒő

•Ÿ‰Ş‘ĺŠw•a‰@–ňÜ•”

‚“c T–ç

‘—§•a‰@‹@\–kŠC“š‚Ş‚ńƒZƒ“ƒ^[–ňÜ‰Č

‚“c łŽj

’ˇč‘ĺŠw•a‰@–ƒŒ‰Č

‘ëěç’ߎq

KKR ŽD–yˆă—ĂƒZƒ“ƒ^[ŠÉ˜aƒPƒA‰Č

“cŒű ‰ęŽq

‘ĺă•{—§Źl•aƒZƒ“ƒ^[ŠĹŒě•”

“c’† ŒjŽq

‚Ş‚ńEŠ´őÇƒZƒ“ƒ^[“s—§‹îž•a‰@ŠÉ˜aƒPƒA‰Č

’ˇ  ”ü—é

š˜H‰Á‘Ű•a‰@ŠÉ˜aƒPƒA‰Č

“Ö‰ę Œ’‹g

–kŠC“š‘ĺŠwˆăŠwŒ¤‹†‰Č–ƒŒEŽüpŠúˆăŠw•Ş–ě

•yˆŔ Žu˜Y

’ˇčŽs—§Žs–Ż•a‰@–ƒŒ‰ČEŠÉ˜aƒPƒAƒ`[ƒ€

’†ě ‹M”V

‹ž“s‘ĺŠw–ňŠwŒ¤‹†‰Čś‘Ě‹@”\‰đÍŠw•Ş–ě

’†ź ^—

Ý‘îŠĹŒěŒ¤‹†ƒZƒ“ƒ^[LLP “ú–{Ý‘îŠĹŒěƒVƒXƒeƒ€

Ź“c  ”N

Ż–ň‰Č‘ĺŠw–ň•i“ŐŤŠw‹łŽş

ź‰Ş Oť

–źŒĂ‰Ž‹L”O•a‰@‘‡“ŕ‰Č

”\¨ ˝ˆę

’ˇč‘ĺŠw•a‰@–ňÜ•”

•l–ě  ~

‘ĺ˜aƒNƒŠƒjƒbƒN

—Ń  Í•q

š˜H‰Á‘Ű•a‰@ŠÉ˜aƒPƒA‰Č

—Ń ‚ď‚čŽq

“Ą‘ňĂ“ě‘ä•a‰@ŠĹŒě•”

‹v‰i ‹M”V

’}”gƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[•a‰@ŠÉ˜aˆă—ÉČ

‹vŒ´  K

ŽčˆîŒkm‰ď•a‰@‚Ş‚ńŽĄ—ĂŠÇ—ƒZƒ“ƒ^[ŠÉ˜aƒPƒAŽşEŠÉ˜aƒPƒA ƒ`[ƒ€

”ö“Ą ˝Ži

NHO “Œ‹žˆă—ĂƒZƒ“ƒ^[‹łˆçŒ¤C•”/—Տ°‰uŠwŒ¤‹†Žş

œA‰Ş ‰Ŕ‘ă

š˜H‰ÁŠĹŒě‘ĺŠwŠĹŒěŽŔ‘HŠJ”­Œ¤‹†ƒZƒ“ƒ^[

•{ě”üšŽq

–k—˘‘ĺŠw•a‰@–ňÜ•”

–kžŠ”ü”\—Ż

’ˇč‘ĺŠw•a‰@–ƒŒ‰ČEŠÉ˜aƒPƒAƒ`[ƒ€

×ě –LŽj

‹ž“s•{—§ˆă‰Č‘ĺŠw–ƒŒ‰Č

×’J  ŽĄ

éź‘ĺŠw–ňŠw•”–ňÜŠwuŔ

–{“c ťŽq

š˜H‰ÁŠĹŒě‘ĺŠwŠĹŒěŽŔ‘HŠJ”­Œ¤‹†ƒZƒ“ƒ^[

‘O–x ’ź”ü

Š”ŽŽ‰ďŽĐƒŒ[ƒxƒ“ƒvƒ‰ƒ“@ƒŒƒ‚ƒ“–ň‹ÇŽO•űŒ´“X

źâ  r

ŽčˆîŒkm‰ď•a‰@‘‡“ŕ‰Č/Š´őÇ‰ČEŠÉ˜aƒPƒAƒ`[ƒ€

ź“c —zˆę

‘ĺă‘ĺŠw‘ĺŠw‰@ˆăŠwŒnŒ¤‹†‰Č–ƒŒEW’†ŽĄ—ĂˆăŠwuŔ

ź–{ ’źŽq

š˜H‰ÁŠĹŒě‘ĺŠw}‘ŠŮ

ź–{ ’ő‹v

‘—§‚Ş‚ńŒ¤‹†ƒZƒ“ƒ^[“Œ•a‰@ŠÉ˜aˆă—ÉȁE¸_ŽîᇉČ

ŽO‰Y —˘D

Œcœä‹`m‘ĺŠw•a‰@ŠĹŒě•”

‘şă •qŽj

‘—§‚Ş‚ńŒ¤‹†ƒZƒ“ƒ^[’†‰›•a‰@ŠÉ˜aˆă—ÉȁE¸_ŽîᇉČ

‘ş“c Š°–ž

’ˇč‘ĺŠwˆăŠw•”–ƒŒŠw‹łŽş

X˜e r˜a

’}”g‘ĺŠw‘ĺŠw‰@Á‰ťŠí“ŕ‰ČkŠO•”ˆĎˆől

”ŞŒË ‚ˇ‚¸

‡“V“°‘ĺŠw‚Ş‚ńŽĄ—ĂƒZƒ“ƒ^[ŠÉ˜aƒPƒAƒ`[ƒ€

ŽRŒű Œh‰î

‡“V“°‘ĺŠwˆăŠw•”–ƒŒ‰ČƒyƒCƒ“ƒNƒŠƒjƒbƒNuŔ

ŽRŒű  ’

’}”gƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[•a‰@ŠÉ˜aˆă—ÉČ

ŽR–{  —ş

˛‹v‘‡•a‰@‘‡f—ÉȁEŠÉ˜aƒPƒAƒ`[ƒ€

‰ˇňě^—R

‘—§‚Ş‚ńŒ¤‹†ƒZƒ“ƒ^[Œ¤‹†ŠŽîᇃQƒmƒ€‰đÍEî•ńŒ¤‹†•”

—]‹{‚Ť‚Ě‚Ý

é‹ĘŒ§—§‚Ş‚ńƒZƒ“ƒ^[ŠÉ˜aƒPƒA‰Č

—´  Œb”ü

’ˇč‘ĺŠw•a‰@–ňÜ•”EŠÉ˜aƒPƒAƒ`[ƒ€

“nç˛ hÍ

Ă‰ŞŒ§—§Ă‰Ş‚Ş‚ńƒZƒ“ƒ^[ŠÉ˜aˆă—ÉČ

“nçł áÁ—

_“ŢěŒ§—§‚Ş‚ńƒZƒ“ƒ^[’nˆćˆă—Ă˜AŒgŽş

y•]‰żˆĎˆőz

”Ń–ě ‹žŽq

‘—§ŠĹŒě‘ĺŠwZŹlŠĹŒěŠw

‰Á“Ą —T‹v

ş˜a‘ĺŠw–ňŠw•”ˆă–ň•iî•ńŠw‹łŽşkŠO•”ˆĎˆől

ě‰z ł•˝

‚ ‚¨‚ź‚çf—ÏŠ

–ŘŕV ‹`”V

’}”g‘ĺŠw‘ĺŠw‰@lŠÔ‘‡‰ČŠwŒ¤‹†‰Č

‰şŽR ’źl

‘—§‚Ş‚ńŒ¤‹†ƒZƒ“ƒ^[“Œ•a‰@ŠÉ˜aˆă—ÉȁE¸_ŽîᇉČ

’ƒ’J łŽj

‘ĺă˜JĐ•a‰@•úŽËü‰ČkŠO•”ˆĎˆől

P“Ą  ‹Ĺ

‘ĺă‘ĺŠw‘ĺŠw‰@ˆăŠwŒnŒ¤‹†‰ČŠÉ˜aˆă—ĂŠw

’†“‡ N—Y

šƒ}ƒŠƒAƒ“ƒiˆă‰Č‘ĺŠw•úŽËüˆăŠw‹łŽşkŠO•”ˆĎˆől

’†ŽR Œ’•v

‹ž“s‘ĺŠwŒ’Nî•ńŠwkŠO•”ˆĎˆől

“Ţ—Ç—Ń ŽŠ

é‹Ęˆă‰Č‘ĺŠw‘Űˆă—ĂƒZƒ“ƒ^[•ďŠ‡“I‚Ş‚ńƒZƒ“ƒ^[ŠÉ˜aˆă—ÉČ

ŒüŽR —Yl

ŠŕŒ¤—L–ž•a‰@ŠÉ˜aƒPƒA‰Č

‘şě ˜ad

•şŒÉˆă‰Č‘ĺŠwáu’ɐ§Œä‰ČŠwEƒyƒCƒ“ƒNƒŠƒjƒbƒN•”

iŒÜ\‰š‡j


‚QD2014 ”N”Ĺ‚ĚěŹ‰ß’ö

–{ƒKƒCƒhƒ‰ƒCƒ“‚́C“ú–{ŠÉ˜aˆă—ĂŠw‰ď‚́uŠÉ˜aˆă—ĂƒKƒCƒhƒ‰ƒCƒ“ˆĎˆő‰ď@‚Ş‚ńáu’É–ň•¨—Ă–@ƒKƒCƒhƒ‰ƒCƒ“‰ü’ůWPGviˆČ‰şCˆĎˆő‰ďj‚ށC2010 ”N”łɐV‹K–ňÜ‚̒ljÁ‚âV‚ľ‚˘’mŒŠ‚Ě”˝‰f‚đs‚Á‚ďCł‚ľ‚˝B

„§‚Ě•ĎX‚Í‚Č‚Š‚Á‚˝‚˝‚߁CV‚˝‚Ƀfƒ‹ƒtƒ@ƒC–@‚âŠO•”•]‰ż‚͍s‚í‚Č‚Š‚Á‚˝B

❶ ŠT@—v

“ú–{ŠÉ˜aˆă—ĂŠw‰ď‚É‚¨‚˘‚ÄˆĎˆő‰ď‚đ‘gD‚ľCƒKƒCƒhƒ‰ƒCƒ“‚̍쐬‚Ě‚˝‚ß‚ĚŽč‡‚đěŹ‚ľ‚˝BŽŸ‚ɁCŠeˆĎˆő‚Š‚çV‹K‚ɒljÁ‚ˇ‚ׂŤ–ňÜC€–ځCCł‚ˇ‚ׂŤ–â‘č“_‚đŽűW‚ľC‰ü’ů‚ˇ‚ׂŤ“_‚đW–ń‚ľ‚˝B‘ą‚˘‚āCŽˇ•MŽŇ‚Ş•Ş’S‚ľ‚āCŒn““I•śŒŁŒŸő‚ĆŠY“–•śŒŁ‚ĚŽűW‚đs‚˘CŠî€‚đ–ž‚˝‚ˇ˜_•ś‚đ’Šo‚ľC—Տ°‹^–â‚ɑ΂ˇ‚é’Ç‹LCCł‚đs‚˘Œ´ˆÄ‚đěŹ‚ľ‚˝BŒ´ˆÄ‚́CƒXƒeƒAƒŠƒ“ƒOˆĎˆő‚ŏCłCŽˇ•MŽŇ‚É‚ć‚éCł‚đŒJ‚č•Ô‚ľ‚čŏI”Ĺ‚đěŹ‚ľ‚˝B

❷ —Տ°‹^–â‚̐ݒč

2010 ”N”Ĺ‚Ě—Ő°‹^–â‚đ—p‚˘‚˝B

❸ Œn““I•śŒŁŒŸő

•śŒŁŒŸő‚́C2010 ”N‚Ě•ű–@‚đ“ĽP‚ľCŒŸőŠúŠÔ‚Í2000 ”N1 ŒŽ1 “ú`2012 ”N12 ŒŽ31 “ú‚Ć‚ľ‚˝B2010 ”N”Ĺ‚ÉŒfÚ‚ľ‚˝ŒŸőŽŽ‚đŽg—p‚ľC2008 ”N‚Š‚çŠúŠÔ‚đ‰„’ˇ‚ľ‚ÄŒŸő‚Ć•śŒŁŽűW‚đs‚Á‚˝B‚˝‚ž‚ľCV‹K‚ɒljÁ‚ľ‚˝–ňÜ‚ŞŠÜ‚Ü‚ę‚é—Տ°‹^–â‚ɂ‚˘‚ẮC2010 ”N”Ĺ‚ĚŒŸőŽŽ‚ɐV‹K‚Ě–ňÜ–ź‚đ’ljÁ‚ľC2000 ”N‚Š‚ç2012 ”N‚Ü‚ĹŠúŠÔ‚đŠg‘ĺ‚ľ‚ÄŒŸő‚đs‚Á‚˝B•śŒŁ‚Ěƒ\[ƒX‚¨‚ć‚Ń“KŠiŠî€‚Ȃǂ́C2010 ”N”Ĺ‚Ě•ű–@‚đŽg—p‚ľ‚˝B•śŒŁŒŸő‚Ě‘ÎŰ‚Ć‚ľ‚˝ŠúŠÔ‚ɂ‚˘‚ẮC€–Ú‚˛‚Ƃɐݒ肾‚˝iⅣ-2 •śŒŁ‚ĚŒŸőŽŽŽQĆjB

❹ ƒKƒCƒhƒ‰ƒCƒ“

ŽQlŽ‘—ż‚Ć‚ľ‚āC2010 ”N”Ĺ‚ĹŽg—p‚ľ‚˝ƒKƒCƒhƒ‰ƒCƒ“‚ɉÁ‚Ś‚āCˆČ‰ş‚Ě‚ŕ‚Ě‚đŽg—p‚ľ‚˝B

  • EAPC ƒKƒCƒhƒ‰ƒCƒ“i2012j
    Caraceni A, Hanks G, Kaasa S, et alGEuropean Palliative Care Research CollaborativeiEPCRCjGEuropean Association for Palliative CareiEAPCj. Use of opioid analgesics in the treatment of cancer painFevidence-based recommendations from the EAPC. Lancet Oncol 2012G13Fe58-68
  • ESMO ƒKƒCƒhƒ‰ƒCƒ“i2012j
    Ripamonti CI, Santini D, Maranzano E, et alGESMO Guidelines Working Group. Management of cancer painFESMO Clinical Practice Guidelines. Ann Oncol 2012G23iSuppl 7jFvii139-54
  • “ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ďƒKƒCƒhƒ‰ƒCƒ“i2011j
    _ŒoáŠQŤáu’É–ň•¨—Ă–@ƒKƒCƒhƒ‰ƒCƒ“i“ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ď_ŒoáŠQŤáu’É–ň•¨—Ă–@ƒKƒCƒhƒ‰ƒCƒ“ěŹƒ[ƒLƒ“ƒOƒOƒ‹[ƒv@•ŇjC“Œ‹žC^‹ťŒđˆŐˆă‘o”Ĺ•”C2011
❺ ‘Ă“–Ť‚ĚŒŸŘ

i1jˆĎˆő‰ď‚É‚ć‚éCł

–{ƒKƒCƒhƒ‰ƒCƒ“‚́C2010 ”N”ł̉ü’ů”Ĺ‚Ĺ‚ ‚é‚ą‚Ć‚đ‚Ó‚Ü‚ŚCƒXƒeƒAƒŠƒ“ƒOˆĎˆői13 –źj‚ރfƒ‹ƒtƒ@ƒCˆĎˆő‚đŒ“‚Ë‚é‚ą‚Ć‚Ć‚ľC„§‚Ě•ĎX‚ސś‚ś‚˝ę‡‚É‚Ě‚Ýƒfƒ‹ƒtƒ@ƒC‚đs‚¤‚ą‚Ć‚đ—\’č‚ľ‚˝B

ŠeŽˇ•MŽŇ‚É‚ć‚é‘ć1 e‚đƒXƒeƒAƒŠƒ“ƒOˆĎˆő‰ď‚Ĺ•]‰żCCł‚ľC‚ť‚ĚŒ‹‰Ę‚𔽉f‚ł‚š‚˝‘ć2 e‚đ‚ł‚ç‚ɃXƒeƒAƒŠƒ“ƒOˆĎˆő‰ď‚Ĺ‚Ě•]‰ż‚ƏCł‚đs‚˘CĹIŒ´e‚đˆĎˆő’ˇi—]‹{‚Ť‚̂݁j‚Ş“K‹X•›ˆĎˆő’ˇiX“c’B–çj‚Ć‚ĚŒŸ“˘‚Ě‚¤‚ŚW–ń‚ľ‚˝B‚ť‚ĚŒăC“–Šw‰ď—Ž–‰ď‚̏ł”F‚đŒo‚ÄŠŽŹ‚ľ‚˝B

’Á’ɕ⏕–ň‚̍€–Ú‚É‚¨‚˘‚āC„§ƒŒƒxƒ‹‚¨‚ć‚ŃƒGƒrƒfƒ“ƒXƒŒƒxƒ‹‚ɂ‚˘‚čČŸ“˘‚ľ‚˝‚ށC„§‚đ•ĎX‚ˇ‚é‚Ü‚Ĺ‚É‚ÍŽŠ‚ç‚Č‚˘‚Ć”ť’f‚ľ‚˝BŒ‹‰Ę“I‚ɁC„§‚Í‚ˇ‚ׂÄ2010 ”N”Ĺ‚Ć•Ď‚í‚ç‚Č‚˘‚˝‚߁Cƒfƒ‹ƒtƒ@ƒCC‚¨‚ć‚ŃŠO•”ˆĎˆő‚ĆAGREE ƒKƒCƒhƒ‰ƒCƒ“‚É‚ć‚é•]‰ż‚ÍŽó‚Ż‚Č‚˘‚ą‚Ć‚Ć‚ľ‚˝B

i2j”wŒi’mŽŻ‚Ĺ‚ĚŠÖ˜AŠw‰ď‚Ě‹LÚ

”wŒi’mŽŻ‚Ě‚¤‚żC–ň•¨—Ă–@ˆČŠO‚Ě’É‚ÝŽĄ—Ă–@‚ÉŠÖ‚ľ‚ẮCu•úŽËüŽĄ—ÁvCuŒo”ç“I’Ĺ‘ĚŒ`ŹpiœƒZƒƒ“ƒgjvCu_ŒoƒuƒƒbƒNv‚đC‚ť‚ę‚ź‚ęC“ú–{•úŽËüŽîᇊw‰ďC“ú–{ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒiƒ‹ƒ‰ƒWƒIƒƒW[Šw‰ďC“ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ď‚Ɉ˗Š‚ľ‚˝B

❻ ŠÉ˜aˆă—ĂŠw‰ď‚̏ł”F

“ú–{ŠÉ˜aˆă—ĂŠw‰ď‚É‚¨‚˘‚ďł”F‚ľ‚˝B

❼ ƒKƒCƒhƒ‰ƒCƒ“ěŹŽŇ‚Ć—˜‰v‘Š”˝

ˆČ‰ş‚É2014 ”N”Ĺ‚ĚƒKƒCƒhƒ‰ƒCƒ“ěŹŽŇ‚Ć—˜‰v‘Š”˝‚đŽŚ‚ˇB

m—˜‰v‘Š”˝ŠJŽŚŽ–€n

“ú–{ŠÉ˜aˆă—ĂŠw‰ď‚Ě—˜‰v‘Š”˝‚ÉŠÖ‚ˇ‚éŽwjC×‘ĽC•ńŽ–€CQ&A ‚ɂ‚˘‚Ä‚ÍŠw‰ďƒz[ƒ€ƒy[ƒWij‚đ‚˛Šm”F‚˘‚˝‚ž‚Ť‚˝‚˘B

m–đˆőEˆĎˆő“™‚Ě—˜‰v‘Š”˝ŠJŽŚŽ–€iŠT—vjn
  1. 1•ń‘Ώ۩é‹Ć“™‚̐EˆőCŒÚ–âE‚Š
  2. 2‹‹—^E•ńV“™100 –œ‰~ˆČă
  3. 3u‰‰—żEŒ´e—żE•ńV“™ 50 –œ‰~ˆČă
  4. 4Žó‘őŒ¤‹†”ďiŽĄŒąj“™200 –œ‰~ˆČă
  5. 5Œ¤‹†•Ź‹ŕiŠń•t‹ŕj“™200 –œ‰~ˆČă
  6. 6Š”ŽŽ“™Ž‚ż•Ş10“ˆČă
  7. 7ę–ĺ“IŘŒžE•Œž“™100 –œ‰~ˆČă
  8. 8Š”ŽŽEoŽ‘‹ŕ“™Ž‚ż•Ş1,000 –œ‰~ˆČă
mŠJŽŚŠúŠÔn

2012 ”N4 ŒŽ1 “ú`2013 ”N3 ŒŽ31 “ú

mŠÉ˜aˆă—ĂƒKƒCƒhƒ‰ƒCƒ“ˆĎˆő‰ďn

—˜‰v‘Š”˝

ˆĎˆő’ˇ

‘ž“cœ¨ˆę˜N š˜H‰Á‘Ű•a‰@Á‰ťŠíƒZƒ“ƒ^[/Á‰ťŠíEˆę”ĘŠO‰Č ŠY“–‚Č‚ľ

•›ˆĎˆő’ˇ
’S“–ˆĎˆő

“c’† ŒjŽq ‚Ş‚ńEŠ´őÇƒZƒ“ƒ^[“s—§‹îž•a‰@ŠÉ˜aƒPƒA‰Č ŠY“–‚Č‚ľ
—]‹{‚Ť‚Ě‚Ý é‹ĘŒ§—§‚Ş‚ńƒZƒ“ƒ^[ŠÉ˜aƒPƒA‰Č ŠY“–‚Č‚ľ

m‚Ş‚ńáu’É–ň•¨—Ă–@ƒKƒCƒhƒ‰ƒCƒ“‰ü’ůWPGn

—˜‰v‘Š”˝

WPG ˆő’ˇ

—]‹{‚Ť‚Ě‚Ý é‹ĘŒ§—§‚Ş‚ńƒZƒ“ƒ^[ŠÉ˜aƒPƒA‰Č ŠY“–‚Č‚ľ

WPG •›ˆő’ˇ

X“c ’B–ç š—ęŽO•űŒ´•a‰@ŠÉ˜aŽxŽŽĄ—Ă‰Č ŠY“–‚Č‚ľ

WPG ˆő

ˆŔ•” –r”ü ź]Žs—§•a‰@ŠÉ˜aƒPƒAEƒyƒCƒ“ƒNƒŠƒjƒbƒN‰Č ŠY“–‚Č‚ľ
ě‘şŽOŠóŽq ŽD–yŽs—§‘ĺŠwŠĹŒěŠw•” ŠY“–‚Č‚ľ
ŹŽR  O ‘—§•a‰@‹@\‹ž“sˆă—ĂƒZƒ“ƒ^[‘‡“ŕ‰ČkŠO•”ˆĎˆől ŠY“–‚Č‚ľ
˛–ě Œł•F é‹Ęˆă‰Č‘ĺŠw‘‡ˆă—ĂƒZƒ“ƒ^[–ňÜ•” ŠY“–‚Č‚ľ
“c’† ŒjŽq ‚Ş‚ńEŠ´őÇƒZƒ“ƒ^[“s—§‹îž•a‰@ŠÉ˜aƒPƒA‰Č ŠY“–‚Č‚ľ
•yˆŔ Žu˜Y ˆă—Ă–@lŒőm‰ďź“c•a‰@–ƒŒ‰Č ŠY“–‚Č‚ľ
‹vŒ´ KŽč ˆîŒkm‰ď•a‰@‚Ş‚ńŽĄ—ĂŠÇ—ƒZƒ“ƒ^[ŠÉ˜aƒPƒAŽş/ŠÉ˜aƒPƒAƒ`[ƒ€ ŠY“–‚Č‚ľ
”ö“Ą ˝Ži ‘—§•a‰@‹@\“Œ‹žˆă—ĂƒZƒ“ƒ^[
—Տ°Œ¤‹†ƒZƒ“ƒ^[—Տ°‰uŠwŒ¤‹†ŽşkŠO•”ˆĎˆől
ŠY“–‚Č‚ľ
–kžŠ”ü”\—Ż ’ˇč‘ĺŠw•a‰@–ƒŒ‰Č/ŠÉ˜aƒPƒAƒ`[ƒ€ ŠY“–‚Č‚ľ
ŽR–{  —ş ˛‹v‘‡•a‰@˛‹vˆă—ĂƒZƒ“ƒ^[ŠÉ˜aƒPƒA“ŕ‰Č ŠY“–‚Č‚ľ
—´  Œb”ü ’ˇč‘ĺŠw•a‰@–ňÜ•”/ŠÉ˜aƒPƒAƒ`[ƒ€ ŠY“–‚Č‚ľ

Žˇ•MŽŇ

Ô–Ř  “O ‘—§‚Ş‚ńŒ¤‹†ƒZƒ“ƒ^[’†‰›•a‰@–ňÜ•” ŠY“–‚Č‚ľ
‘Ť—§ ˝Ži ’šŽćŽs—§•a‰@‘‡f—ÉČ/’nˆćˆă—Ă‘‡Žx‰‡ƒZƒ“ƒ^[ ŠY“–‚Č‚ľ
rˆä •Ű“T šƒ}ƒŠƒAƒ“ƒiˆă‰Č‘ĺŠw•úŽËüˆăŠwuŔC
“ú–{ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒiƒ‹ƒ‰ƒWƒIƒƒW[Šw‰ďkŠO•”ˆĎˆől
ŠY“–‚Č‚ľ
V”Ś ’qŽq ’}”g‘ĺŠw‘ĺŠw‰@lŠÔ‘‡‰ČŠwŒ¤‹†‰ČŠĹŒě‰ČŠwęU ŠY“–‚Č‚ľ
—L‰ę ‰xŽq ’é‹ž‘ĺŠwˆăŠw•”ŠÉ˜aˆă—ĂŠwuŔ ŠY“–‚Č‚ľ
’r‰i š”V —„ěƒLƒŠƒXƒg‹ł•a‰@ƒzƒXƒsƒXE‚ą‚Ç‚ŕƒzƒXƒsƒX•a‰@ƒzƒXƒsƒX‰Č ŠY“–‚Č‚ľ
ˆÉ¨ —Y–ç “ú–{ˆă‰Č‘ĺŠw•t‘Ž•a‰@–ňÜ•” ŠY“–‚Č‚ľ
ˆäŠÖ ‰ëŽq ‡“V“°‘ĺŠwˆăŠw•”–ƒŒ‰ČŠwEƒyƒCƒ“ƒNƒŠƒjƒbƒNuŔ u‰‰—żCŒ´e—żC•ńV“™F‹vŒőť–ňŠ”ŽŽ‰ďŽĐCƒtƒ@ƒCƒU[Š”ŽŽ‰ďŽĐ
Ąˆä Œ˜Œá š—ęŽO•űŒ´•a‰@ƒzƒXƒsƒX‰Č ŠY“–‚Č‚ľ
”~“c  Œb Š”ŽŽ‰ďŽĐŠÉ˜aƒPƒAƒp[ƒgƒi[ƒY ŠY“–‚Č‚ľ
‘ĺâ  ŠŢ Ă‰ŞŒ§—§Ă‰Ş‚Ş‚ńƒZƒ“ƒ^[ŠÉ˜aˆă—Ă‰Č ŠY“–‚Č‚ľ
‘ĺŕV ‹§O –źŒĂ‰ŽŽs—§‘ĺŠw‘ĺŠw‰@–ňŠwŒ¤‹†‰Č_Œo–ň—Šw•Ş–ě ŠY“–‚Č‚ľ
ŹŠ}Œ´—˜Ž} ‰Ą•lŽs—§‚Ý‚Č‚ĆÔ\Žš•a‰@ŠĹŒě•” ŠY“–‚Č‚ľ
‰Ş–{ ’őW Žs—§ˆ°‰Ž•a‰@–ňÜ‰Č ŠY“–‚Č‚ľ
‰œ’Ă ‹P’j ’ߊމˇň•a‰@ ŠY“–‚Č‚ľ
‰Á‰ę’J ”Ł –žŽĄ–ň‰Č‘ĺŠw—Տ°–ňÜŠw‹łŽş ŠY“–‚Č‚ľ
•—ŠÔ ˆčŽq ’}”g‘ĺŠw•‘Ž•a‰@ŠĹŒě•” ŠY“–‚Č‚ľ
_’J _•˝ ŽRŒ`Œ§—§’†‰›•a‰@ŠÉ˜aˆă—Ă‰Č ŠY“–‚Č‚ľ
–؉ş Š°–ç ‘—§‚Ş‚ńŒ¤‹†ƒZƒ“ƒ^[“Œ•a‰@ŠÉ˜aˆă—Ă‰Č ŠY“–‚Č‚ľ
ŒIŽR r”V ˜a‰ĚŽRŒ§—§ˆă‰Č‘ĺŠw•‘Ž•a‰@ŽîᇃZƒ“ƒ^[ŠÉ˜aƒPƒA•”–ĺ ŠY“–‚Č‚ľ
‘•Ş G–ç –k—˘‘ĺŠw•a‰@–ňÜ•” ŠY“–‚Č‚ľ
Ź™ Žő•ś ˛‰ęŒ§ˆă—ĂƒZƒ“ƒ^[DśŠŮŠÉ˜aƒPƒA‰ČC“ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ď ŠY“–‚Č‚ľ
ŹŒ´ O”V Œ§—§L“‡•a‰@ŠÉ˜aƒPƒA‰Č ŠY“–‚Č‚ľ
Ź‹{ KŽq ‰Ą•lŽs—§‘ĺŠw•‘Ž•a‰@–ňÜ•” ŠY“–‚Č‚ľ
˛“Ą ‹ąŽq ş˜a‘ĺŠw•a‰@ƒŠƒnƒrƒŠƒe[ƒVƒ‡ƒ“‰Č ŠY“–‚Č‚ľ
˛“Ą “NŠĎ O‘O‘ĺŠwˆăŠw•”•‘Ž•a‰@–ƒŒ‰Č/ŠÉ˜aƒPƒAf—ĂŽş ŠY“–‚Č‚ľ
Žl•ű  “N ŽOdŒ§—§ˆęŽu•a‰@kŠO•”ˆĎˆől ŠY“–‚Č‚ľ
ŽÂŒ´ –žŽq ăűň–Ř’†‰›çΉ@ ŠY“–‚Č‚ľ
Žu^ ‘וv ’}”gƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[•a‰@ŠÉ˜aˆă—Ă‰Č ŠY“–‚Č‚ľ
´…‚í‚ŠŽq ŒN’Ă’†‰›•a‰@•úŽËüŽĄ—ÉȁC“ú–{•úŽËüŽîᇊw‰ď ŠY“–‚Č‚ľ
{‰ę ş•F Ă‰ŞĎś‰ď‘‡•a‰@ŠÉ˜aˆă—Ă‰Č ŠY“–‚Č‚ľ
—é–Ř  •× Ż–ň‰Č‘ĺŠw–ň•i“ŐŤŠw‹łŽş Žó‘őŒ¤‹†”ď“™F‰––ě‹`ť–ňŠ”ŽŽ‰ďŽĐC‹vŒőť–ňŠ”ŽŽ‰ďŽĐ
Œ¤‹†•Ź‹ŕ“™Fş˜a–ň•i‰ťHŠ”ŽŽ‰ďŽĐ
—é–Ř łŠ° NTT “Œ“ú–{ŠÖ“Œ•a‰@ŠÉ˜aƒPƒA‰Č ŠY“–‚Č‚ľ
űüŁ ‹vŒő –k—¤‘ĺŠw—Տ°–ňŠw‹łˆçƒZƒ“ƒ^[ ŠY“–‚Č‚ľ
‘ëěç’ߎq KKR ŽD–yˆă—ĂƒZƒ“ƒ^[ŠÉ˜aƒPƒA‰Č Žó‘őŒ¤‹†”ď“™F‘ĺ–Q–ň•iH‹ĆŠ”ŽŽ‰ďŽĐ
“cŒű“Ţ’ĂŽq ç—t‘ĺŠwˆăŠw•”•‘Ž•a‰@–ƒŒEáu’ɁEŠÉ˜aˆă—Ă‰Č ŠY“–‚Č‚ľ
“c’† rs ‚č‘‡ˆă—ĂƒZƒ“ƒ^[ŠO‰Č/ŠÉ˜aˆă—Ă‰Č ŠY“–‚Č‚ľ
“c‘ş ŒbŽq ‹ž“s‘ĺŠw‘ĺŠw‰@ˆăŠwŒ¤‹†‰ČlŠÔŒ’N‰ČŠwŒnęU
—Տ°ŠĹŒěŠwuŔŠÉ˜aƒPƒAE˜V”NŠĹŒěŠw•Ş–ě
ŠY“–‚Č‚ľ
’ˇ  ”ü—é š˜H‰Á‘Ű•a‰@ŠÉ˜aƒPƒA‰Č ŠY“–‚Č‚ľ
’Ř“c MŽO ˆ¤•Q‘ĺŠw‘ĺŠw‰@ˆăŠwŒnŒ¤‹†‰Č–ƒŒEŽüpŠúŠwC
“ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ď
ŠY“–‚Č‚ľ
’†ě ‹M”V ‹ž“s‘ĺŠwˆăŠw•”•‘Ž•a‰@–ňÜ•” ŠY“–‚Č‚ľ
‰i‘q ‹v‘× KKR ŽD–yˆă—ĂƒZƒ“ƒ^[•úŽËü‰ČC“ú–{•úŽËüŽîᇊw‰ď ŠY“–‚Č‚ľ
’†ŽR—S‹IŽq ‰zě•a‰@ŠĹŒě•” ŠY“–‚Č‚ľ
’ˇ˜E  I ˆ¤•Q‘ĺŠw‘ĺŠw‰@ˆăŠwŒnŒ¤‹†‰Č–ƒŒEŽüpŠúŠwC
“ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ď
ŠY“–‚Č‚ľ
Ź“c  ”N Ż–ň‰Č‘ĺŠw–ň—Šw‹łŽş Œ¤‹†•Ź‹ŕ“™F“úŽY‰ťŠwH‹ĆŠ”ŽŽ‰ďŽĐ
ź‰Ş Oť _ŒËŽs—§ˆă—ĂƒZƒ“ƒ^[’†‰›Žs–Ż•a‰@‘‡f—Ă‰Č ŠY“–‚Č‚ľ
–ě‘ş Šî—Y ˆ¤’mŒ§‚Ş‚ńƒZƒ“ƒ^[’†‰›•a‰@–ň•¨—Ă–@•” ŠY“–‚Č‚ľ
•l–ě  ~ ’}”g‘ĺŠwˆăŠwˆă—ĂŒn‘‡f—ĂƒOƒ‹[ƒvEŠÉ˜aƒPƒAƒ`[ƒ€ ŠY“–‚Č‚ľ
—Ń  Í•q š˜H‰Á‘Ű•a‰@ŠÉ˜aƒPƒA‰Č u‰‰—żCŒ´e—żC•ńV“™F‹Ś˜a”­yƒLƒŠƒ“Š”ŽŽ‰ďŽĐ
—Ń ‚ď‚čŽq “Ą‘ňĂ“ě‘ä•a‰@ŠĹŒě•” ŠY“–‚Č‚ľ
‹v‰i ‹M”V ’}”gƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[•a‰@ŠÉ˜aˆă—Ă‰Č ŠY“–‚Č‚ľ
•˝ě“ޏ”ü ˛‰ę‘ĺŠwˆăŠw•”–ƒŒE‘hśŠwC“ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ď ŠY“–‚Č‚ľ
œA‰Ş ‰Ŕ‘ă “Œ‹žˆă‰ČŽ•‰Č‘ĺŠw‘ĺŠw‰@•ŰŒ’‰qśŠwŒ¤‹†‰Č
ŠĹŒěƒVƒXƒeƒ€ƒ}ƒlƒWƒƒ“ƒgŠw
ŠY“–‚Č‚ľ
×’J  ŽĄ éź‘ĺŠw–ňŠw•”–ňÜŠwŒ¤‹†Žş ŠY“–‚Č‚ľ
×–î ”ü‹I ‘—§‚Ş‚ńŒ¤‹†ƒZƒ“ƒ^[‚Ş‚ń‘΍ôî•ńƒZƒ“ƒ^[
‚Ş‚ńˆă—ĂŽx‰‡Œ¤‹†•”‹łˆçŒ¤CŽş
ŠY“–‚Č‚ľ
ź“c —zˆę ‘ĺă‘ĺŠw‘ĺŠw‰@ˆăŠwŒnŒ¤‹†‰Č–ƒŒEW’†ŽĄ—ĂˆăŠwuŔ ŠY“–‚Č‚ľ
ź–{ ’ő‹v ‘—§‚Ş‚ńŒ¤‹†ƒZƒ“ƒ^[“Œ•a‰@ŠÉ˜aˆă—Ă‰Č ŠY“–‚Č‚ľ
”ŞŒË ‚ˇ‚¸ ‡“V“°‘ĺŠwˆăŠw•”•‘Ž‡“V“°ˆă‰@ŠÉ˜aˆă—ĂŠwŒ¤‹†Žş ŠY“–‚Č‚ľ
ˆŔ“cr‘ž˜Y ‘—§‚Ş‚ńŒ¤‹†ƒZƒ“ƒ^[’†‰›•a‰@–ňÜ•” ŠY“–‚Č‚ľ
ŽRŒű Œh‰î ‡“V“°‘ĺŠwˆăŠw•”–ƒŒ‰ČŠwEƒyƒCƒ“ƒNƒŠƒjƒbƒNuŔ ŠY“–‚Č‚ľ
“nç˛ hÍ Ź–qŽs–Ż•a‰@ŠÉ˜aƒPƒA‰Č ŠY“–‚Č‚ľ

iŒÜ\‰š‡j


2D•śŒŁ‚ĚŒŸőŽŽ

1D2010 ”N”Ĺ‚Ě•śŒŁŒŸőŽŽ

‚P
  ‹¤’Ę‚ˇ‚éáu’ÉŽĄ—Ă

‚P
’Á’É–ň‚Ş“Š—^‚ł‚ę‚Ä‚˘‚Č‚˘Œy“x‚Ě’É‚Ý‚Ě‚ ‚é‚Ş‚ńŠłŽŇ

œ ’Á’É–ň‚Ş“Š—^‚ł‚ę‚Ä‚˘‚Č‚˘Œy“x‚Ě’É‚Ý‚Ě‚ ‚é‚Ş‚ńŠłŽŇ‚ɑ΂ľ‚āC—LŒř‚ČŽĄ—Â͉˝‚ŠH

m—Տ°‹^–â1niŽQĆj

’Á’É–ň‚Ş“Š—^‚ł‚ę‚Ä‚˘‚Č‚˘Œy“x‚Ě’É‚Ý‚Ě‚ ‚é‚Ş‚ńŠłŽŇ‚ɑ΂ľ‚āCs‚¤‚ׂŤ•]‰ż‚͉˝‚ŠH

•śŒŁŒŸő‚͍s‚í‚Č‚Š‚Á‚˝B

m—Տ°‹^–â2niŽQĆj

’Á’É–ň‚Ş“Š—^‚ł‚ę‚Ä‚˘‚Č‚˘Œy“x‚Ě’É‚Ý‚Ě‚ ‚é‚Ş‚ńŠłŽŇ‚ɑ΂ľ‚āCƒAƒZƒgƒAƒ~ƒmƒtƒFƒ“‚́Cƒvƒ‰ƒZƒ{‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC36 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ2 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1. Cancer
#2. Pain
#3. Acetaminophen
Limits: 1965/01/01 to 2008/12/31, Humans, English, Japanese,

Meta-analysis/Randomized controlled trial

m—Տ°‹^–â3niŽQĆj

’Á’É–ň‚Ş“Š—^‚ł‚ę‚Ä‚˘‚Č‚˘Œy“x‚Ě’É‚Ý‚Ě‚ ‚é‚Ş‚ńŠłŽŇ‚ɑ΂ľ‚āCNSAIDs ‚́Cƒvƒ‰ƒZƒ{‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC90 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ4 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1. Cancer
#2. Pain
#3. NSAIDs
Limits: 1965/01/01 to 2008/12/31, Humans, English, Japanese,

Meta-analysis/Randomized controlled trial

m—Տ°‹^–â4niŽQĆj

’Á’É–ň‚Ş“Š—^‚ł‚ę‚Ä‚˘‚Č‚˘Œy“x‚Ě’É‚Ý‚Ě‚ ‚é‚Ş‚ńŠłŽŇ‚ɑ΂ľ‚āC‚ ‚é”ńƒIƒsƒIƒCƒh’Á’É–ňiNSAIDsEƒAƒZƒgƒAƒ~ƒmƒtƒFƒ“j‚́C‘ź‚Ě”ńƒIƒsƒIƒCƒh’Á’É–ň‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC113 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ5 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1. Cancer
#2. Pain
#3. NSAIDs OR Acetaminophen OR Coxibs
Limits: 1965/01/01 to 2008/12/31, Humans, English, Japanese,

Meta-analysis/Randomized controlled trial

m—Տ°‹^–â5niŽQĆj

’É‚Ý‚ĹNSAIDs ‚đ“Š—^‚ł‚ę‚Ä‚˘‚é‚Ş‚ńŠłŽŇ‚É‚¨‚˘‚āCƒvƒƒXƒ^ƒOƒ‰ƒ“ƒWƒ“ťÜCƒvƒƒgƒ“ƒ|ƒ“ƒv‘jŠQ–ňCH2Žó—e‘̝hR–ň‚́Cƒvƒ‰ƒZƒ{‚É”äŠr‚ľ‚Ĉݒ×ᇂ̔­ś‚đ—\–h‚ˇ‚é‚ŠH

Œn““I•śŒŁŒŸő‚đV‚˝‚ɂ͍s‚í‚Č‚Š‚Á‚˝BÁ‰ťŤ’×ᇐf—ĂƒKƒCƒhƒ‰ƒCƒ“i2009 ”Nj‚đ—p‚˘‚ÄŒŸ“˘‚đs‚Á‚˝B

‚Q
”ńƒIƒsƒIƒCƒh’Á’É–ň‚ŏ\•Ş‚Č’Á’ÉŒř‰Ę‚Ş“ž‚ç‚ę‚Č‚˘C‚Ü‚˝‚́C’†“™“xˆČă‚Ě’É‚Ý‚Ě‚ ‚é‚Ş‚ńŠłŽŇ

œ ”ńƒIƒsƒIƒCƒh’Á’É–ň‚ŏ\•Ş‚Č’Á’ÉŒř‰Ę‚Ş“ž‚ç‚ę‚Č‚˘C‚Ü‚˝‚́C’†“™“xˆČă‚Ě’É‚Ý‚Ě‚ ‚é‚Ş‚ńŠłŽŇ‚ɑ΂ľ‚āC—LŒř‚ČŽĄ—Â͉˝‚ŠH

m—Տ°‹^–â6niŽQĆj

”ńƒIƒsƒIƒCƒh’Á’É–ň‚ŏ\•Ş‚Č’Á’ÉŒř‰Ę‚Ş“ž‚ç‚ę‚Č‚˘C‚Ü‚˝‚́C’†“™“xˆČă‚Ě’É‚Ý‚Ě‚ ‚é‚Ş‚ńŠłŽŇ‚ɑ΂ľ‚āCs‚¤‚ׂŤ•]‰ż‚͉˝‚ŠH

•śŒŁŒŸő‚͍s‚í‚Č‚Š‚Á‚˝B

m—Տ°‹^–â7niŽQĆj

”ńƒIƒsƒIƒCƒh’Á’É–ň‚ŏ\•Ş‚Č’Á’ÉŒř‰Ę‚Ş“ž‚ç‚ę‚Č‚˘C‚Ü‚˝‚́C’†“™“xˆČă‚Ě’É‚Ý‚Ě‚ ‚é‚Ş‚ńŠłŽŇ‚ɑ΂ľ‚āCƒIƒsƒIƒCƒh‚́Cƒvƒ‰ƒZƒ{‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC584 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żCƒyƒ“ƒ^ƒ]ƒVƒ“CƒuƒvƒŒƒmƒ‹ƒtƒBƒ“‚ÉŠÖ‚ˇ‚é‚ŕ‚Ě‚đœ‚ŤC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ2 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dmorphine OR oxycodone OR fentanyl OR codeine OR opioid
#4D#1 AND #2 AND #3
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

m—Տ°‹^–â8niŽQĆj

”ńƒIƒsƒIƒCƒh’Á’É–ň‚ŏ\•Ş‚Č’Á’ÉŒř‰Ę‚Ş“ž‚ç‚ę‚Č‚˘C‚Ü‚˝‚́C’†“™“xˆČă‚Ě’É‚Ý‚Ě‚ ‚é‚Ş‚ńŠłŽŇ‚ɑ΂ľ‚āC‚ ‚éƒIƒsƒIƒCƒh‚́C‘ź‚ĚƒIƒsƒIƒCƒh‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠC•›ě—p‚ޏ­‚Č‚˘‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC584 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żCƒyƒ“ƒ^ƒ]ƒVƒ“CƒuƒvƒŒƒmƒ‹ƒtƒBƒ“‚ÉŠÖ‚ˇ‚é‚ŕ‚Ě‚đœ‚ŤC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ15 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝BŒn““IƒŒƒrƒ…[‚ÉŠÜ‚Ü‚ę‚éd•Ą‚ˇ‚é˜_•ś‚Í‚Č‚Š‚Á‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dmorphine OR oxycodone OR fentanyl OR codeine OR opioid
#4D#1 AND #2 AND #3
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

m—Տ°‹^–â9niŽQĆj

ƒIƒsƒIƒCƒh‚̐ťÜ‚â“Š—^•ű–@‚É‚ć‚čC’Á’ÉŒř‰Ę‚â•›ě—p‚ɍˇ‚Ş‚ ‚é‚ŠH

9|1iŽQĆj
ƒ‚ƒ‹ƒqƒl‚Ě‘Ź•úŤťÜ‚́C™•úŤťÜ‚É”äŠr‚ľ‚āC’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠC•›ě—p‚ޏ­‚Č‚˘‚ŠH
9|2iŽQĆj
ƒ‚ƒ‹ƒqƒl‚Ě‚ ‚鏙•úŤťÜ‚́C‘ź‚̏™•úŤťÜ‚É”äŠr‚ľ‚āC’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠC•›ě—p‚ޏ­‚Č‚˘‚ŠH
9|3iŽQĆj
ƒ‚ƒ‹ƒqƒl‚Ě24 ŽžŠÔ™•úŤťÜ‚Ě’Š1 ‰ń“Š—^‚́C–é1 ‰ń“Š—^‚É”äŠr‚ľ‚āC’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠC•›ě—p‚ޏ­‚Č‚˘‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC584 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ2 Œ ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dmorphine OR oxycodone OR fentanyl OR codeine OR opioid
#4D#1 AND #2 AND #3
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

m—Տ°‹^–â10niŽQĆj

ƒIƒsƒIƒCƒh‚đŠJŽn‚ˇ‚鎞‚ɁC§“f–ň‚đ“Š—^‚ˇ‚é‚ą‚Ƃ́C“Š—^‚ľ‚Č‚˘‚ą‚Ć‚É”äŠr‚ľ‚ĈŤSEšq“f‚đŒ¸­‚ł‚š‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC26 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚đŒŸő‚ľ‚˝‚ށC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ‚ŕ‚Ě‚Í0 Œ‚Ĺ‚ ‚Á‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dmorphine OR oxycodone OR fentanyl OR codeine OR opioid
#4DMetclopramide OR prochlorperazine OR diphenhydramine OR haloperidol OR promethazine OR Steroid OR Risperidone OR Domperidone
#5D#1 AND #2 AND #3 AND #4
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

m—Տ°‹^–â11niŽQĆj

ƒIƒsƒIƒCƒh‚đŠJŽn‚ˇ‚鎞‚ɁC‰şÜ‚đ“Š—^‚ˇ‚é‚ą‚Ƃ́C“Š—^‚ľ‚Č‚˘‚ą‚Ć‚É”äŠr‚ľ‚Ä•Ö”é‚đŒ¸­‚ł‚š‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC19 Œ‚ŞŠY“–‚ľ‚˝Bhand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚đŒŸő‚ľ‚˝‚ށC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ‚ŕ‚Ě‚Í0 Œ‚Ĺ‚ ‚Á‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dmorphine OR oxycodone OR fentanyl OR codeine OR opioid
#4Dlaxative OR preventive
#5D#1 AND #2 AND #3 AND #4
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

m—Տ°‹^–â12niŽQĆj

”ńƒIƒsƒIƒCƒh’Á’É–ň‚ŏ\•Ş‚Č’Á’ÉŒř‰Ę‚Ş“ž‚ç‚ę‚Č‚˘‚Ş‚ńŠłŽŇ‚ɑ΂ľ‚āC”ńƒIƒsƒIƒCƒh’Á’É–ň‚𒆎~‚š‚¸‚ɃIƒsƒIƒCƒh‚đŠJŽn‚ˇ‚é‚ą‚Ƃ́C”ńƒIƒsƒIƒCƒh’Á’É–ň‚𒆎~‚ľ‚ăIƒsƒIƒCƒh‚đŠJŽn‚ˇ‚é‚ą‚Ć‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC55 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ4 Œ ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dmorphine OR oxycodone OR fentanyl OR codeine OR opioid
#4Dsparing effect OR addition
#5D#1 AND #2 AND #3 AND #4
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

‚R
ƒIƒsƒIƒCƒh‚Ş“Š—^‚ł‚ę‚Ä‚˘‚銳ŽŇ

 ƒIƒsƒIƒCƒh‚Ş“Š—^‚ł‚ę‚Ä‚˘‚銳ŽŇ‚ŁCŽ‘ą’ɂފɘa‚ł‚ę‚Ä‚˘‚Č‚˘ę‡C—LŒř‚ČŽĄ—Â͉˝‚ŠH

m—Տ°‹^–â13niŽQĆj

Ž‘ą’É‚Ě‚ ‚銳ŽŇ‚É‚¨‚˘‚āCs‚¤‚ׂŤ•]‰ż‚͉˝‚ŠH

•śŒŁŒŸő‚͍s‚í‚Č‚Š‚Á‚˝B

m—Տ°‹^–â14niŽQĆj

ƒIƒsƒIƒCƒh‚Ĺ’Á’ÉŒř‰Ę‚Ş“ž‚ç‚ę‚Č‚˘Ž‘ą’É‚Ě‚ ‚銳ŽŇ‚É‚¨‚˘‚āC”ńƒIƒsƒIƒCƒh’Á’É–ň‚đƒIƒsƒIƒCƒh‚Ć•š—p‚ˇ‚é‚ą‚Ƃ́C•š—p‚ľ‚Č‚˘ę‡‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

V‚˝‚É•śŒŁŒŸő‚͍s‚í‚Č‚Š‚Á‚˝B—Տ°‹^–â12‚đŽQĆ‚ľ‚˝BⅡ-3 WHO •űŽŽ‚Ş‚ńáu’ÉŽĄ—Ă–@‚̍€ŽQĆB

m—Տ°‹^–â15niŽQĆj

ƒIƒsƒIƒCƒh‚Ě’čŠú“Š—^‚É‚ć‚č’Á’ÉŒř‰Ę‚Ş“ž‚ç‚ę‚Č‚˘Ž‘ą’É‚Ě‚ ‚銳ŽŇ‚É‚¨‚˘‚āC’čŠú“Š—^—Ę‚Ě‘—Ę‚Í’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC97 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚đŒŸő‚ľ‚˝‚ށC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ‚ŕ‚Ě‚Í0 Œ‚Ĺ‚ ‚Á‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dmorphine OR fentanyl OR oxycodone OR codeine OR opioid
#4Ddose titration OR titrated OR escalation OR elevation OR increment
#5D#1 AND #2 AND #3 AND #4
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

m—Տ°‹^–â16niŽQĆj

‚ ‚éƒIƒsƒIƒCƒh‚Ĺ“KŘ‚Č’Á’ÉŒř‰Ę‚Ş“ž‚ç‚ę‚Č‚˘ŠłŽŇ‚É‚¨‚˘‚āC‘ź‚ĚƒIƒsƒIƒCƒh‚Ö‚Ě•ĎXiƒIƒsƒIƒCƒhƒXƒCƒbƒ`ƒ“ƒOj‚âC‘ź‚ĚƒIƒsƒIƒCƒh‚̒ljÁ‚Í’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

16|1iŽQĆj

‚ ‚éƒIƒsƒIƒCƒh‚Ĺ“KŘ‚Č’Á’ÉŒř‰Ę‚Ş“ž‚ç‚ę‚Č‚˘ŠłŽŇ‚É‚¨‚˘‚āC‘ź‚ĚƒIƒsƒIƒCƒh‚É•ĎX‚ˇ‚é‚ą‚Ƃ́C’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC25 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ4 Œ ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dmorphine OR fentanyl OR oxycodone OR codeine OR opioid
#4Dswitching OR substitution OR rotation
#5D#1 AND #2 AND #3 AND #4
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

16|2iŽQĆj

‚ ‚éƒIƒsƒIƒCƒh‚Ĺ“KŘ‚Č’Á’ÉŒř‰Ę‚Ş“ž‚ç‚ę‚Č‚˘ŠłŽŇ‚É‚¨‚˘‚āC‘ź‚ĚƒIƒsƒIƒCƒh‚đ’ljÁ‚ˇ‚é‚ą‚Ƃ́C’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC194 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ1 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dmorphine OR fentanyl OR oxycodone OR codeine OR opioid
#4Daddition OR additive OR combi–
#5D#1 AND #2 AND #3 AND #4
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

m—Տ°‹^–â17niŽQĆj

‚ ‚éƒIƒsƒIƒCƒh‚ĚŒoŒű“Š—^‚Ü‚˝‚Í“\•tÜ‚Ĺ“KŘ‚Č’Á’ÉŒř‰Ę‚Ş“ž‚ç‚ę‚Č‚˘ŠłŽŇ‚É‚¨‚˘‚āCƒIƒsƒIƒCƒh‚đŽ‘ąĂ’EŽ‘ą”牺’‚É•ĎX‚ˇ‚é‚ą‚Ƃ́C’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC4 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ2 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour –mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dmorphine OR fentanyl OR oxycodone OR codeine OR opioid
#4Dswitching OR substitution OR rotation
#5Dparenteral OR intravenous OR subcutaneous
#6D#1 AND #2 AND #3 AND #4 AND #5
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

m—Տ°‹^–â18niŽQĆj

ƒIƒsƒIƒCƒh‚Ĺ“KŘ‚Č’Á’ÉŒř‰Ę‚Ş“ž‚ç‚ę‚Č‚˘ŠłŽŇ‚É‚¨‚˘‚āCƒIƒsƒIƒCƒh‚ĆƒPƒ^ƒ~ƒ“‚Ě•š—p‚́CƒIƒsƒIƒCƒh’P“Ć‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

Œn““IƒŒƒrƒ…[‚Ş‘śÝ‚ľ‚˝‚˝‚߁CŒn““I•śŒŁŒŸő‚đV‚˝‚ɂ͍s‚í‚Č‚Š‚Á‚˝BŒn““IƒŒƒrƒ…[‚Ě‚Č‚Š‚Ěˆř—p•śŒŁ‚Š‚çC“KŠiŠî€‚đ–ž‚˝‚ˇ5 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

m—Տ°‹^–â19niŽQĆj

ƒIƒsƒIƒCƒh‚Ĺ“KŘ‚Č’Á’ÉŒř‰Ę‚Ş“ž‚ç‚ę‚Č‚˘ŠłŽŇ‚É‚¨‚˘‚āCƒIƒsƒIƒCƒh‚ĆƒRƒ‹ƒ`ƒRƒXƒeƒƒCƒh‚Ě•š—p‚́CƒIƒsƒIƒCƒh’P“Ć‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC20 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ3 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dmorphine OR fentanyl OR oxycodone OR codeine OR opioid
#4Dsteroids
#5D#1 AND #2 AND #3 AND #4
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

 ƒIƒsƒIƒCƒh‚Ş“Š—^‚ł‚ę‚Ä‚˘‚銳ŽŇ‚ŁC“ˏo’ɂފɘa‚ł‚ę‚Ä‚˘‚Č‚˘ę‡C—LŒř‚ČŽĄ—Â͉˝‚ŠH

m—Տ°‹^–â20niŽQĆj

“ˏo’É‚Ě‚ ‚銳ŽŇ‚É‚¨‚˘‚āCs‚¤‚ׂŤ•]‰ż‚͉˝‚ŠH

•śŒŁŒŸő‚͍s‚í‚Č‚Š‚Á‚˝B

m—Տ°‹^–â21niŽQĆj

“ˏo’É‚Ě‚ ‚銳ŽŇ‚É‚¨‚˘‚āCƒIƒsƒIƒCƒh‚ĚƒŒƒXƒLƒ…[–ň‚́Cƒvƒ‰ƒZƒ{‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC62 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ6 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour –mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–mtiabnOR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesiammeshFnoexpn
#3Dmorphine OR fentanyl OR remifentanil OR oxycodone OR codeine OR dihydrocodeine OR pentazocine OR buprenorphine OR tramadol OR opioid OR opiate OR opioids OR opiates
#4Dbreakthrough OR episodic OR transient OR transitory OR incident OR flare
#5Drescue OR as-needed OR supplemental OR breakthrough
#6Dresearch designmmhnOR clinical trialsmmhnOR comparative studymptnOR placebosmmhnOR multicenter studymptnOR clinical trialmptnOR random–mtiabnOR placebo–mtiabnOR clinical trial–mtiabnOR controlled clinical trialmptnOR randomized controlled trialmptnOR practice guidelinemptnOR feasibility studiesmmhnOR clinical protocolsmmhnOR single blind–mtiabn
#7D#1 AND #2 AND #3 AND #4 AND #5 AND #6
LimitsFhuman, English, Japanese

m—Տ°‹^–â22niŽQĆj

’莞’Á’É–ň‚̐؂ę–ڂ̒ɂ݁iend-of-dose failurej‚Ě‚ ‚é‚Ş‚ńŠłŽŇ‚É‚¨‚˘‚āCƒIƒsƒIƒCƒh‚Ě’čŠú“Š—^—Ę‚Ě‘—ʁE“Š—^ŠÔŠu‚Ě’Zk‚́C‘—ʁE“Š—^ŠÔŠu‚Ě’Zk‚đ‚ľ‚Č‚˘ę‡‚É”äŠr‚ľ‚āC’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC14 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ2 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–mtiabnOR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesiammeshFnoexpn
#3Dmorphine OR fentanyl OR remifentanil OR oxycodone OR codeine OR dihydrocodeine OR pentazocine OR buprenorphine OR tramadol OR opioid OR opiate OR opioids OR opiates
#4Dgend of doseh OR night OR gbed timeh
#5Dresearch designmmhnOR clinical trialsmmhnOR comparative studymptnOR placebosmmhnOR multicenter studymptnOR clinical trialmptnOR random–mtiabnOR placebo–mtiabnOR clinical trial–mtiabnOR controlled clinical trialmptnOR randomized controlled trialmptnOR practice guidelinemptnOR feasibility studiesmmhnOR clinical protocolsmmhnOR single blind–mtiabn
#6D#1 AND #2 AND #3 AND #4 AND #5
LimitsFhuman, English, Japanese

m—Տ°‹^–â23niŽQĆj

ƒŒƒXƒLƒ…[–ň‚Ě“Š—^‚Ĺ’Á’ÉŒř‰Ę‚Ş•s\•Ş‚Č“Ëo’É‚Ě‚ ‚銳ŽŇ‚É‚¨‚˘‚āCƒIƒsƒIƒCƒh‚Ě’čŠú“Š—^—Ę‚Ě‘—ʂ́C‘—Ę‚ľ‚Č‚˘ę‡‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC18 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ1 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour –mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati– mtiabnOR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesiammeshFnoexpn
#3Dmorphine OR fentanyl OR remifentanil OR oxycodone OR codeine OR dihydrocodeine OR pentazocine OR buprenorphine OR tramadol OR opioid OR opiate OR opioids OR opiates
#4Dbreakthrough OR episodic OR transient OR transitory OR incident OR flare
#5Dgdose uph OR gbase uph OR gincrease doseh OR titration
#6Dresearch designmmhnOR clinical trialsmmhnOR comparative studymptnOR placebosmmhnOR multicenter studymptnOR clinical trialmptnOR random–mtiabnOR placebo–mtiabnOR clinical trial–mtiabnOR controlled clinical trialmptnOR randomized controlled trialmptnOR practice guidelinemptnOR feasibility studiesmmhnOR clinical protocolsmmhnOR single blind–mtiabn
#7D#1 AND #2 AND #3 AND #4 AND #5 AND #6
LimitsFhuman, English, Japanese

m—Տ°‹^–â24niŽQĆj

“ˏo’É‚Ě‚ ‚銳ŽŇ‚É‚¨‚˘‚āCƒIƒsƒIƒCƒh‚É”ńƒIƒsƒIƒCƒh’Á’É–ň‚đ•š—p‚ˇ‚é‚ą‚Ƃ́C•š—p‚ľ‚Č‚˘ę‡‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC28 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ‚ŕ‚Ě‚Í0 Œ‚Ĺ‚ ‚Á‚˝B‚ ‚í‚š‚āC—Տ°‹^–â12 ‚đŽQĆ‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–mtiabnOR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesiammeshFnoexpn
#3Dbreakthrough OR episodic OR transient OR transitory OR incident OR flare
#4Dgnon steroid anti inflammatory drugh OR nsaid OR nsaids OR acetaminophen
#5Dresearch designmmhnOR clinical trialsmmhnOR comparative studymptnOR placebosmmhnOR multicenter studymptnOR clinical trialmptnOR random–mtiabnOR placebo–mtiabnOR clinical trial–mtiabnOR controlled clinical trialmptnOR randomized controlled trialmptnOR practice guidelinemptnOR feasibility studiesmmhnOR clinical protocolsmmhnOR single blind–mtiabn
#6D#1 AND #2 AND #3 AND #4 AND #5
LimitsFhuman, English, Japanese

‚Q
  ƒIƒsƒIƒCƒh‚É‚ć‚é•›ě—p

‚P
ˆŤSEšq“f

œ ƒIƒsƒIƒCƒh‚Ş“Š—^‚ł‚ę‚˝ŠłŽŇ‚É‚¨‚˘‚āCˆŤSEšq“f‚Ş”­Œť‚ľ‚˝Žž‚É—LŒř‚ČŽĄ—Â͉˝‚ŠH

m—Տ°‹^–â25niŽQĆj

ƒIƒsƒIƒCƒh‚Ş“Š—^‚ł‚ęCˆŤSEšq“f‚Ş”­Œť‚ľ‚˝ŠłŽŇ‚ɑ΂ľ‚āCs‚¤‚ׂŤ•]‰ż‚͉˝‚ŠH

•śŒŁŒŸő‚͍s‚í‚Č‚Š‚Á‚˝B

m—Տ°‹^–â26niŽQĆj

ƒIƒsƒIƒCƒh‚Ş“Š—^‚ł‚ęCˆŤSEšq“f‚Ş”­Œť‚ľ‚˝ŠłŽŇ‚ɑ΂ľ‚āC§“f–ň‚́Cƒvƒ‰ƒZƒ{‚É”äŠr‚ľ‚ĈŤSEšq“f‚đ‰ü‘P‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC176 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ11Œ‚ɂ‚˘‚ÄŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dmorphine OR fentanyl OR oxycodone OR codeine OR opioid
#4Dantiemetic ORlevomepromazine OR haloperidol OR metoclopramide OR domperidone OR prochlorperazine OR ondansetron OR dexamethasone OR serotonin antagonists OR nausea OR vomiting OR emesis OR emetics
#5D#1 AND #2 AND #3 AND #4
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

m—Տ°‹^–â27niŽQĆj

ƒIƒsƒIƒCƒh‚Ş“Š—^‚ł‚ęCˆŤSEšq“f‚Ş”­Œť‚ľ‚˝ŠłŽŇ‚ɑ΂ľ‚āCƒIƒsƒIƒCƒh‚Ě•ĎXiƒIƒsƒIƒCƒhƒXƒCƒbƒ`ƒ“ƒOj‚́C•ĎX‚ľ‚Č‚˘‚ą‚Ć‚É”äŠr‚ľ‚ĈŤSEšq“f‚đ‰ü‘P‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC185 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ4 Œ‚ɂ‚˘‚ÄŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dmorphine OR fentanyl OR oxycodone OR codeine OR opioid
#4Dopioid switching OR opioid rotation OR dexamethasone OR nausea OR vomiting OR emesis OR emetics
#5D#1 AND #2 AND #3 AND #4
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

m—Տ°‹^–â28niŽQĆj

ƒIƒsƒIƒCƒh‚Ş“Š—^‚ł‚ęCˆŤSEšq“f‚Ş”­Œť‚ľ‚˝ŠłŽŇ‚ɑ΂ľ‚āCƒIƒsƒIƒCƒh‚Ě“Š—^Œo˜H‚Ě•ĎX‚́C•ĎX‚ľ‚Č‚˘‚ą‚Ć‚É”äŠr‚ľ‚ĈŤSEšq“f‚đ‰ü‘P‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC32 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ1 Œ‚ɂ‚˘‚ÄŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dopioid OR opiate
#4Dswitch OR switching OR rotate OR rotation OR substitute OR substitution
#5D#1 AND #2 AND #3 AND #4
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

‚Q
•Ö@”é

œ ƒIƒsƒIƒCƒh‚Ş“Š—^‚ł‚ę‚˝ŠłŽŇ‚É‚¨‚˘‚āC•Ö”é‚Ş”­Œť‚ľ‚˝Žž‚É—LŒř‚ČŽĄ—Â͉˝‚ŠH

m—Տ°‹^–â29niŽQĆj

ƒIƒsƒIƒCƒh‚Ş“Š—^‚ł‚ęC•Ö”é‚Ş”­Œť‚ľ‚˝ŠłŽŇ‚ɑ΂ľ‚āCs‚¤‚ׂŤ•]‰ż‚͉˝‚ŠH

•śŒŁŒŸő‚͍s‚í‚Č‚Š‚Á‚˝B

m—Տ°‹^–â30niŽQĆj

ƒIƒsƒIƒCƒh‚Ş“Š—^‚ł‚ęC•Ö”é‚Ş”­Œť‚ľ‚˝ŠłŽŇ‚ɑ΂ľ‚āC‰şÜ‚́Cƒvƒ‰ƒZƒ{‚É”äŠr‚ľ‚Ä•Ö”é‚đ‰ü‘P‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC71 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ5 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dmorphine OR fentanyl OR oxycodone OR codeine OR opioid
#4Dconstipation OR sodium picosulfate OR lactulose OR senna OR laxante
#5D#1 AND #2 AND #3 AND #4
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

m—Տ°‹^–â31niŽQĆj

ƒIƒsƒIƒCƒh‚Ş“Š—^‚ł‚ęC•Ö”é‚Ş”­Œť‚ľ‚˝ŠłŽŇ‚ɑ΂ľ‚āCƒIƒsƒIƒCƒh‚Ě•ĎXiƒIƒsƒIƒCƒhƒXƒCƒbƒ`ƒ“ƒOj‚́C•ĎX‚ľ‚Č‚˘‚ą‚Ć‚É”äŠr‚ľ‚Ä•Ö”é‚đ‰ü‘P‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC93 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ5 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dmorphine OR fentanyl OR oxycodone OR codeine OR opioid
#4Dopioid switching OR opioid rotation OR constipation OR bowel dysfunction OR laxante
#5D#1 AND #2 AND #3 AND #4
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

‚R
–°@‹C

œ ƒIƒsƒIƒCƒh‚Ş“Š—^‚ł‚ę‚˝ŠłŽŇ‚É‚¨‚˘‚āC–°‹C‚Ş”­Œť‚ľ‚˝Žž‚É—LŒř‚ČŽĄ—Â͉˝‚ŠH

m—Տ°‹^–â32niŽQĆj

ƒIƒsƒIƒCƒh‚Ş“Š—^‚ł‚ęC–°‹C‚Ş”­Œť‚ľ‚˝ŠłŽŇ‚ɑ΂ľ‚āCs‚¤‚ׂŤ•]‰ż‚͉˝‚ŠH

•śŒŁŒŸő‚͍s‚í‚Č‚Š‚Á‚˝

m—Տ°‹^–â33niŽQĆj

ƒIƒsƒIƒCƒh‚Ş“Š—^‚ł‚ęC–°‹C‚Ş”­Œť‚ľ‚˝ŠłŽŇ‚ɑ΂ľ‚āC¸_ŽhŒƒ–ňCƒRƒŠƒ“ƒGƒXƒeƒ‰[ƒ[‘jŠQ–ňCƒJƒtƒFƒCƒ“‚́Cƒvƒ‰ƒZƒ{‚É”äŠr‚ľ‚Ä–°‹C‚đ‰ü‘P‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC19 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ6 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Ddrowsiness OR drowsy OR sleepiness OR sleepy OR somnolence OR somnolent OR narcosis OR sedation OR sedated
#4Dmethylphenidate OR donepezil OR modafinil OR pemoline OR caffeine OR gcentral nervous system stimulantsh OR rotat–OR switch–OR substitut–
#5D#1 AND #2 AND #3 AND #4
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

m—Տ°‹^–â34niŽQĆj

ƒIƒsƒIƒCƒh‚Ş“Š—^‚ł‚ęC–°‹C‚Ş”­Œť‚ľ‚˝ŠłŽŇ‚ɑ΂ľ‚āCƒIƒsƒIƒCƒh‚Ě•ĎXiƒIƒsƒIƒCƒhƒXƒCƒbƒ`ƒ“ƒOj‚́C•ĎX‚ľ‚Č‚˘‚ą‚Ć‚É”äŠr‚ľ‚Ä–°‹C‚đ‰ü‘P‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC19 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ5 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Ddrowsiness OR drowsy OR sleepiness OR sleepy OR somnolence OR somnolent OR narcosis OR sedation OR sedated
#4Dmethylphenidate OR donepezil OR modafinil OR pemoline OR caffeine OR gcentral nervous system stimulantsh OR rotat–OR switch–OR substitut–
#5D#1 AND #2 AND #3 AND #4
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

m—Տ°‹^–â35niŽQĆj

ƒIƒsƒIƒCƒh‚Ş“Š—^‚ł‚ęC–°‹C‚Ş”­Œť‚ľ‚˝ŠłŽŇ‚ɑ΂ľ‚āCƒIƒsƒIƒCƒh‚Ě“Š—^Œo˜H‚Ě•ĎX‚́C•ĎX‚ľ‚Č‚˘‚ą‚Ć‚É”äŠr‚ľ‚Ä–°‹C‚đ‰ü‘P‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC19 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ1 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Ddrowsiness OR drowsy OR sleepiness OR sleepy OR somnolence OR somnolent OR narcosis OR sedation OR sedated
#4Dmethylphenidate OR donepezil OR modafinil OR pemoline OR caffeine OR gcentral nervous system stimulantsh OR rotat–OR switch–OR substitut–
#5D#1 AND #2 AND #3 AND #4
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

‚S
‚š‚ń–Ď

œ ƒIƒsƒIƒCƒh‚Ş“Š—^‚ł‚ę‚˝ŠłŽŇ‚É‚¨‚˘‚āC‚š‚ń–Ď‚Ş”­Œť‚ľ‚˝Žž‚É—LŒř‚ČŽĄ—Â͉˝‚ŠH

m—Տ°‹^–â36niŽQĆj

ƒIƒsƒIƒCƒh‚Ş“Š—^‚ł‚ęC‚š‚ń–Ď‚Ş”­Œť‚ľ‚˝ŠłŽŇ‚ɑ΂ľ‚āCs‚¤‚ׂŤ•]‰ż‚͉˝‚ŠH

•śŒŁŒŸő‚͍s‚í‚Č‚Š‚Á‚˝B

m—Տ°‹^–â37niŽQĆj

ƒIƒsƒIƒCƒh‚Ş“Š—^‚ł‚ęC‚š‚ń–Ď‚Ş”­Œť‚ľ‚˝ŠłŽŇ‚ɑ΂ľ‚āCR¸_•a–ň‚́Cƒvƒ‰ƒZƒ{‚É”äŠr‚ľ‚Ä‚š‚ń–Ď‚đ‰ü‘P‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC8 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ5 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Ddelirium OR gcognitive impairmenth OR gcognitive disorderh OR gcognitive dysfunctionh OR cognitive OR confusion–OR hallucination–OR delusion–OR delirious OR agitat–OR delirious OR gconsciousness disordersh OR disorient–OR dysorient–
#4Dhaloperidol OR risperidone OR aripiprazole OR chlorpromazine OR fluphenazine OR olanzapine OR perospirone OR perphenazine OR pimozide OR quetiapine OR sulpiride OR thioridazine OR trifluoperazine OR zotepine OR tiapride OR levomepromazine OR droperidol OR neurolept–OR gdopamine antagonistsh OR rotat–OR switch–OR substitut–
#5D#1 AND #2 AND #3 AND #4
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

m—Տ°‹^–â38niŽQĆj

ƒIƒsƒIƒCƒh‚Ş“Š—^‚ł‚ęC‚š‚ń–Ď‚Ş”­Œť‚ľ‚˝ŠłŽŇ‚ɑ΂ľ‚āCƒIƒsƒIƒCƒh‚Ě•ĎXiƒIƒsƒIƒCƒhƒXƒCƒbƒ`ƒ“ƒOj‚́C•ĎX‚ľ‚Č‚˘‚ą‚Ć‚É”äŠr‚ľ‚Ä‚š‚ń–Ď‚đ‰ü‘P‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC8 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ7 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Ddelirium OR gcognitive impairmenth OR gcognitive disorderh OR gcognitive dysfunctionh OR cognitive OR confusion–OR hallucination–OR delusion–OR delirious OR agitat–OR delirious OR gconsciousness disordersh OR disorient–OR dysorient–
#4Dhaloperidol OR risperidone OR aripiprazole OR chlorpromazine OR fluphenazine OR olanzapine OR perospirone OR perphenazine OR pimozide OR quetiapine OR sulpiride OR thioridazine OR trifluoperazine OR zotepine OR tiapride OR levomepromazine OR droperidol OR neurolept–OR gdopamine antagonistsh OR rotat–OR switch–OR substitut–
#5D#1 AND #2 AND #3 AND #4
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

m—Տ°‹^–â39niŽQĆj

ƒIƒsƒIƒCƒh‚Ş“Š—^‚ł‚ęC‚š‚ń–Ď‚Ş”­Œť‚ľ‚˝ŠłŽŇ‚ɑ΂ľ‚āCƒIƒsƒIƒCƒh‚Ě“Š—^Œo˜H‚Ě•ĎX‚́C•ĎX‚ľ‚Č‚˘‚ą‚Ć‚É”äŠr‚ľ‚Ä‚š‚ń–Ď‚đ‰ü‘P‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC8 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ1 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Ddelirium OR gcognitive impairmenth OR gcognitive disorderh OR gcognitive dysfunctionh OR cognitive OR confusion–OR hallucination–OR delusion–OR delirious OR agitat–OR delirious OR gconsciousness disordersh OR disorient–OR dysorient–
#4Dhaloperidol OR risperidone OR aripiprazole OR chlorpromazine OR fluphenazine OR olanzapine OR perospirone OR perphenazine OR pimozide OR quetiapine OR sulpiride OR thioridazine OR trifluoperazine OR zotepine OR tiapride OR levomepromazine OR droperidol OR neurolept–OR gdopamine antagonistsh OR rotat–OR switch–OR substitut–
#5D#1 AND #2 AND #3 AND #4
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

‚R
  ‚Ş‚ńáu’Ƀ}ƒlƒWƒƒ“ƒg‚É‚¨‚Ż‚銳ŽŇ‹łˆç

œ ‚Ş‚ńáu’Ƀ}ƒlƒWƒƒ“ƒg‚đŽó‚Ż‚Ä‚˘‚銳ŽŇ‚ɁCáu’Ƀ}ƒlƒWƒƒ“ƒg‚ɂ‚˘‚Ä‹łˆç‚đs‚¤‚ą‚Ć‚Í—LŒř‚ŠH

m—Տ°‹^–â40niŽQĆj

‚Ş‚ńáu’Ƀ}ƒlƒWƒƒ“ƒg‚ɂ‚˘‚ÄŠłŽŇ‚É‹łˆç‚đs‚¤‚ą‚ƂŁC’ɂ݂͊ɘa‚ˇ‚é‚ŠH

m—Տ°‹^–â41niŽQĆj

‚Ş‚ńáu’Ƀ}ƒlƒWƒƒ“ƒg‚ɂ‚˘‚Ä‚Ě‹łˆç‚́C‚ǂ̂悤‚ɍs‚¤‚ׂŤ‚ŠH

•śŒŁƒf[ƒ^ƒx[ƒXOvid MEDLINEi1950`jCOvid CINAHLi1950`jCˆăŠw’†‰›ŽGŽWEB ”Łi1983`j‚đ—p‚˘‚˝B•śŒŁŒŸő‚Ě‘ÎŰ‚ĆŒŸő“ú‚́COvid MEDLINE ‚Í1950 ”NˆČ~`2007 ”N3 ŒŽ17 “úiŒŸő“ú2007 ”N4 ŒŽ17 “újCOvid CINAHL ‚Í1982`2007 ”N4 ŒŽ23 “úiŒŸő“ú2007 ”N4 ŒŽ23 “újCˆăŠw’†‰›ŽGŽWEB ”Ĺ‚Í1983`2007 ”NiŒŸő“ú2007 ”N4 ŒŽ23 “új‚Ć‚ľ‚˝BŒŸőŒę‚́Cu‚Ş‚ńv‚ÉŠÖ˜A‚ˇ‚éŒę‚́mcancerCmalignantCneoplasmsCneoplasiaCtumorCtumourCŠŕC‚Ş‚ńCŽîᇁnCuáu’Ɂv‚́mpainCáu’ɁC’ɂ݁nCuŠłŽŇ‹łˆçv‚́meducationCinterventionCadvocateCcoachingCneedsassessmentCprogramCfocus groupCknowledgeCencouragementCinformationCmanagementCsupportCfollow upCguidanceC‹łˆçC‰î“üCƒAƒhƒ{ƒP[ƒgCŠłŽŇ‚ĚŒ —˜—iŒěCƒR[ƒ`ƒ“ƒOCŽw“ąCŽů—v•]‰żCƒj[ƒYƒAƒZƒXƒƒ“ƒgCƒvƒƒOƒ‰ƒ€CŽŠ•ƒOƒ‹[ƒvCƒTƒ|[ƒgƒOƒ‹[ƒvCƒtƒH[ƒJƒXƒOƒ‹[ƒvC’mŽŻCî•ńCƒtƒHƒ[ƒAƒbƒvCƒKƒCƒ_ƒ“ƒXn‚đ‘I‘đ‚ľ‚˝BŒŸő€–ڂ̓^ƒCƒgƒ‹C´˜^CŒ–ź•W–ځiƒVƒ\[ƒ‰ƒX‚Ě—pŒęj‚Ć‚ľ‚˝B‚ł‚ç‚ÉOvid MEDLINECOvid CINAHL ‚́CRochester ‘ĺŠw}‘ŠŮ‚É‚ć‚錟őƒtƒBƒ‹ƒ^[‚đŽQl‚ɁCƒ‰ƒ“ƒ_ƒ€‰ť”äŠrŽŽŒąCƒƒ^ƒAƒiƒŠƒVƒX‚̍iž‚Ý‚đs‚Á‚˝B‚ł‚ç‚Éhand search ‚đ’ljÁ‚ľC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ11 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

‚S
  “Á’č‚Ě•a‘Ô‚É‚ć‚é’ɂ݂ɑ΂ˇ‚鎥—Ă

‚P
_ŒoáŠQŤáu’É

œ ‚Ş‚ń‚É‚ć‚é_ŒoáŠQŤáu’ɂɑ΂ˇ‚é—LŒř‚ČŽĄ—Â͉˝‚ŠH

m—Տ°‹^–â42niŽQĆj

‚Ş‚ń‚É‚ć‚é_ŒoáŠQŤáu’É‚Ě‚ ‚銳ŽŇ‚ɑ΂ľ‚āCs‚¤‚ׂŤ•]‰ż‚͉˝‚ŠH

•śŒŁŒŸő‚͍s‚í‚Č‚Š‚Á‚˝B

m—Տ°‹^–â43niŽQĆj

‚Ş‚ń‚É‚ć‚é_ŒoáŠQŤáu’É‚Ě‚ ‚銳ŽŇ‚ɑ΂ľ‚āC”ńƒIƒsƒIƒCƒh’Á’É–ňEƒIƒsƒIƒCƒh‚É‚ć‚éáu’ÉŽĄ—ẤCƒvƒ‰ƒZƒ{‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC47 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ4 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neopas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–ihumansmmhnj
#2Dneuropathic pain
#3Dopioid
#4Drandomized controlled trialmptnOR randomizedmtiabnOR placebomtiabnORiclinical trials as topicmmeshFnoexpnjORicontrolled clinical trialmptnjOR randomlymtiabnOR trialmtin
#5D#1 AND #2 AND #3 AND #4
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese

m—Տ°‹^–â44niŽQĆj

‚Ş‚ń‚É‚ć‚é_ŒoáŠQŤáu’É‚Ě‚ ‚銳ŽŇ‚ɑ΂ľ‚āCR‚Ż‚˘‚ę‚ń–ňCR‚¤‚–ňCR•sŽ–Ź–ňCNMDA Žó—e‘̝hR–ňCƒRƒ‹ƒ`ƒRƒXƒeƒƒCƒh‚́Cƒvƒ‰ƒZƒ{‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

<ƒKƒoƒyƒ“ƒ`ƒ“>

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC25 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ5 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neopas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dgabapentin
#4Drandomized controlled trialmptnOR randomizedmtiabnOR placebomtiabnORiclinical trials as topicmmeshFnoexpnjORicontrolled clinical trialmptnjOR randomlymtiabnOR trialmtin
#5Dhumansmmhn
#6D#1 AND #2 AND #3 AND #4 AND #5
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese

<ƒKƒoƒyƒ“ƒ`ƒ“ˆČŠO‚̍R‚Ä‚ń‚Š‚ń–ň>

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC19 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ4 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neopas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dopioid
#4Danticonvulsant
#5Drandomized controlled trialmptnOR randomizedmtiabnOR placebomtiabnORiclinical trials as topicmmeshFnoexpnjORicontrolled clinical trialmptnjOR randomlymtiabnOR trialmtin
#6Dhumansmmhn
#7D#1 AND #2 AND #3 AND #4 AND #5 AND #6
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese

<R•sŽ–Ź–ň>

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC30 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ5 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neopas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dopioid
#4Dlolal anesthetic agents
#5Drandomized controlled trialmptnOR randomizedmtiabnOR placebomtiabnORiclinical trials as topicmmeshFnoexpnjORicontrolled clinical trialmptnjOR randomlymtiabnOR trialmtin
#6Dhumansmmhn
#7D#1 AND #2 AND #3 AND #4 AND #5 AND #6
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese

<R‚¤‚–ň>

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC9 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ2 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neopas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dopioid
#4Dantidepressants
#5Drandomized controlled trialmptnOR randomizedmtiabnOR placebomtiabnORiclinical trials as topicmmeshFnoexpnjORicontrolled clinical trialmptnjOR randomlymtiabnOR trialmtin
#6Dhumansmmhn
#7D#1 AND #2 AND #3 AND #4 AND #5 AND #6
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese

m—Տ°‹^–â45niŽQĆj

‚Ş‚ń‚É‚ć‚é_ŒoáŠQŤáu’É‚Ě‚ ‚銳ŽŇ‚ɑ΂ľ‚āC‚ ‚é’Á’ɕ⏕–ň‚đ‘—Ę‚ľ‚Ä‚ŕŒř‰Ę‚Ş‚Č‚˘ę‡C‘ź‚Ě’Á’ɕ⏕–ň‚Ö‚Ě•ĎX‚â•š—p‚́Cs‚í‚Č‚˘‚ą‚Ć‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC86 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ1 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neopas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Drandomized controlled trialmptnOR randomizedmtiabnOR placebomtiabnORiclinical trials as topicmmeshFnoexpnjORicontrolled clinical trialmptnjOR randomlymtiabnOR trialmtin
#4Dhumansmmhn
#5D#1 AND #2 AND #3 AND #4
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese

‚Q
œ“]ˆÚ‚É‚ć‚é’É‚Ý

œ œ“]ˆÚ‚É‚ć‚é’ɂ݂ɑ΂ˇ‚é—LŒř‚ČŽĄ—Â͉˝‚ŠH

m—Տ°‹^–â46niŽQĆj

œ“]ˆÚ‚É‚ć‚é’É‚Ý‚Ě‚ ‚é‚Ş‚ńŠłŽŇ‚ɑ΂ľ‚āCs‚¤‚ׂŤ•]‰ż‚͉˝‚ŠH

•śŒŁŒŸő‚͍s‚í‚Č‚Š‚Á‚˝B

m—Տ°‹^–â47niŽQĆj

œ“]ˆÚ‚É‚ć‚é’É‚Ý‚Ě‚ ‚é‚Ş‚ńŠłŽŇ‚ɑ΂ľ‚āC”ńƒIƒsƒIƒCƒh’Á’É–ňEƒIƒsƒIƒCƒh‚É‚ć‚éáu’ÉŽĄ—ẤCƒvƒ‰ƒZƒ{‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC51 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ‚ŕ‚Ě‚Í0 Œ‚Ĺ‚ ‚Á‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dopioid OR morphine OR fentanyl OR oxycodone
#4Dbone pain OR bone metastasis
#5D#1 AND #2 AND #3 AND #4
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

m—Տ°‹^–â48niŽQĆj

œ“]ˆÚ‚É‚ć‚é’É‚Ý‚Ě‚ ‚é‚Ş‚ńŠłŽŇ‚ɑ΂ľ‚āCƒrƒXƒzƒXƒzƒl[ƒgCƒfƒmƒXƒ}ƒu‚Č‚Ç‚Ěbone-modifying agentsiBMAj‚́Cƒvƒ‰ƒZƒ{‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

Œn““I•śŒŁŒŸő‚͍s‚킸Cochrane Library ‚Š‚çŠY“–‚ˇ‚éƒ^ƒCƒgƒ‹1 Œ‚đ‘I‘đ‚ľ‚˝B

‚R
äX‘Ÿ‚Ş‚ń‚Č‚Ç‚É‚ć‚éă• •”‚Ě’É‚Ý

œ äX‘Ÿ‚Ş‚ń‚Č‚Ç‚É‚ć‚éă• •”‚̒ɂ݂ɑ΂ˇ‚é—LŒř‚ČŽĄ—Â͉˝‚ŠH

m—Տ°‹^–â49niŽQĆj

äX‘Ÿ‚Ş‚ń‚Č‚Ç‚É‚ć‚éă• •”‚Ě’É‚Ý‚Ě‚ ‚銳ŽŇ‚ɑ΂ľ‚āCs‚¤‚ׂŤ•]‰ż‚͉˝‚ŠH

•śŒŁŒŸő‚͍s‚í‚Č‚Š‚Á‚˝B

m—Տ°‹^–â50niŽQĆj

äX‘Ÿ‚Ş‚ń‚Č‚Ç‚É‚ć‚éă• •”‚Ě’É‚Ý‚Ě‚ ‚銳ŽŇ‚ɑ΂ľ‚āC”ńƒIƒsƒIƒCƒh’Á’É–ňEƒIƒsƒIƒCƒh‚É‚ć‚éáu’ÉŽĄ—ẤCƒvƒ‰ƒZƒ{‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠHH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC340 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ‚ŕ‚Ě‚Í0 Œ‚Ĺ‚ ‚Á‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dopioid OR morphine OR fentanyl OR oxycodone
#4Dabdominal OR epigastrium OR middle OR upper abdomen OR pancreas cancer
#5Danesthesia OR medication
#6D#1 AND #2 AND #3 AND #4 AND #5
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

m—Տ°‹^–â51niŽQĆj

äX‘Ÿ‚Ş‚ń‚Č‚Ç‚É‚ć‚éă• •”‚Ě’É‚Ý‚Ě‚ ‚銳ŽŇ‚ɑ΂ľ‚āC_ŒoƒuƒƒbƒN‚́C–ň•¨—Ă–@‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC340 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ‚ŕ‚Ě‚Í2 Œ‚Ĺ‚ ‚Á‚˝BŒn““IƒŒƒrƒ…[‚ÉŠÜ‚Ü‚ę‚éd•Ą‚ˇ‚é˜_•ś‚͏œ‚˘‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dopioid OR morphine OR fentanyl OR oxycodone
#4Dabdominal OR epigastrium OR middle OR upper abdomen OR pancreas cancer
#5Danesthesia OR medication
#6Dnerve block
#7D#1 AND #2 AND #3 AND #4 AND #5 AND #6
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

‚S
‹š•”‚Ě’É‚Ý

œ ‹š•”‚̒ɂ݂ɑ΂ˇ‚é—LŒř‚ČŽĄ—Â͉˝‚ŠH

m—Տ°‹^–â52niŽQĆj

‹š•”‚Ě’É‚Ý‚Ě‚ ‚é‚Ş‚ńŠłŽŇ‚ɑ΂ľ‚āCs‚¤‚ׂŤ•]‰ż‚͉˝‚ŠH

•śŒŁŒŸő‚͍s‚í‚Č‚Š‚Á‚˝B

m—Տ°‹^–â53niŽQĆj

‹š•”‚Ě’É‚Ý‚Ě‚ ‚é‚Ş‚ńŠłŽŇ‚ɑ΂ľ‚āC”ńƒIƒsƒIƒCƒh’Á’É–ňEƒIƒsƒIƒCƒh‚É‚ć‚éáu’ÉŽĄ—ẤCƒvƒ‰ƒZƒ{‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC239 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ‚ŕ‚Ě‚Í0 Œ‚Ĺ‚ ‚Á‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dopioid OR morphine OR fentanyl OR ocycodone
#4Dchest OR thoracic OR back OR mamma OR esophagus OR mediastinum
#5Danesthesia OR medication
#6D#1 AND #2 AND #3 AND #4 AND #5
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

m—Տ°‹^–â54niŽQĆj

‹š•”‚Ě’É‚Ý‚Ě‚ ‚é‚Ş‚ńŠłŽŇ‚ɑ΂ľ‚āC_ŒoƒuƒƒbƒN‚́C–ň•¨—Ă–@‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC239 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ‚ŕ‚Ě‚Í0 Œ‚Ĺ‚ ‚Á‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dchest OR thoracic OR back OR mamma OR esophagus OR mediastinum
#4Dopioid OR morphine OR fentanyl OR ocycodone
#5Danesthesia OR medication
#6Dblock OR cordotomy OR ablation
#7D#1 AND #2 AND #3 AND #4
#8D#1 AND #2 AND #4 AND #5
#9D#1 AND #2 AND #3 AND #6
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

‚T
’ź’°‚Ş‚ń‚Č‚Ç‚É‚ć‚é‰ď‰A•”‚Ě’É‚Ý

œ ’ź’°‚Ş‚ń‚Č‚Ç‚É‚ć‚é‰ď‰A•”‚̒ɂ݂ɑ΂ˇ‚é—LŒř‚ČŽĄ—Â͉˝‚ŠH

m—Տ°‹^–â55niŽQĆj

’ź’°‚Ş‚ń‚Č‚Ç‚É‚ć‚é‰ď‰A•”‚Ě’É‚Ý‚Ě‚ ‚銳ŽŇ‚ɑ΂ľ‚āCs‚¤‚ׂŤ•]‰ż‚͉˝‚ŠH

•śŒŁŒŸő‚͍s‚í‚Č‚Š‚Á‚˝B

m—Տ°‹^–â56niŽQĆj

’ź’°‚Ş‚ń‚Č‚Ç‚É‚ć‚é‰ď‰A•”‚Ě’É‚Ý‚Ě‚ ‚銳ŽŇ‚ɑ΂ľ‚āC”ńƒIƒsƒIƒCƒh’Á’É–ňEƒIƒsƒIƒCƒh‚É‚ć‚éáu’ÉŽĄ—ẤCƒvƒ‰ƒZƒ{‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC301 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ‚ŕ‚Ě‚Í0 Œ‚Ĺ‚ ‚Á‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dblock OR anesthesia
#4Drectal OR pelvis OR pelvic OR perineal OR perineum OR anal OR anus OR perianal OR genital OR genitalia OR urogenital OR lumbosacral OR sacral OR coccygeal OR saddle
#5D#1 AND #2 AND #3 AND #4
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

m—Տ°‹^–â57niŽQĆj

’ź’°‚Ş‚ń‚Č‚Ç‚É‚ć‚é‰ď‰A•”‚Ě’É‚Ý‚Ě‚ ‚銳ŽŇ‚ɑ΂ľ‚āC_ŒoƒuƒƒbƒN‚́C–ň•¨—Ă–@‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC301 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ1 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dblock OR anesthesia
#4Drectal OR pelvis OR pelvic OR perineal OR perineum OR anal OR anus OR perianal OR genital OR genitalia OR urogenital OR lumbosacral OR sacral OR coccygeal OR saddle
#5D#1 AND #2 AND #3 AND #4
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

‚U
ˆŤŤ’°˜‹ŘÇŒóŒQ‚É‚ć‚é’É‚Ý
i’°˜‹Ř‚Ö‚Ě‚Ş‚ń‚̐ZE“]ˆÚ‚É”ş‚Á‚Ä‹N‚ą‚é‘lŒa•”E‘ĺ‘ځE•G‚̒ɂ݁j

œ ˆŤŤ’°˜‹ŘÇŒóŒQ‚É‚ć‚é’ɂ݂ɑ΂ˇ‚é—LŒř‚ČŽĄ—Â͉˝‚ŠH

m—Տ°‹^–â58niŽQĆj

ˆŤŤ’°˜‹ŘÇŒóŒQ‚É‚ć‚é’É‚Ý‚Ě‚ ‚é‚Ş‚ńŠłŽŇ‚ɑ΂ľ‚āCs‚¤‚ׂŤ•]‰ż‚͉˝‚ŠH

•śŒŁŒŸő‚͍s‚í‚Č‚Š‚Á‚˝B

m—Տ°‹^–â59niŽQĆj

ˆŤŤ’°˜‹ŘÇŒóŒQ‚É‚ć‚é’É‚Ý‚Ě‚ ‚é‚Ş‚ńŠłŽŇ‚ɑ΂ľ‚āC”ńƒIƒsƒIƒCƒh’Á’É–ňEƒIƒsƒIƒCƒh‚É‚ć‚éáu’ÉŽĄ—ẤCƒvƒ‰ƒZƒ{‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC3 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ‚ŕ‚Ě‚Í0 Œ‚Ĺ‚ ‚Á‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dpsoas syndrome OR malignant psoas syndrome
#4D#1 AND #2 AND #3
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

m—Տ°‹^–â60niŽQĆj

ˆŤŤ’°˜‹ŘÇŒóŒQ‚É‚ć‚é’É‚Ý‚Ě‚ ‚é‚Ş‚ńŠłŽŇ‚ɑ΂ľ‚āC‹Ř’oŠÉ–ň‚́Cƒvƒ‰ƒZƒ{‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC3 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ‚ŕ‚Ě‚Í0 Œ‚Ĺ‚ ‚Á‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dpsoas syndrome OR malignant psoas syndrome
#4D#1 AND #2 AND #3
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

m—Տ°‹^–â61niŽQĆj

ˆŤŤ’°˜‹ŘÇŒóŒQ‚É‚ć‚é’É‚Ý‚Ě‚ ‚é‚Ş‚ńŠłŽŇ‚ɑ΂ľ‚āC_ŒoƒuƒƒbƒN‚́C–ň•¨—Ă–@‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC3 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ‚ŕ‚Ě‚Í0 Œ‚Ĺ‚ ‚Á‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dpsoas syndrome OR malignant psoas syndrome
#4D#1 AND #2 AND #3
LimitsF1995/01/01 to 2008/07/31, Humans, English, Japanese,

clinicaltrial/Meta-analysis/Randomized controlled trial/Controlled
clinical trial

‚V
Á‰ťŠÇ•ÂÇ‚É‚ć‚é’É‚Ý

œ Á‰ťŠÇ•ÂÇ‚É‚ć‚é’ɂ݂ɑ΂ˇ‚é—LŒř‚ČŽĄ—Â͉˝‚ŠH

m—Տ°‹^–â62niŽQĆj

Á‰ťŠÇ•ÂÇ‚É‚ć‚é’É‚Ý‚Ě‚ ‚é‚Ş‚ńŠłŽŇ‚ɑ΂ľ‚āCs‚¤‚ׂŤ•]‰ż‚͉˝‚ŠH

•śŒŁŒŸő‚͍s‚í‚Č‚Š‚Á‚˝B

m—Տ°‹^–â63niŽQĆj

Á‰ťŠÇ•ÂÇ‚É‚ć‚é’É‚Ý‚Ě‚ ‚é‚Ş‚ńŠłŽŇ‚ɑ΂ľ‚āC”ńƒIƒsƒIƒCƒh’Á’É–ňEƒIƒsƒIƒCƒh‚É‚ć‚éáu’ÉŽĄ—ẤCƒvƒ‰ƒZƒ{‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC16 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ‚ŕ‚Ě‚Í0 Œ‚Ĺ‚ ‚Á‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dmorphine OR fentanyl OR oxycodone OR opioid OR opiate OR pentazocine OR buprenorphine OR tramadol OR codeine
#4DIntestinal obstruction ORiibowel OR intestine OR gastrointestinal OR colon OR colorectal OR retrosigmoidj ANDiobstruct OR blockagejj
#5D#1 AND #2 AND #3 AND #4
LimitsFPublication Date from 1995/01/01 to 2008/07/31, Humans, English, Japanese, All AdultF19{years

m—Տ°‹^–â64niŽQĆj

Á‰ťŠÇ•ÂÇ‚É‚ć‚é’É‚Ý‚Ě‚ ‚é‚Ş‚ńŠłŽŇ‚ɑ΂ľ‚āCÁ‰ťŠÇ•Ş”ĺ—}§–ňiƒIƒNƒgƒŒƒIƒ`ƒh|Ž_‰–Cƒuƒ`ƒ‹ƒXƒRƒ|ƒ‰ƒ~ƒ“L‰ť•¨j‚́Cƒvƒ‰ƒZƒ{‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC12 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ3 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–ORmetastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dsomatostatin OR octreotide
#4Dscopolamine butylbromideh OR ghyoscinebutylbromideh OR gButylscopolammonium Bromideh
#5DIntestinal obstruction ORiibowel OR intestine OR gastrointestinal OR colon OR colorectal OR retrosigmoidjANDiobstruct OR blockagejj
#6D#1 AND #2 AND #5 ANDi#3 OR #4j
LimitsFPublication Date from 1995/01/01 to 2008/07/31, Humans, English, Japanese, All AdultF19{years

m—Տ°‹^–â65niŽQĆj

Á‰ťŠÇ•ÂÇ‚É‚ć‚é’É‚Ý‚Ě‚ ‚é‚Ş‚ńŠłŽŇ‚ɑ΂ľ‚āCƒRƒ‹ƒ`ƒRƒXƒeƒƒCƒh‚́Cƒvƒ‰ƒZƒ{‚É”äŠr‚ľ‚Ä’É‚Ý‚đŠÉ˜a‚ˇ‚é‚ŠH

ˆČ‰ş‚ĚŒŸőŽŽ‚ĹPUBMED ‚đŒŸő‚ľ‚˝‚Ć‚ą‚ëC12 Œ‚ŞŠY“–‚ľ‚˝B‚ą‚ę‚ɉÁ‚Ś‚āChand searchCCochrane Library ‚ĚŠY“–€–ځCŠů‘ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Č‚Ç‚Ěˆř—p•śŒŁ‚Ě‚¤‚żC—Տ°‹^–â‚ÉŠÖ˜A‚ľC“KŠiŠî€‚đ–ž‚˝‚ˇ3 Œ‚ɂ‚ŤŒŸ“˘‚ľ‚˝B

#1DneoplasmsmmeshFexpnOR neoplas–mtiabnOR cancer–mtiabnOR carcinoma–mtiabnOR tumour–mtiabnOR tumormtiabnOR tumorsmtiabnOR adenocarcinoma–mtiabnOR leukemi–mtiabnOR leukaemi–mtiabnOR lymphoma–mtiabnOR malignan–mtiabnOR oncolog–mtiabnOR metastati–OR metastas–
#2Dpain–mtiabnOR nocicept–mtiabnOR neuropath–mtiabnOR analgesi–mtiabnOR painmmeshF expnOR analgesicsmmeshFexpnOR analgesiammeshFnoexpn
#3Dmorphine OR fentanyl OR oxycodone OR opioid OR opiate OR pentazocine OR buprenorphine OR tramadol OR codeine
#4DAdrenal Cortex Hormones ORi17-ketosteroids OR androstenedione OR androsterone ORiestrone next sulphatejOR etiocholanolone OR prasterone OR dehydroepiandrosterone OR hydroxycorticosteroids ORi11 next hydroxycorticosteroidjOR 17-hydrocorticosteroids OR deoxycorticosterone OR deoxycorticosterone OR pregnenolone OR corticosteroids OR hydrocortisone OR budesonide OR prednisolone OR methylprednisolone OR efcortesol OR hydrocortisone ORisolu next cortexjOR budesonide OR entocort–OR budenofalk ORideltacortril next entericjOR equllenin OR 18-hydroxycorticosterone OR aldosterone OR corticosterone OR hydrocortisone OR hydrocortisone OR tetrahydrocortisol OR tetrahydrocortisol OR cortisone OR cortodoxonej
#5DIntestinal obstruction ORiibowel OR intestine OR gastrointestinal OR colon OR colorectal OR retrosigmoidjANDiobstruct OR blockagejj
#6D#1 AND #2 AND #4 AND #5
LimitsFPublication Date from 1995/01/01 to 2008/07/31, Humans, English, Japanese, All AdultF19{years

iŽÂŒ´–žŽqA—L‰ę‰xŽqj

2D2014 ”N”Ĺ‚ĚŒŸőŽŽ

2010 ”N”Ĺ‚ĚŒŸőŽŽ‚đ—p‚˘‚āC2008 ”N‚Š‚ç2012 ”N12 ŒŽ‚Ü‚ĹŠúŠÔ‚đ‰„’ˇ‚ľ‚ÄŒŸő‚đs‚Á‚˝B‚˝‚ž‚ľCV‹K‚ɒljÁ‚ľ‚˝–ňÜ‚ŞŠÜ‚Ü‚ę‚é—Տ°‹^–â‚ɂ‚˘‚ẮC2010 ”N”Ĺ‚ĚŒŸőŽŽ‚ɐV‹K‚Ě–ňÜ–ź‚đ’ljÁ‚ľC2000 ”N‚Š‚ç2012 ”N12 ŒŽ‚Ü‚ĹŠúŠÔ‚đŠg‘ĺ‚ľ‚ÄŠeŽˇ•MŽŇ‚ŞŒŸő‚đs‚¤‚ą‚Ć‚Ć‚ľ‚˝BÚ×‚ĚŒŸőŒ‹‰Ę‚Í‹LÚ‚ľ‚Č‚˘B

i—]‹{‚Ť‚̂݁CX“c’B–çj


3DĄŒă‚ĚŒŸ“˘‰Ű‘č

1D2010 ”N”Ĺ‚Ĺ‚ĚĄŒă‚ĚŒŸ“˘‰Ű‘č

ˆČ‰ş‚ĚˆÄŒ‚ɂ‚˘‚Ä‚Í2010”N”Ĺ‚ĚƒKƒCƒhƒ‰ƒCƒ“‚̍쐬‰ß’ö‚É‚¨‚˘‚āC‹c˜_‚ľ‚˝‚ŞŽű‘Š‚Ĺ‚Ť‚Č‚Š‚Á‚˝‚˝‚ß‚ŠCŽć‚čă‚°‚ç‚ę‚˝‚ޏ\•Ş‚Č‹c˜_‚đs‚¤ŽžŠÔ‚Ş‚Č‚Š‚Á‚˝‚˝‚߁CŽŸ‰ń‚̉ü’ů‚ĚŰ‚ÉÄ“xŒŸ“˘‚ˇ‚é‚ą‚Ć‚Ć‚ľ‚˝Bu”wŒi’mŽŻv‚ł́C—pŒę‚Ě“ˆę‚ÉŠÖ‚ˇ‚邢‚­‚‚Š‚Ě‹c˜_‚Ş•s\•Ş‚Ĺ‚ ‚čCĄŒăC“ú–{ƒyƒCƒ“ƒNƒŠƒjƒbƒNŠw‰ď‚Č‚Ç‚ĚŠÖ˜AŠw‰ď‚Ć‚ŕ‹Ś—Í‚ľ‚˝‚¤‚Ś‚Ĺ—pŒę‚̐Ž—‚đs‚¤•K—v‚Ş‚ ‚éBu„§v‚ł́CÚ×‚đ‹ď‘Ě“I‚É‹LÚ‚Ĺ‚Ť‚Č‚Š‚Á‚˝€–ڂŁCƒGƒrƒfƒ“ƒX‚Ş•s\•Ş‚Ĺ‚ ‚Á‚˝‚˝‚߁C‚ą‚ę‚ç‚Ě—Ěˆć‚Ě—Ő°Œ¤‹†‚𐄐i‚ˇ‚é•K—v‚Ş‚ ‚éB

❶ 2010 ”N”Ĺ‚ĚƒKƒCƒhƒ‰ƒCƒ“‚ł́C‘Ήž‚ľ‚Č‚Š‚Á‚˝‚ą‚Ƃɂ‚˘‚Ä
  • ‚˘‚í‚ä‚éƒg[ƒ^ƒ‹ƒyƒCƒ“‚Ć‚ľ‚Ä‚Ě’É‚Ý‚Ě•]‰ż‚â‘Ήž‚đŒŸ“˘‚ˇ‚é‚ą‚Ć
  • ŠłŽŇE‰Ć‘°‚Ć‚Ě’É‚Ý‚ÉŠÖ‚ˇ‚éƒRƒ~ƒ…ƒjƒP[ƒVƒ‡ƒ“‚ɂ‚˘‚ÄŽ–€‚đŒŸ“˘‚ˇ‚é‚ą‚Ć
  • ŠÉ˜aƒPƒA‚đ’S“–‚ˇ‚éˆăŽt‚ƁC‚Ş‚ń‚ĚŽĄ—Ă‚É‚ ‚˝‚éˆăŽt‚Č‚ÇŠÉ˜aƒPƒA‚đę–ĺ‚Ć‚ľ‚Č‚˘ˆăŽtCŠĹŒěŽtC–ňÜŽt‚Č‚Ç‚Ě˜AŒg‚âƒ`[ƒ€ˆă—Âɂ‚˘‚Ä‚Ě€–Ú‚đŒŸ“˘‚ˇ‚é‚ą‚Ć
  • “Á‚ɍݑîˆă—Ă‚Ĺ‚Ěáu’ÉŽĄ—Âɂ‚˘‚ÄŒŸ“˘‚ˇ‚é‚ą‚Ć
  • ƒ_ƒCƒWƒFƒXƒg”Ĺ‚Č‚Ç‚ć‚čŠČ•Ö‚Č•‹y”Ĺ‚đěŹ‚ˇ‚é‚ą‚Ć
  • ŒÂX‚Ě–ňÜ‚Ě‹ď‘Ě“I‚ČŽg—p•ű–@‚đÚ×‚ɁCŠČ•Ö‚É‹LÚ‚ˇ‚é‚ą‚Ć
  • ƒKƒCƒhƒ‰ƒCƒ“‚ÉŠî‚Ă‚­f—Ă‚ĚŽż‚đ•]‰ż‚ˇ‚é•ű–@iclinical indicatorj‚đěŹ‚ˇ‚é‚ą‚Ć
  • “ú–{ŠÉ˜aˆă—ĂŠw‰ď‚Ě’ńŽŚ‚ľ‚Ä‚˘‚é‘ź‚ĚŽ–‹Ć‚ĹŽg—p‚ł‚ę‚Ä‚˘‚éáu’ɃKƒCƒhƒ‰ƒCƒ“‚Ƃ̐Ž‡Ť‚ɂ‚˘‚ÄÚ×‚Č‹LÚ‚đ‚ˇ‚é‚ą‚Ć
  • „§‚Ě‹­‚ł‚ĆƒGƒrƒfƒ“ƒXƒŒƒxƒ‹‚Ě•]‰ż‚ĚƒvƒƒZƒX‚ĚÚ×‚đ‹LÚ‚ˇ‚é‚ą‚Ć
❷ ”wŒi’mŽŻC—pŒę‚Ě’č‹`‚ɂ‚˘‚Ä
  • uáu’Ɂv‚Ɓu’ɂ݁v‚Ě‹ć•Ę‚ɂ‚˘‚ďڍׂɌŸ“˘‚ˇ‚é‚ą‚Ć
  • u‚Ş‚ńáu’Ɂv‚Ɓu‚Ş‚ńŤáu’Ɂv‚Ě‹ć•Ę‚ɂ‚˘‚ďڍׂɌŸ“˘‚ˇ‚é‚ą‚Ć
  • u‚Ş‚ńáu’Ɂv‚Ě•Ş—Ţiu‚Ş‚ń‚É‚ć‚éáu’Ɂv‚âu‚Ş‚ńŽŠ‘Ě‚É‚ć‚éáu’Ɂv‚Ě•\‹L‚Ȃǁj‚ƁC‚Ş‚ńáu’É‚Ş‚Ç‚Ě”ÍˆÍ‚đŽw‚ˇ‚Ě‚Š‚ɂ‚˘‚ďڍׂɌŸ“˘‚đs‚¤‚ą‚Ć
  • Oncology emergency ‚ĚĹ‚ŕ“KŘ‚Č“ú–{Œę–ó‚ɂ‚˘‚ÄÚ×‚ĚŒŸ“˘‚đs‚¤‚ą‚Ć
  • “ˏo’É‚ĚƒTƒuƒ^ƒCƒv‚Ě•Ş—Ţ‚ĆCu”ş’ɁvCu‘Ě“ŽŽž’Ɂv‚Ě’č‹`‚ɂ‚˘‚Ä‚ć‚čÚ×‚ÉŒŸ“˘‚ˇ‚é‚ą‚Ć
  • “ˏo’É‚Ě‚¤‚żC’É‚Ý‚Ě—Uˆö‚Ě‚Č‚˘‚ŕ‚́i—Uˆö‚Ě‚Č‚˘“ˏo’ɁCspontaneous painj‚Ě“ú–{Œę–ó‚đÚ×‚ÉŒŸ“˘‚ˇ‚é‚ą‚Ć
  • End-of-dose failure ‚Ě“ú–{Œę–ó‚Ć‚ľ‚āCu’莞’Á’É–ň‚́E’čŠú’Á’É–ň‚́vuŘ‚ęŰ‚́EŘ‚ę–ڂ́vu’ɂ݁Eáu’Ɂv‚Ě‘g‚ݍ‡‚í‚š‚Ě‚˘‚¸‚ę‚ŞĹ‚ŕ“KŘ‚Š‚đÚ×‚ÉŒŸ“˘‚ˇ‚é‚ą‚Ć
  • End-of-dose failure ‚đ“ˏo’É‚Ć‚ľ‚Ĉľ‚¤‚ׂŤ‚ŠCŽ‘ą’É‚Ć‚ľ‚Ĉľ‚¤‚ׂŤ‚Š‚đ‚ł‚ç‚ɏڍׂɌŸ“˘‚ˇ‚é‚ą‚Ć
  • —ŐŽž’ljÁ“Š—^—Ę‚Ě‹LÚ•ű–@‚ށCu—ŐŽž’ljÁ“Š—^—ʁiƒŒƒXƒLƒ…[Eƒh[ƒYjvCuƒŒƒXƒLƒ…[Eƒh[ƒYv‚Č‚Ç‚˘‚¸‚ę‚Ş“KŘ‚Š‚ɂ‚˘‚ďڍׂɌŸ“˘‚ˇ‚é‚ą‚Ć
  • u従Ž’Ɂv‚Ɓuál’Ɂv‚ĚˆŮ“Ż‚ɂ‚˘‚ďڍׂɌŸ“˘‚ˇ‚é‚ą‚Ć
  • u’ɂ݂̕“I•]‰żv‚Ć‚˘‚Á‚˝ę‡‚ɁC¸_“ICŽĐ‰ď“ICƒXƒsƒŠƒ`ƒ…ƒAƒ‹‚Č‹ę’É‚ĚŒŸ“˘‚đŠÜ‚ß‚é“_‚É‚Ü‚ĹŒž‹y‚ˇ‚é‚Š‚đŒŸ“˘‚ˇ‚é‚ą‚ƁC‚¨‚ć‚сCu’ɂ݂̕“I•]‰żv‚Ć‚˘‚¤•\Œť‚đŒŠ’ź‚ľ‚Ä‚ć‚č“KŘ‚Č•\Œť‚ɏCł‚ˇ‚é‚ą‚Ć
  • ’ɂ݂̐Ťó‚Ě•\Œť‚Ć‚ľ‚āCuŽÜ‚Ż‚é‚悤‚ȁvCuƒr[ƒ“‚Ć‘–‚é‚悤‚ȁvCu‘„‚Ĺ“Ë‚Ť‚Ę‚Š‚ę‚é‚悤‚ȁvˆČŠO‚Ě•\Œť‚ɂ‚˘‚С‚荾‚Ţ‚ą‚Ć
  • ’É‚Ý‚đ•]‰ż‚ˇ‚é‚˝‚ß‚Ě•Ą”‚ĚŽÚ“x‚â•ű–@‚Ě‚¤‚ż‚Ç‚ĚŽg—p‚đ„§‚ˇ‚é‚Š‚𖞊m‚É‹LÚ‚ˇ‚é‚ą‚Ć
  • ƒIƒsƒIƒCƒh‚Ě‘ĺ—Ę“Š—^‚É”ş‚Á‚Đś‚ś‚é’ÉŠo‰ß•q‚đŠÜ‚ŢÇŒóŒQiparadoxical painCopioid-induced neurotoxicityCopioid hyperalgesia ‚Ȃǁj‚̐f’fŠî€‚đ–ž‹L‚ˇ‚é‚ą‚Ć
  • uáu’ÉŽĄ—Áv‚Ɓuáu’Ƀ}ƒlƒWƒƒ“ƒgv‚Ě’č‹`‚ɂ‚˘‚ÄÚ×‚đŒŸ“˘‚ˇ‚é‚ą‚Ć
  • ƒIƒsƒIƒCƒhƒ[ƒe[ƒVƒ‡ƒ“CƒIƒsƒIƒCƒh‚Ě•ĎXCopioid switching ‚Ě‚˘‚¸‚ę‚Ě—pŒę‚Ş“KŘ‚Ĺ‚ ‚é‚Š‚đÚ×‚ÉŒŸ“˘‚ˇ‚é‚ą‚Ć
  • u‹¤’Ę‚ˇ‚éáu’ÉŽĄ—Áv‚đ•Ö‹X“I‚É’u‚˘‚˝‚ą‚Ć‚Ě‘Ă“–Ť‚đÚ×‚ÉŒŸ“˘‚ˇ‚é‚ą‚Ć
  • ˆŤŤ’°˜‹ŘÇŒóŒQ‚đŒÂ•Ę‚Ɉľ‚¤ˆÓ‹`‚ɂ‚˘‚ďڍׂɌŸ“˘‚ˇ‚é‚ą‚Ć
  • t•s‘SC“§ÍŠłŽŇ‚ɑ΂ˇ‚éƒIƒsƒIƒCƒh‚Ě‘I‘đ‚âŽg—p•ű–@‚đ‹ď‘Ě“I‚É‹LÚ‚ˇ‚é‚ą‚Ć
  • ƒuƒvƒŒƒmƒ‹ƒtƒBƒ“Cƒyƒ“ƒ^ƒ]ƒVƒ“‚ȂǁC–{ƒKƒCƒhƒ‰ƒCƒ“‚̐„§‚ŐG‚ę‚Č‚Š‚Á‚˝ƒI
  • ƒsƒIƒCƒh‚ɂ‚˘‚Ä‚ĚÚ×‚đ‹LÚ‚ˇ‚é‚ą‚Ć
❸ ĄŒă‚ĚŒŸ“˘‚âCV‚˝‚ČŒ¤‹†‚Ě•K—v‚Č‚ą‚Ć
  • ”ńƒXƒeƒƒCƒhŤÁ‰Š’Á’É–ňiNSAIDsj‚đŒř‰Ę•s\•Ş‚Č‚˝‚ß•ĎX‚ˇ‚鎞‚́C‹ď‘Ě“I‚ČNSAIDs ‚ĚŽí—ނƁC•ĎX‰ń”‚ɂ‚˘‚Ä‹LÚ‚ˇ‚é‚ą‚Ć
  • ƒIƒsƒIƒCƒh–˘“Š—^‚ĚŠłŽŇ‚ɁCƒtƒFƒ“ƒ^ƒjƒ‹“\•tÜ‚đ“Š—^‚ˇ‚é‘ÎŰ‚â“K‰ž‚Ȃǂɂ‚˘‚Ä‹LÚ‚ˇ‚é‚ą‚Ć
  • ƒIƒsƒIƒCƒh‚đŠJŽn‚ˇ‚鎞‚ɁC‰şÜ‚đ•š—p‚ľ•Ö”é‚đ—\–h‚ˇ‚é‚ć‚č‹ď‘Ě“I‚Č•ű–@‚ɂ‚˘‚Ä‹LÚ‚ˇ‚é‚ą‚Ć
  • ƒIƒsƒIƒCƒh‚đŠJŽn‚ˇ‚鎞‚ɁC§“f–ň‚đ•š—p‚ľˆŤSEšq“f‚đ—\–h‚ˇ‚é‚ć‚č‹ď‘Ě“I‚Č•ű–@‚ɂ‚˘‚Ä‹LÚ‚ˇ‚é‚ą‚Ć
  • ƒIƒsƒIƒCƒh‚Ĺ“KŘ‚Č’Á’ÉŒř‰Ę‚Ş“ž‚ç‚ę‚Č‚˘ŽžCƒIƒsƒIƒCƒh‚ĆƒRƒ‹ƒ`ƒRƒXƒeƒƒCƒh‚Ş—LŒř‚Ĺ‚ ‚éCŠłŽŇ‚Ě“ÁŤC•a‘ԁC’ɂ݂̐ŤóC“Á’Ľ‚ɂ‚˘‚ďڍׂđ‹LÚ‚ˇ‚é‚ą‚Ć
  • ’莞’Á’É–ň‚̐؂ę–ڂ̒ɂ݁iend-of-dose failurej‚Ě‚ ‚銳ŽŇ‚ɑ΂ľ‚āC‚ǂ̂悤‚ČŽĄ—Ă‚đs‚¤‚ŠC‚ć‚č‹ď‘Ě“I‚É‹LÚ‚ˇ‚é‚ą‚Ć
  • ƒIƒsƒIƒCƒh‚đŠJŽnŒă‚ɁCˆŤSEšq“f‚Ş‚ ‚銳ŽŇ‚ɑ΂ľ‚āC‘z’č‚ł‚ę‚é•a‘Ԃɉž‚ś‚Ч“f–ň‚đ“Š—^‚ˇ‚é‚ą‚Ƃ́Cˆę—Ľ‚É“Żˆę‚̐§“f–ň‚đ“Š—^‚ˇ‚é‚ą‚Ć‚Ć”äŠr‚ľ‚āCˆŤSEšq“f‚đ‰ü‘P‚ˇ‚é‚Š‚đŒŸ“˘‚ˇ‚é‚ą‚Ć
  • •Ö”é‚Ě’č‹`‚ɂ‚˘‚ďڍׂɌŸ“˘‚ľC‘€ě“I‚Č’č‹`‚đ‹LÚ‚ˇ‚é‚ą‚Ć
  • ƒIƒsƒIƒCƒh‚đŠJŽnŒă‚ɁC‚š‚ń–Ď‚Ş‚ ‚銳ŽŇ‚ɑ΂ľ‚āCR¸_•a–ň‚đ“Š—^‚ˇ‚é‚ą‚Ƃ̐„§“x‚đŒŸ“˘‚ˇ‚é‚ą‚Ć
  • _ŒoáŠQŤáu’ɂɑ΂ľ‚āC’Á’ɕ⏕–ň‚đ“Š—^‚ˇ‚é‚ą‚Ƃ̐„§“x‚đŒŸ“˘‚ˇ‚é‚ą‚Ć
  • _ŒoáŠQŤáu’ɂɑ΂ľ‚āC’Á’ɕ⏕–ň‚Ş—LŒř‚Ĺ‚ ‚éCŠłŽŇ‚Ě“ÁŤC•a‘ԁC’ɂ݂̐ŤóC“Á’Ľ‚đ‹LÚ‚ˇ‚é‚ą‚Ć
  • _ŒoáŠQŤáu’ɂɑ΂ľ‚āC’Á’ɕ⏕–ň‚đ“Š—^Œă‚ɁCŒř‰Ę•s\•Ş‚Ĺ‚ ‚Á‚˝ę‡‚ɁC’Á’ɕ⏕–ň‚đ•ĎXC‘—ʁC•š—p‚ˇ‚é‚ą‚Ć‚Ě—Ő°“I‘Ă“–Ť‚đ‹LÚ‚ˇ‚é‚ą‚ƁEÁ‰ťŠÇ•ÂÇ‚É‚ć‚é’É‚Ý‚Ě‚ ‚銳ŽŇ‚ɑ΂ľ‚āCNSAIDs ‚Ş—LŒř‚Ĺ‚ ‚é‚Š‚đ‹LÚ‚ˇ‚é‚ą‚Ć
2D2014 ”N”łł̐V‚˝‚ČŒŸ“˘‰Ű‘č
❶ Ą‰ń‚ĚƒKƒCƒhƒ‰ƒCƒ“‚ł́C‘Ήž‚ľ‚Č‚Š‚Á‚˝‚ą‚Ƃɂ‚˘‚Ä
  • –łěˆ×‰ť”äŠrŽŽŒą‚ĹŒř‰Ę‚Č‚ľ‚Ć•ń‚ł‚ę‚˝CƒPƒ^ƒ~ƒ“‚Ě’Á’ɕ⏕–ň‚Ć‚ľ‚Ă̐„§‚ɂ‚˘‚ÄÚ×‚ČŒŸ“˘‚đs‚¤‚ą‚Ć

i—]‹{‚Ť‚̂݁CX“c’B–çj


4DŠCŠO‘ź‹@ŠÖ‚É‚ć‚éáu’ɃKƒCƒhƒ‰ƒCƒ“‚Ě”˛ˆ

–{ƒKƒCƒhƒ‰ƒCƒ“‚ł́C‚Ş‚ńáu’É‚ÉŠÖ‚ľ‚āCŠw‰ď‚Ü‚˝‚Í‚ť‚ę‚ɏ€‚ś‚é‘gD‚ŞěŹEł”F‚ľ‚Ä‚˘‚é‰p•ś‚ĚƒKƒCƒhƒ‰ƒCƒ“‚đƒKƒCƒhƒ‰ƒCƒ“ƒv[ƒ‹‚Ć‚ľ‚˝iƒKƒCƒhƒ‰ƒCƒ“ƒv[ƒ‹EƒŠƒXƒgŽQĆjB

‚ť‚Ě‚Č‚Š‚Š‚çCěŹƒvƒƒZƒX‚Ě•ű–@˜_‚ޏq‚ׂç‚ę‚Ä‚¨‚čC—Տ°“I‚É—LˆÓ‹`‚ĆŽv‚í‚ę‚é8 •Ň‚đ‘I‘đ‚ľC‚ť‚ę‚ç‚Ě‹LÚ‚Ě‚¤‚ż–ň•¨—Ă–@‚ÉŠÖ˜A‚ˇ‚éŠî–{“I‚Č•”•Şi“Á‚ɐ„§ƒŒƒxƒ‹‚Ş‹LÚ‚ł‚ę‚˝•”•ŞjC—Տ°“I‚ɈӋ`‚Ě‚ ‚é‚ĆŽv‚í‚ę‚é•”•Şi‘ź‚̐ę–ĺ‰Ć‚É‘Š’k‚ˇ‚é‚˝‚ß‚É’m‚Á‚Ä‚¨‚­‚ׂŤ‚ą‚ƂȂǁj‚𔲐ˆ‚ľ“K‹X•â‘Ť‚ľ‚āCŽQl‚Ć‚Č‚é‚悤‚ÉˆČ‰ş‚É—v–ń‚ľ‚˝B

‚PDŹl‚Ě‚Ş‚ńáu’ɁFNCCN ‚Ě—Ő°ƒKƒCƒhƒ‰ƒCƒ“iWeb, 2012j
  • National Comprehensive Cancer NetworkiNCCNj‚Ěƒpƒlƒ‹ƒƒ“ƒo[‚É‚ć‚čěŹ‚ł‚ę‚˝ƒRƒ“ƒZƒ“ƒTƒXEƒŒƒ|[ƒg‚ŁC„§ƒJƒeƒSƒŠ[‚Í‚ˇ‚ׂām2An‚Ĺ‚ ‚éi„§ƒJƒeƒSƒŠ[‚́m1C2AC2BC3n‚Ě4 ’iŠK‚ŁCm2An‚́u—Տ°ŒoŒą‚đŠÜ‚Ţ‚â‚â’ႢƒŒƒxƒ‹‚ĚƒGƒrƒfƒ“ƒX‚ÉŠî‚Ă‚ŤC„§‚Ş“KŘ‚Ĺ‚ ‚é‚Ć‚˘‚¤“_‚ĹNCCN “ŕ‚ĚƒRƒ“ƒZƒ“ƒTƒX‚Ş“ˆę‚ľ‚Ä‚˘‚év‚Ć‚ł‚ę‚éjBáu’ɏdÇ“x‚É‚ć‚鎥—ĂƒAƒ‹ƒSƒŠƒYƒ€i}1j‚đŽŚ‚ľ‚Ä‚˘‚é“_CŒÂ•Ę“I‚Č‘˝—lŤ‚đ”F‚ß‚˝‚¤‚Ś‚Ĺ‹ď‘Ě“I‚ȏˆ•ű—Ę‚â‘—Ę‚Ěƒ^ƒCƒ~ƒ“ƒO‚Č‚Ç‚đ—ᎌ‚ľ‚Ä‚˘‚é“_‚đ“Á’Ľ‚Ć‚ˇ‚éBáu’ÉŽĄ—ÁiŠÉ˜aƒPƒAj‚ށC‚Ş‚ńŠłŽŇ‚̐ś‘ś—Ś‚ɉe‹ż‚ˇ‚é‚Ć‚˘‚¤ƒGƒrƒfƒ“ƒX‚Ş“ž‚ç‚ę‚Ä‚Ť‚Ä‚¨‚čC‚Ş‚ńŽĄ—Ă‚ĚŽĄ—ĂŒř‰Ę‚đĹ‘ĺŒŔ‚É“ž‚é‚˝‚ß‚É‚ŕ’É‚Ý‚ĚƒRƒ“ƒgƒ[ƒ‹‚͏d—v‚Ĺ‚ ‚é‚Ć‹­’˛‚ľ‚Ä‚˘‚éB
1j•ďŠ‡“I•]‰ż
  • ’É‚Ý‚ĚdÇ“x‚đNRS ‚Č‚Ç‚đŽg—p‚ľ‚Ä•]‰ż‚ˇ‚éB‚ł‚ç‚ɁC’É‚Ý‚Ě•”ˆĘCśŠˆ‚Ö‚ĚŽxáCŽžŠÔˆöŽqi”­ÇŽžŠúC”­Ç‚Š‚ç‚ĚŒo‰ßCŽ‘ą’É‚Š“ˏo’É‚ŠjCŤói“d‹C‚Ş‘–‚é‚悤‚ȂǁjC‘ˆŤˆöŽq‚ĆŒy‰őˆöŽqC•š‘śÇóCŒťÝ‚Ěáu’ÉŽĄ—Ă‚Ć‚ť‚ĚŒř‰Ę‚Č‚Ç‚đ•]‰ż‚ˇ‚éB
2jNSAIDs ‚ĆƒAƒZƒgƒAƒ~ƒmƒtƒFƒ“
  • ŠłŽŇ‚ŞŒř‰Ę‚đŽŔŠ´‚ˇ‚é–ňÜ‚Ě‚˘‚¸‚ę‚Š‚đŽg—p‚ˇ‚éBˆę”ʂɂ́CƒCƒuƒvƒƒtƒFƒ“400 mg/‰ńC4 ‰ń/“úiĹ‘ĺ3,200 mg/“újC‚Ü‚˝‚́CƒAƒZƒgƒAƒ~ƒmƒtƒFƒ“650 mg ‚đ4 ŽžŠÔ–ˆ‚Ü‚˝‚Í1,000 mg ‚đ6 ŽžŠÔ–ˆiĹ‘ĺ4,000 mg/“új‚đŽg—p‚ˇ‚éBŠĚ‹@”\áŠQ‚ĚŒœ”O‚Š‚çƒIƒsƒIƒCƒh‚Ć‚Ě‡Ü‚͐„§‚ł‚ꂸCFDA ‚ĚĹ‹ß‚Ě„§‚Í3,000 mg/“úˆČ‰ş‚Ć‚Č‚Á‚Ä‚˘‚éB‘I‘đ“ICOX-2 ‘jŠQ–ň‚́CŒŒŹ”‹@”\‚ɉe‹ż‚Ş‚Č‚­CÁ‰ťŠÇ‚̉e‹ż‚ŕ­‚Č‚˘‚ށCt‹@”\áŠQ‚đŒyŒ¸‚ˇ‚é‚ą‚Ć‚ÍŽŚ‚ł‚ę‚Ä‚˘‚Č‚˘B
3jƒIƒsƒIƒCƒh
  • ”ńƒIƒsƒIƒCƒh’Á’É–ň‚đăŒŔ—ĘŽg—pŽžC‚Ü‚˝‚ÍNRS 4 ˆČă‚ĚŽžCƒIƒsƒIƒCƒh‚đŠJŽn‚ˇ‚éB“ˏo’Ɂi‘Ě“ŽŽž’É‚đŠÜ‚ށjC’莞•ž—p‘O‚Ěáu’É‘ˆŤ‚ĚŽž‚ȂǂɁCŒoŒűƒŒƒXƒLƒ…[–ň‚Ć‚ľ‚Ä1 “ú—Ę‚Ě10`20“—Ę‚Ě‘Ź•úŤťÜ‚đ•K—vŽž1 ŽžŠÔˆČă‚ ‚Ż‚Ä•ž—p‚ľC’ź‹ß24 ŽžŠÔ‚ĚŽg—p—Ę‚đ‚ŕ‚Ć‚ÉŽŠ“K—Ę‚đŒˆ’č‚ľ‚Ä‘—Ę‚ˇ‚éB‘—Ę‚Ě‘Ź‚ł‚͏dÇ“x‚É‚ć‚čˆŮ‚Č‚éi}1jB
  • ƒgƒ‰ƒ}ƒh[ƒ‹‚̐„§—ʂ́C50`100 mg/‰ńC4 ‰ń/“úiĹ‘ĺ400 mg/“új‚ž‚ށCĹ‘ĺ—p—Ę‚đ—p‚˘‚˝ę‡‚Ĺ‚ŕ‚ť‚Ě’Á’ÉŒř‰Ę‚̓‚ƒ‹ƒqƒl‚Č‚Ç‚Ě‹­ƒIƒsƒIƒCƒh‚ć‚č‚͎ア‚ą‚Ć‚É—ŻˆÓ‚Ş•K—v‚Ĺ‚ ‚éB
  • ƒIƒsƒIƒCƒhƒXƒCƒbƒ`ƒ“ƒO‚̍ہCáu’ɃRƒ“ƒgƒ[ƒ‹‚ޗǍD‚ž‚Á‚˝ę‡‚ÍŒđˇ‘ĎŤ‚Ş•sŠŽ‘S‚Ĺ‚ ‚é‰Â”\Ť‚đl—ś‚ľ‚ÄŒvŽZă“™—͉ż‚ĚŠˇŽZ—Ę‚ć‚č25`50“Œ¸—Ę‚ľCƒRƒ“ƒgƒ[ƒ‹•s—Ç‚ž‚Á‚˝ę‡‚Í25“‘—ʁC‚Ü‚˝‚Í“Ż“™—Ę‚ĹŠJŽn‚ˇ‚éBƒuƒvƒŒƒmƒ‹ƒtƒBƒ“Cƒyƒ“ƒ^ƒ]ƒVƒ“‚͐„§‚ł‚ę‚Č‚˘B
  • ƒtƒFƒ“ƒ^ƒjƒ‹“\•tÜ‚ĚŽg—p‚́C’É‚Ý‚Ş•sˆŔ’č‚Čę‡‚͐„§‚ł‚ę‚Č‚˘B‘—Ę‚Í2`3 “ú‚Ě’číó‘ÔŒă‚ĚƒŒƒXƒLƒ…[–ň‚ĚŽg—p—Ę‚đ‚ŕ‚Ć‚ÉŒˆ’股‚éBƒIƒsƒIƒCƒhƒXƒCƒbƒ`ƒ“ƒO‚ĚŰ‚ÍCŒÂlˇ‚Ş‘ĺ‚Ť‚˘‚Ě‚Ĺ“K‹X’˛Ž‚Ş•K—v‚Ĺ‚ ‚éB
  • ƒtƒFƒ“ƒ^ƒjƒ‹”S–Œ‹zŽűÜ‚É‚ć‚郌ƒXƒLƒ…[–ň‚́C‘ź‚ĚƒIƒsƒIƒCƒh‚Ć‚ĚŠˇŽZ”ä‚Í‚Č‚­Cí‚ɍŏ­—Ę‚Š‚çŠJŽn‚ˇ‚é‚ą‚Ć‚Ş–]‚Ü‚ľ‚˘B
  • ƒƒTƒhƒ“‚ĚŽg—p‚́Cę–ĺ‰Ć‚Ö‚Ě‘Š’k‚Ě‚ŕ‚Ć‚És‚¤‚ׂŤ‚Ĺ‚ ‚éB”źŒ¸Šú‚Ş’ˇ‚­CŒÂlˇ‚Ş‘ĺ‚Ť‚˘‚ą‚ƁCƒ‚ƒ‹ƒqƒl‚Ě“Š—^—Ę‚Ş‘‚Ś‚é‚ĆŠˇŽZ”ä‚Ş•Ď‚í‚Á‚Ä‚­‚é‚ą‚ƁCƒ‚ƒ‹ƒqƒl‚Š‚烁ƒTƒhƒ“‚Ö‚ĚŠˇŽZ”ä‚đ‚ť‚Ě‚Ü‚ÜƒƒTƒhƒ“‚Š‚烂ƒ‹ƒqƒl‚Ö‚ĚŠˇŽZ”ä‚Ć‚ľ‚Ä‚ÍŽg—p‚Ĺ‚Ť‚Č‚˘‚ą‚ƁCQTc ‰„’ˇ‚Ě•›ě—p‚Ş‚ ‚é‚ą‚Ć‚Č‚Ç‚É—ŻˆÓ‚ˇ‚ׂŤ‚Ĺ‚ ‚éB

}1@áu’ɏdÇ“x‚ĆƒIƒsƒIƒCƒhŽg—p‚Ě—L–ł‚É‚ć‚鎥—ĂƒAƒ‹ƒSƒŠƒYƒ€

kNCCN ƒKƒCƒhƒ‰ƒCƒ“‚ć‚č‰ü•Ďl

4jƒIƒsƒIƒCƒh‚Ě•›ě—p‘΍ô
  • ƒIƒsƒIƒCƒh‚Ě•›ě—p‚Ě‚¤‚ż•Ö”éˆČŠO‚͈ę”ʂɑϐŤ‚ސś‚ś‚é‚ŞC•›ě—p‚ŞŒp‘ą‚ľ“Ť‚Ěę‡‚́C‘ź‚ĚŒ´ˆö‚đœŠO‚ľ‚˝‚¤‚Ś‚ĹƒIƒsƒIƒCƒhƒXƒCƒbƒ`ƒ“ƒO‚đŒŸ“˘‚ˇ‚éB
  • •Ö@”éFƒZƒ“ƒi‚Č‚Ç‚Ě‘ĺ’°ŽhŒƒ–ň‚đŽg—p‚ľCˆů…EH•¨‘@ˆŰ‚̐ێć‚â‰^“Ž‚đ‘Ł‚ľ‚Ä•Ö”é‚đ—\–h‚ˇ‚éB‘ź‚Ƀ}ƒOƒlƒVƒEƒ€ÜCƒrƒTƒRƒWƒ‹ÜCƒ‰ƒNƒcƒ[ƒXCƒƒgƒNƒƒvƒ‰ƒ~ƒh‚Č‚Ç‚ĹŽĄ—Ă‚ˇ‚éB

  • ˆŤ@SFƒIƒsƒIƒCƒhˆ•űŽž‚ɂ͐§“f–ňiƒvƒƒNƒƒ‹ƒyƒ‰ƒWƒ“CƒnƒƒyƒŠƒh[ƒ‹CƒƒgƒNƒƒvƒ‰ƒ~ƒh‚Ȃǁj‚đ“Ú—pˆ•ű‚ľC‚˘‚‚łŕŽg—p‚Ĺ‚Ť‚é‚悤‚É‚ˇ‚éB

  • ‚š‚ń–ρFƒnƒƒyƒŠƒh[ƒ‹i0.5`2 mg ‚đ4`6 ŽžŠÔ–ˆ‚ÉŒoŒű/Ă’j‚Ü‚˝‚Í‚ť‚Ě‘ź‚̍R¸_•a–ňiƒIƒ‰ƒ“ƒUƒsƒ“2.5`5 mg ŒoŒű/ă‰şCƒŠƒXƒyƒŠƒhƒ“0.25`0.5 mg ŒoŒűj‚ĹŽĄ—Ă‚ˇ‚éB

  • ŒÄ‹z—}§FˆÓŽŻáŠQ‚ސś‚ś‚éę‡CƒiƒƒLƒ\ƒ“iś—H‰–…‚ĹŠóŽß‚ľC0.04`0.08 mg ‚đ30`60 •b–ˆ‚ɁCÇó‚މü‘P‚ˇ‚é‚Ü‚ĹŒJ‚č•Ô‚ˇj‚őΉž‚ˇ‚éBƒIƒsƒIƒCƒh‚Ě”źŒ¸Šú‚̓iƒƒLƒ\ƒ“‚Ě”źŒ¸Šú‚ć‚č’ˇ‚˘‚Ě‚Ĺ’ˆÓ‚ˇ‚éB10 •ŞˆČ“ŕ‚É1 mg Žg—p‚ľ‚Ä‚ŕˆÓŽŻ‚Ş–ß‚ç‚Č‚˘ę‡‚Í•Ę‚ĚŒ´ˆö‚đl‚Ś‚éB

  • –°‹CE’ÁĂFƒJƒtƒFƒCƒ“Cƒƒ`ƒ‹ƒtƒFƒjƒf[ƒgCdextroamphetamineCƒ‚ƒ_ƒtƒBƒjƒ‹‚Č‚Ç‚Ě•š—pCƒIƒsƒIƒCƒh‚ĚŒ¸—ʁC•p‰ń•ŞŠ„“Š—^‚Č‚Ç‚đŽŽ‚Ý‚éB

5j_ŒoáŠQŤáu’ɂɑ΂ˇ‚é’Á’ɕ⏕–ň
  • _ŒoáŠQŤáu’ɂɑ΂ˇ‚é’Á’ɕ⏕–ň‚Ć‚ľ‚ẮCR‚¤‚–ň‚ƍR‚Ż‚˘‚ę‚ń–ň‚Ş‘ćˆę‘I‘đ‚Ĺ‚ ‚éB
  • R‚¤‚–ňFˆę”ʂɁC‚¤‚•a‚ĚŽĄ—Ă‚Ěę‡‚ć‚č”äŠr“I­—Ę‚ĹŒř‰Ę‚Ş‚ ‚čŒř‰ĘoŒť‚ŕ‘‚˘BƒIƒsƒIƒCƒh‚Ć‚Ě•š—p‚ŁCŽOŠÂŒnR‚¤‚–ň‚đ’á—p—Ę‚ĹŠJŽn‚ľCRƒRƒŠƒ“ě—p‚É‚ć‚é•›ě—p‚É’ˆÓ‚ľ‚Č‚Ş‚ç3`5 “ú–ˆ‚É‘—Ę‚ˇ‚éi—á‚Ś‚΃mƒ‹ƒgƒŠƒvƒ`ƒŠƒ“10`25 mg ‚đAQ‘O‚ĹŠJŽn‚ľC50`150 mg ‚Ü‚Ĺ‘—Ę‚ˇ‚éjB‚˘‚­‚‚Š‚̍R‚¤‚–ňC“Á‚ÉSSRI ‚ÍCYP2D6 ‚Ě—}§‚É‚ć‚čŠĚ‘ăŽÓ‚Ě–ň•¨‚Ě‘ăŽÓ‚ɉe‹ż‚đ—^‚Ś‚é‚ą‚Ć‚Ş–ž‚ç‚Š‚É‚Č‚Á‚Ä‚¨‚čC—ŻˆÓ‚Ş•K—v‚Č–ň•¨‘ŠŒÝě—p‚ŕ•ń‚ł‚ę‚Ä‚˘‚éB

  • R‚Ż‚˘‚ę‚ń–ňFƒIƒsƒIƒCƒh‚Ć•š—p‚ŁCƒKƒoƒyƒ“ƒ`ƒ“100`300 mg AQ‘O‚ĹŠJŽn‚ľC3 “ú–ˆ‚É900`3,600 mgi•Ş2`3j‚Ü‚Ĺ‘—Ę‚ˇ‚é‚ŞC‚—îŽŇEt•s‘SÇ—á‚Ĺ‚Í’ˆÓ‚Ş•K—v‚Ĺ‚ ‚éBƒvƒŒƒKƒoƒŠƒ“‚Ĺ‚Í150 mgi•Ş3j‚ć‚čŠJŽn‚ľC300 mgi•Ş3j‚Ü‚Ĺ‘—Ę‚ˇ‚éB

  • ƒRƒ‹ƒ`ƒRƒXƒeƒƒCƒhF‹Ů‹}Ť‚̍‚‚˘Œƒ’ɂ⍜E_Œo‘p‚ޏáŠQ‚ł‚ę‚˝‚ą‚Ć‚É‚ć‚錃’É‚Ěę‡‚É—L—p‚Ć‚ł‚ę‚éB

6j•a‘Ô‚É‚ć‚é–ňÜ‚Ě‘I‘đ
  • ‰ŠÇ‚É”ş‚¤’É‚Ý‚É‚ÍNSAIDs ‚Ü‚˝‚̓Rƒ‹ƒ`ƒRƒXƒeƒƒCƒhC œ“]ˆÚ’É‚É‚ÍNSAIDsE•úŽËüŽĄ—ÁE_ŒoƒuƒƒbƒNEƒrƒXƒzƒXƒzƒl[ƒgEŠ´ŽóŤ‚Ş‚ ‚éę‡‚É‚Í“ŕ•Ş”ĺ—Ă–@‚≝Šw—Ă–@EƒRƒ‹ƒ`ƒRƒXƒeƒƒCƒh‚ȂǁC_Œoˆł”—‚ɂ̓Rƒ‹ƒ`ƒRƒXƒeƒƒCƒhC_ŒoáŠQŤáu’ɂɂ͍R‚¤‚–ňER‚Ż‚˘‚ę‚ń–ň‚đŽg—p‚ˇ‚éB
7j–ň•¨—Ă–@ˆČŠO‚̑Ήž
  • —Šw—Ă–@“I‚ČƒTƒ|[ƒgi—Šw—Ă–@C“úíśŠˆ“Žě‚ĚƒTƒ|[ƒgCƒ}ƒbƒT[ƒWC‰ˇŠŚŽhŒƒCčI‹„‚ȂǁjC¸_“I‚ČƒTƒ|[ƒgiƒCƒ[ƒW—Ă–@CƒŠƒ‰ƒNƒZ[ƒVƒ‡ƒ“C”F’ms“Ž—Ă–@CƒXƒsƒŠƒ`ƒ…ƒAƒ‹ƒPƒA‚Ȃǁj‚đs‚¤B
  • _ŒoƒuƒƒbƒN‚Ĺ’Á’ÉŒř‰Ę‚̉”\Ť‚Ş‚ ‚éę‡iäX‘Ÿ‚Ş‚ńCă•”Á‰ťŠí‚Ş‚ń‚Ě• o_Œo‘pƒuƒƒbƒN‚âC˜]ŠÔ_ŒoƒuƒƒbƒN‚Ȃǁj‚âCƒIƒsƒIƒCƒhŽĄ—Ă‚Ĺ’Á’ÉŒř‰Ę‚đ“ž‚é‚Ě‚Ş˘“ď‚Čę‡CƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“ŽĄ—Ă‚đ‘Š’k‚ˇ‚éB
‚QD‚Ş‚ńáu’ɂɑ΂ˇ‚éƒIƒsƒIƒCƒh‚ĚŽg—pFƒGƒrƒfƒ“ƒX‚ÉŠî‚Ă‚˘‚˝EAPC ‚̐„§iLancet Oncol, 2012j
  • European Palliative Care Research CollaborativeiEPCRCj‚̐ę–ĺ‰Ćě‹Ć•”‰ď‚ށCŠů‘ś‚ĚEuropean Association for Palliative CareiEAPCjƒKƒCƒhƒ‰ƒCƒ“‚đ‘ź‚ĚƒKƒCƒhƒ‰ƒCƒ“‚Ć”äŠr‚ľ‚čČŸ“˘‚ľCƒVƒXƒeƒ}ƒeƒBƒbƒNƒŒƒrƒ…[‚É‚ć‚éƒGƒrƒfƒ“ƒXƒŒƒxƒ‹‚ɏ]‚Á‚č쐬‚ľ‚˝„§•ś‚Ĺ‚ ‚éB
  • WHO ƒXƒeƒbƒv2 ‚ĚƒIƒsƒIƒCƒhFŒy“x‚Š‚ç’†“™“x‚̒ɂ݁C‚Ü‚˝‚́CƒAƒZƒgƒAƒ~ƒmƒtƒFƒ“‚âNSAIDs ‚ŏ\•Şœ’É‚Ĺ‚Ť‚Č‚˘’ɂ݂ɁCƒXƒeƒbƒv2 ‚ĚŒoŒűƒIƒsƒIƒCƒh‚đ’ljÁ‚ˇ‚é‚ą‚ƂŁCd“Ä‚Č•›ě—p‚ŕ‚Č‚­“KŘ‚ȏœ’É‚Ş“ž‚ç‚ę‚éBƒRƒfƒCƒ“‚âƒgƒ‰ƒ}ƒh[ƒ‹‚Ě‘ă‚í‚č‚ɁCƒXƒeƒbƒv3 ‚ĚƒIƒsƒIƒCƒh‚đ’á—p—Ę‚ĹŽg—p‚ľ‚Ä‚ŕ‚悢mŽă‚˘„§nB

  • WHO ƒXƒeƒbƒv3 ‚Ĺ‚ĚƒIƒsƒIƒCƒh‚Ě‘ćˆę‘I‘đFŒoŒű‚Ěƒ‚ƒ‹ƒqƒlCƒIƒLƒVƒRƒhƒ“Chydromorphone ŠÔ‚É–ž‚ç‚Š‚ȍˇ‚Í‚Č‚˘‚̂ŁC’†“™“xˆČă‚Ě‚Ş‚ńáu’ɂɑ΂ľC‚˘‚¸‚ę‚Š‚đ‘ćˆę‘I‘đ–ň‚Ć‚ľ‚ÄŽg—p‚ˇ‚émŽă‚˘„§nB

  • ƒƒTƒhƒ“F–ň•¨“Ž‘Ô‚Í•ĄŽG‚ŁC”źŒ¸Šú‚Í’ˇ‚˘Bę–ĺ‰Ć‚Ě‚Ý‚ŞC’†“™“xˆČă‚Ě‚Ş‚ńáu’ɂɑ΂ľCƒXƒeƒbƒv3 ‚Ě‘ćˆę‘I‘đ–ň‚ ‚邢‚Í‚ť‚ĚŽŸ‚Ě‘I‘đ–ň‚Ć‚ľ‚ÄŽg—p‚ˇ‚émŽă‚˘„§nB

  • ƒXƒeƒbƒv3 ‚ĚƒIƒsƒIƒCƒh‚ɒljÁ‚ˇ‚éƒAƒZƒgƒAƒ~ƒmƒtƒFƒ“‚âNSAIDs ‚Ě–đŠ„F’Á’ÉŒř‰Ę‚đ‚‚ß‚é‚˝‚߁C‚ ‚邢‚Í’Á’É‚É•K—v‚ČƒIƒsƒIƒCƒh‚Ě—Ę‚đŒ¸‚ç‚ˇ‚˝‚߁CƒXƒeƒbƒv3 ‚ĚƒIƒsƒIƒCƒh‚ÉNSAIDs ‚đ’ljÁ‚ˇ‚éB‚ľ‚Š‚ľCNSAIDs ‚ĚŽg—p‚͏d‘ĺ‚Č•›ě—p‚𔺂¤ƒŠƒXƒN‚Ş‚ ‚é‚̂ŁC“Á‚ɁC‚—îŽŇ‚ât•s‘SCŠĚ•s‘SCS•s‘S‚ĚŠłŽŇ‚Ĺ‚ÍŽg—p‚đ§ŒŔ‚ˇ‚éBƒAƒZƒgƒAƒ~ƒmƒtƒFƒ“‚́CNSAIDs ‚ć‚č•›ě—p‚ޏ­‚Č‚˘‚ą‚ƂŁCƒXƒeƒbƒv3 ‚ĚƒIƒsƒIƒCƒh‚Ćˆę‚ɍD‚ń‚ĹŽg‚í‚ę‚é‚ŞC‚ť‚Ě—LŒřŤ‚ɂ‚˘‚Ä‚ĚŞ‹’‚͏\•Ş‚Ĺ‚Í‚Č‚˘mŽă‚˘„§nB

  • ƒIƒsƒIƒCƒhƒXƒCƒbƒ`ƒ“ƒOFƒXƒeƒbƒv3 ‚ĚƒIƒsƒIƒCƒh‚đŽg—p‚ľ‚Ä‚ŕC\•Ş‚Č’Á’É‚Ş“ž‚ç‚ę‚Č‚˘C•›ě—p‚ޏd“ĂœŤ‚Ĺ‚ ‚éC‚Ü‚˝‚Í‚ť‚Ě—ź•ű‚Ĺ‚ ‚銳ŽŇ‚ł́C‘ź‚ĚƒIƒsƒIƒCƒh‚Ö•ĎX‚ˇ‚émŽă‚˘„§nB

  • ƒIƒsƒIƒCƒh‚Ě“Š—^Œo˜HF”牺“Š—^‚́CŠČ•Ö‚Ĺ‚ ‚č‚Š‚ÂŒř‰Ę“I‚Č•ű–@‚ŁCŒoŒű“Š—^‚âŒo”ç“Š—^i“\•tÜj‚Ş‚Ĺ‚Ť‚Č‚˘ŠłŽŇ‚Ě‘ćˆę‘I‘đ‚Ć‚Č‚éBŽ‘ąĂ’‚́C”牺“Š—^‚Ş‹ÖŠő‚ĚŽži—á‚Ś‚΁C“Š—^—Ę‚Ş‘˝‚˘E––˝•‚ŽîE‹ĂŒĹˆŮí‚ȂǁjC‘‹}‚Éáu’ɃRƒ“ƒgƒ[ƒ‹‚Ş•K—v‚ČŽž‚ÉŽg‚í‚ę‚ém‹­‚˘„§nB

    Ž‘ąĂ’‚⎝‘ą”牺’‚́CŒoŒű“Š—^‚âŒo”ç“Š—^‚ŏ\•Ş‚Č’Á’É‚Ş“ž‚ç‚ę‚Č‚˘ŠłŽŇ‚ÉŽg‚í‚ę‚éBŽŠ•Ş‚ĹƒRƒ“ƒgƒ[ƒ‹‚Ş‚Ĺ‚Ť‚銳ŽŇ‚́CŽ‘ąĂ’‚Ü‚˝‚ÍŽ‘ą”牺’‚É‚ć‚鎊ŒČ’˛ß’Á’É–@iPCAj‚đ‘I‘đ‚Ĺ‚Ť‚éB’ź’°“ŕ“Š—^‚ÍŒř‰Ę“I‚Ĺ‚ ‚é‚ŞC•s‰ő‚Ĺ“KŘ‚Ĺ‚Č‚˘‚ą‚Ć‚ŕ‘˝‚˘‚˝‚ß‘ć“ń‘I‘đ‚Ć‚ˇ‚éB“\•tÜ‚́Cš‹‰ş˘“ď‚ČŠłŽŇ‚ÉŒoŒűƒIƒsƒIƒCƒh‚Ě‘ă‚í‚č‚ɁCƒXƒeƒbƒv3 ‚Ĺ—Dć“I‚ÉŽg‚í‚ę‚éBŒoŒű/”ńŒoŒű“Š—^‚ĚƒIƒsƒIƒCƒhE”ńƒIƒsƒIƒCƒh’Á’É–ň‚ŏ\•Ş‚Č’Á’É‚Ş“ž‚ç‚ę‚Č‚˘C‚ ‚邢‚Í•›ě—p‚Ě‹­‚˘ŠłŽŇ‚ɑ΂ľ‚āCƒIƒsƒIƒCƒh‚đ‹ÇŠ–ƒŒ‚ ‚邢‚̓NƒƒjƒWƒ“‚Ć•š—p‚ľ‚āCd–ŒŠO‚âƒNƒ‚–Œ‰ş‚Ö“Š—^‚ˇ‚é‚ą‚Ć‚đŒŸ“˘‚ˇ‚émŽă‚˘„§nB

  • ƒIƒsƒIƒCƒh‚É‚ć‚éˆŤS‚Ć•Ö”éC‚ť‚Ě‘ź‚Ě•›ě—pFƒIƒsƒIƒCƒh‚É‚ć‚éšq“f‚Ě‚ ‚銳ŽŇ‚ɁCRƒh[ƒpƒ~ƒ“–ňi—á‚Ś‚΃nƒƒyƒŠƒh[ƒ‹j‚â•Ą”‚̍ě—p‚đ‚ŕ‚–ňÜi—á‚Ś‚΃ƒgƒNƒƒvƒ‰ƒ~ƒhj‚đŽg—p‚ˇ‚émŽă‚˘„§nBƒIƒsƒIƒCƒh‚É‚ć‚é•Ö”é‚ĚŠÇ—‚ ‚邢‚Í—\–h‚Ć‚ľ‚Ċɉş–ň‚đ’čŠú“I‚ÉŽg—p‚ˇ‚éB‚ǂ̊ɉş–ň‚Ş—D‚ę‚Ä‚˘‚é‚Š‚Ć‚˘‚¤ƒGƒrƒfƒ“ƒX‚Í‚Č‚˘B“Ť‚Ě•Ö”é‚ɑ΂ľCˆŮ‚Č‚éě—p‚Ě–ňÜ‚Ě•š—p‚ÍŒř‰Ę‚Ş‚ ‚éB’ʏí‚̊ɉş–ň‚ĹŒř‰Ę‚Ş‚Č‚˘ę‡Cmethylnaltrexone ‚̔牺“Š—^‚đl—ś‚ˇ‚ém‹­‚˘„§nBƒIƒsƒIƒCƒh‚É‚ć‚é’ÁĂ‚̉ü‘P‚ɂ̓ƒ`ƒ‹ƒtƒFƒjƒf[ƒg‚đŽg—p‚ˇ‚é‚ą‚Ć‚Ş‚Ĺ‚Ť‚é‚ŞCŽĄ—Ăˆć‚Ş‹ˇ‚­’ˆÓ‚Ş•K—v‚Ĺ‚ ‚éBƒIƒsƒIƒCƒh‚É‚ć‚é‚š‚ń–ρCŒśŠoCƒ~ƒIƒNƒ[ƒkƒXC’ÉŠo‰ß•q‚Ě‚ ‚銳ŽŇ‚ł́CŒ¸—Ę‚âƒIƒsƒIƒCƒhƒXƒCƒbƒ`ƒ“ƒO‚đl—ś‚ˇ‚émŽă‚˘„§nB

  • “ˏo’ɁF“ˏo’ɂ́CŒoŒű‚Ě‘Ź•úŤťÜC‚ ‚邢‚̓tƒFƒ“ƒ^ƒjƒ‹‚ĚŒűoE•@”S–Œ“Š—^‚őΉž‚Ĺ‚Ť‚éBƒtƒFƒ“ƒ^ƒjƒ‹‚ĚŒűoE•@”S–Œ“Š—^‚ĚƒŒƒXƒLƒ…[–ň‚́C‘ŚŒřŤ‚Ş‚ ‚čŒř‰ĘŽ‘ąŽžŠÔ‚ŕ’Z‚˘‚˝‚ߌoŒű‚Ě‘Ź•úŤťÜ‚ć‚čD‚Ü‚ę‚ém‹­‚˘„§nB‘Ź•úŤťÜ‚́C“ˏo’É‚Ş‹N‚ą‚é‚Ć—\‘z‚ł‚ę‚é20`30 •Ş‘O‚É—\–h“I‚ÉŽg—p‚ˇ‚émŽă‚˘„§nB

  • _ŒoáŠQŤáu’ɁF_ŒoáŠQŤáu’ɂ𔺂¤‚Ş‚ńŠłŽŇ‚ŁCƒIƒsƒIƒCƒh‚Ě’Á’ÉŒř‰Ę‚ޏ\•Ş‚Ĺ‚Č‚˘ę‡C’Á’ɕ⏕–ň‚ĚƒAƒ~ƒgƒŠƒvƒ`ƒŠƒ“‚ ‚邢‚̓Kƒoƒyƒ“ƒ`ƒ“‚ĚŽg—p‚đl—ś‚ˇ‚ém‹­‚˘„§nBƒIƒsƒIƒCƒh‚Ć•š—p‚ˇ‚é‚ƁC’†•_ŒoŒn‚Ö‚Ě•›ě—p‚đˆř‚Ť‹N‚ą‚ˇ‚ą‚Ć‚Ş‚ ‚é‚˝‚߁CƒIƒsƒIƒCƒh‚â’Á’ɕ⏕–ň‚Ě—Ę‚É’ˆÓ‚ˇ‚ém‹­‚˘„§nB

  • t•s‘SŠłŽŇ‚Ĺ‚ĚƒIƒsƒIƒCƒhF‚“x‚̐t‹@”\áŠQ‚ĚŠłŽŇieGFRƒ30 mL/minj‚ł́CƒtƒFƒ“ƒ^ƒjƒ‹‚ ‚邢‚̓uƒvƒŒƒmƒ‹ƒtƒBƒ“‚ĚŒoĂ–Ź“Š—^‚ŕ‚ľ‚­‚͔牺“Š—^‚đ‘ćˆę‘I‘đ‚Ć‚ľC’á—p—Ę‚Š‚çŠJŽn‚ľC’ˆÓ[‚­ŽŠ“K—Ę‚đŒˆ‚ß‚Ä‚˘‚­B‘ă‘Ö‚Ć‚ľ‚āC’ZŠúŠÔ‚Ĺ‚ ‚ę‚΃‚ƒ‹ƒqƒl‚Ě—Ę‚â“Š—^‰ń”‚đŒ¸‚ç‚ľ‚đΉž‚ˇ‚é‚ą‚Ć‚ŕ‚ ‚émŽă‚˘„§nB

‚RD‚Ş‚ńáu’É‚Ěƒ}ƒlƒWƒƒ“ƒgFESMO ‚Ě—Ő°ƒKƒCƒhƒ‰ƒCƒ“iAnn Oncol, 2012j
  • European Society for Medical OncologyiESMOjGuidelines working group ‚ŞěŹ‚ľ‚˝‚Ş‚ńáu’É‚ÉŠÖ‚ˇ‚éƒKƒCƒhƒ‰ƒCƒ“‚Ĺ‚ ‚éB2011 ”N”ĹˆČ~ƒGƒrƒfƒ“ƒXƒŒƒxƒ‹‚Ɛ„§ƒŒƒxƒ‹‚Ş•š‹L‚ł‚ęC2012 ”N”Ĺ‚Ĺ‚Í•úŽËüŽĄ—Ă‚â_ŒoƒuƒƒbƒN‚ɂ‚˘‚ďڍׂɐG‚ę‚ç‚ę‚Ä‚˘‚éB
  • American Society of Clinical OncologyiASCOj‚ĹŽg—p‚ł‚ę‚Ä‚˘‚éƒGƒrƒfƒ“ƒXƒŒƒxƒ‹mⅠ`Ⅴ‚É•Ş—Ţn‚Ɛ„§ƒŒƒxƒ‹mA`D ‚É•Ş—Ţn‚đ—p‚˘‚Ä‚˘‚éB
  • ’É‚Ý‚Ě•]‰żF’É‚Ý‚Ě‹­“x‚ĆŽĄ—ĂŒř‰Ę‚Í“KŘ‚ČŽw•WiVASCVRSCNRSj‚đ—p‚˘‚Ä’čŠú“I‚É•]‰ż‚ˇ‚émⅤCDnB”F’m‹@”\‚̏áŠQ‚ł‚ę‚˝ŠłŽŇ‚ł́C’É‚Ý‚É‹Nˆö‚ˇ‚é•\îC‘Ě“ŽC”­ş‚Č‚Ç‚Ĺ‘ă—p‚ˇ‚éię–ĺ‰ĆCƒpƒlƒ‹ƒRƒ“ƒZƒ“ƒTƒXjBS—ŽĐ‰ď“I‹ę’É‚Ě•]‰ż‚ŕs‚¤mⅡCBnB

  • ’É‚Ý‚Ěƒ}ƒlƒWƒƒ“ƒgŒ´‘ĽF’É‚Ý‚Ć‚ť‚Ěƒ}ƒlƒWƒƒ“ƒg‚ɂ‚˘‚ÄŠłŽŇ‚ɏ\•Ş‚ȏî•ń‚đ’ń‹Ÿ‚ľCáu’ÉŽĄ—ÂɐϋɓI‚ÉŽQ‰Á‚ˇ‚é‚悤§—ァ‚émⅡCBnB–Ť’ɂɂ̓ŒƒXƒLƒ…[–ň‘Ήž‚Ĺ‚Í‚Č‚­’莞’Á’É–ň‚đŠî–{‚Ć‚ˇ‚émⅤCDnB’Á’É–ň‚Ě“Š—^Œo˜H‚ÍŒoŒű‚đ‘ćˆę‘I‘đ‚Ć‚ˇ‚émⅣCCnB“ˏo’ɂɂ͒莞’Á’É–ň‚ɉÁ‚Ś‚ăŒƒXƒLƒ…[–ň‚đˆ•ű‚ˇ‚émⅤCDnB

  • ’É‚Ý‚ĚŠÇ—FWHO •űŽŽ‚Ş‚ńáu’ÉŽĄ—Ă–@‚̏œ’Ƀ‰ƒ_[‚ÉŠî‚Ă‚Ť’É‚Ý‚Ě’ö“x‚ɉž‚ś‚Ä’Á’É–ň‚đ‘I‘đ‚ˇ‚émⅡCBnB

  • Œy“x‚̒ɂ݁FƒAƒZƒgƒAƒ~ƒmƒtƒFƒ“ENSAIDs ‚Ş—LŒř‚Ĺ‚ ‚émⅠCAnB—źŽŇ‚Í‹ÖŠő‚Ĺ‚Č‚Ż‚ę‚΁C’É‚Ý‚Ě’ö“x‚É‚ć‚炸ˆę’čŠúŠÔ—LŒř‚Ĺ‚ ‚émⅠCAnB

  • Œy“x‚Š‚ç’†“™“x‚̒ɂ݁FŽăƒIƒsƒIƒCƒhiƒRƒfƒCƒ“Cƒgƒ‰ƒ}ƒh[ƒ‹CƒWƒqƒhƒƒRƒfƒCƒ“‚Ȃǁj‚Ć”ńƒIƒsƒIƒCƒh’Á’É–ň‚đ•š—p‚ˇ‚émⅢCCnBŽăƒIƒsƒIƒCƒh‚Ě‘ă‘Ö–ň‚Ć‚ľ‚Ä’á—p—Ę‚Ě‹­ƒIƒsƒIƒCƒh‚ŕl—ś‚ˇ‚émⅢCCnB

  • ’†“™“x‚Š‚獂“x‚̒ɂ݁FƒIƒsƒIƒCƒh‚Ě‘ćˆę‘I‘đ‚ÍŒoŒűƒ‚ƒ‹ƒqƒl‚Ĺ‚ ‚émⅣCDnBƒ‚ƒ‹ƒqƒl‚ĚŒoŒű“Š—^‚ƐÖŹ“ŕ“Š—^‚Ĺ‚Ě’Á’ɗ͉ż‚Í1F2`1F3mⅡCAn‚ŁC”牺“Š—^‚ŕ“Ż—l‚Ĺ‚ ‚émⅣCCnBt‹@”\áŠQŠłŽŇiCKDj‚É‚¨‚˘‚Ä‚Í‚ˇ‚×‚Ä‚ĚƒIƒsƒIƒCƒhŽg—p‚ÉŰ‚ľŒ¸—Ę‚â“Š—^ŠÔŠu‚̉„’ˇ‚đl—ś‚ˇ‚émⅣCCnB–Ťt‘Ÿ•astage 4 ‚Ü‚˝‚Í5ieGFRƒ30 mL/minj‚ĚŠłŽŇ‚É‚¨‚˘‚āCƒtƒFƒ“ƒ^ƒjƒ‹‚ĆƒuƒvƒŒƒmƒ‹ƒtƒBƒ“‚Ě“\•tÜ‚Ć’ŽËÜ‚ÍĹ‚ŕˆŔ‘S‚ČƒIƒsƒIƒCƒh‚Ĺ‚ ‚émⅣCCnB

  • ‘—ĘƒXƒPƒWƒ…[ƒ‹F’ZŽžŠÔě—pŒ^‚Ěƒ‚ƒ‹ƒqƒl‚đ4 ŽžŠÔ–ˆ‚É“Š—^‚ľC“ˏo’ɂɂ̓ŒƒXƒLƒ…[–ň‚đ•š—p‚ľ‚Ä’˛ß‚ˇ‚émⅣCCnBƒŒƒXƒLƒ…[–ň‚Ě‘Žg—p—Ę‚đl—ś‚Ě‚¤‚ŚC’čŠú“Š—^‚Ěƒ‚ƒ‹ƒqƒl™•úŤťÜ‚ĚŽŠ“K—ʂ𒲐߂ˇ‚émⅣCCnB

  • •›ě—p‚Ě‘ÎˆFŠÉ‰ş–ň‚̓IƒsƒIƒCƒh‚É‚ć‚é•Ö”é‚Ě—\–h‚ĆŠÇ—‚É’čŠú“I‚É—p‚˘‚émⅠCAnBƒƒgƒNƒƒvƒ‰ƒ~ƒh‚ƍRƒh[ƒpƒ~ƒ“–ň‚̓IƒsƒIƒCƒh‚É—R—ˆ‚ˇ‚éˆŤSEšq“f‚ĚŽĄ—Ă‚ÉŽg—p‚ˇ‚émⅢCBnB

  • “ˏo’ɁFƒx[ƒX‚Ě’É‚Ý‚ŞƒRƒ“ƒgƒ[ƒ‹‚ł‚ę‚Ä‚˘‚éę‡‚̓IƒsƒIƒCƒh‘Ź•úŤťÜ‚đ—p‚˘‚émⅠCAnB‘Ě“ŽŽž’É‚âš‹‰şŽž’É‚Č‚Ç‚Ş—\‘z‚ł‚ę‚é“ˏo’ɂɂ́C20 •ŞˆČă‘O‚Ƀ‚ƒ‹ƒqƒl‚Ě‘Ź•úŤťÜ‚đŒoŒű“Š—^‚ˇ‚émⅡCAnBŒoŒűƒ‚ƒ‹ƒqƒl‚Ć”ä‚ׁCĂ’ƒIƒsƒIƒCƒhCƒoƒbƒJƒ‹Eă‰şEŒo•@”S–Œ‹zŽűŒ^ƒtƒFƒ“ƒ^ƒjƒ‹‚ÍŒř‰Ę”­Œť‚Ş‘‚˘mⅠCAnB

  • œ’É‚ĚŽĄ—ÁF’É‚Ý‚Ě—L–ł‚É‚Š‚Š‚í‚炸œ“]ˆÚ‚ĚŽĄ—Ă–ň‚Ě‘I‘đŽˆ‚Ć‚ľ‚ărƒXƒzƒXƒzƒl[ƒg‚đl—ś‚ˇ‚émⅡCBnBƒfƒmƒXƒ}ƒuiRRANKL ƒ‚ƒmƒNƒ[ƒiƒ‹R‘́j‚ÍŒĹŒ`‚Ş‚ń‚̍œ“]ˆÚŽžŠł‚ɑ΂ľ‚āC’É‚Ý‚Č‚Ç‚ĚœŠÖ˜AŽ–Ű”­Œť‚đ’x‰„‚Ĺ‚Ť‚鎥—Ă–ň‚Ć‚ľ‚ărƒXƒzƒXƒzƒl[ƒg‚Ě‘ă‘Ö‚Ć‚Č‚émⅠCAnB‚˘‚¸‚ę‚̐ťÜ‚ŕ‚ť‚Ě“Š—^‘O‚É‚ÍŽ•‰ČŽóf‚Ş•K—v‚Ĺ‚ ‚émⅢCAnB

  • _ŒoáŠQŤáu’ɁF”ńƒIƒsƒIƒCƒh’Á’É–ň‚ĆƒIƒsƒIƒCƒh‚đ‘g‚ݍ‡‚í‚š“Š—^‚ˇ‚émⅢCBnB•›ě—p‚É’ˆÓ‚ľ‚ÄŽOŠÂŒnR‚¤‚–ň‚Ü‚˝‚͍R‚Ż‚˘‚ę‚ń–ň‚đ“Š—^‚ˇ‚émⅠC A ni}2jBœ“]ˆÚ‚É‚ć‚é_ŒoáŠQŤáu’É‚É‚Í20 Gy 5 •ŞŠ„‚Ě•úŽËüĆŽË‚đl—ś‚ˇ‚émⅠCBnB

  • •úŽËüŽĄ—ÁF‚ˇ‚×‚Ä‚Ěœ“]ˆÚ’É‚É8 Gy ’P‰ńĆŽË‚đl—ś‚ˇ‚émⅠCAnB‚—p—ʁE•ŞŠ„ĆŽË‚ɂ‚˘‚Ä‚Í“K‰ž‚đŒŸ“˘‚ˇ‚émⅡCBnB‘Šú‚̐f’fE‰Á—Ă‚Í“]ˆÚŤŇ‘ˆł”—‚ĚŒo‰ß‚É‘ĺ‚Ť‚­‰e‹ż‚ˇ‚émⅠCAnB“]ˆÚŤŇ‘ˆł”—‚ĚŽĄ—Ă‚Í•úŽËüĆŽË’P“Ć‚Ć‚ľCŽčp—Ă–@‚ɂ‚˘‚Ä‚Í“K‰ž‚đŒŸ“˘‚ˇ‚émⅡCBnB“]ˆÚŤŇ‘ˆł”—‚Ö‚ĚĆŽË‰ń”‚͏­‚Č‚­‚ľmⅠCAnCś–˝—\Œă‚Ş’ˇ‚˘ę‡‚Í‘˝•ŞŠ„ĆŽË‚ŕl—ś‚ˇ‚émⅢCBnB“]ˆÚŤŇ‘ˆł”—‚ĚŽĄ—Ă‚É‚ÍƒRƒ‹ƒ`ƒRƒXƒeƒƒCƒh‚đ—p‚˘‚émⅡCAnB•úŽËŤ“ŻˆĘŒł‘fŽĄ—Ă‚Í‘˝”­‘˘œŤ‚̍œ“]ˆÚ‚ĚÇ—á‚É‘I‘đ‚ł‚ę‚émⅡCCnB

  • “Ťáu’ɂւ̐NP“IŽĄ—ÁFę–ĺ‰Ć‚É‘Š’k‚Ě‚¤‚ŚCŇ‘’Á’É–@id–ŒŠO’Á’É–@CƒNƒ‚–Œ‰ş’Á’É–@j‚Ě“K‰ž‚đl—ś‚ˇ‚émⅡCBni}3jB• o_Œo‘pƒuƒƒbƒN‚ÍäX‘Ÿ‚Ş‚ń‚Ě’É‚Ý‚É—LŒř‚ĹˆŔ‘S‚ČŽč‹Z‚Ĺ‚ ‚čCŽ{sŒă6 ƒJŒŽŠÔ‚Í•W€’Á’ÉŽĄ—Ă‚ć‚č—LŒř‚Ĺ‚ ‚émⅡCBnB

}2@_ŒoáŠQŤáu’É‚Ě•]‰ż‚ĆŽĄ—Ă

kESMO ƒKƒCƒhƒ‰ƒCƒ“‚ć‚čˆę•”‰ü•Ďl

}3@“Ť‚Ş‚ńáu’É‚Ö‚ĚƒNƒ‚–Œ‰ş’“ü

kESMO ƒKƒCƒhƒ‰ƒCƒ“‚ć‚čˆę•”‰ü•Ďl

‚SDŒoŒűƒ‚ƒ‹ƒqƒl‚Ě•›ě—p‘΍ôFƒGƒrƒfƒ“ƒX‚ÉŠî‚Ă‚˘‚˝ESMO ‚ĚƒŒƒ|[ƒgiJCO, 2001j
  • European Association for Palliative CareiEAPCj‚̐ę–ĺ‰Ćě‹Ć•”‰ď‚ŞěŹ‚ľ‚˝ƒIƒsƒjƒIƒ“ƒŒƒ|[ƒg‚Ĺ‚ ‚éB
  • ƒIƒsƒIƒCƒhŽg—pŽž‚É•›ě—p‚ޏoŒť‚ľ‚˝Ű‚́C‘ź‚ĚŒ´ˆö‚Ƃ̊ӕʐf’f‚ޏd—v‚Ĺ‚ ‚éB①’†•_ŒoŤi”]“]ˆÚC‘–Œ”dŽíC”]ŒŒŠÇáŠQCd–ŒŠOoŒŒjC②‘ăŽÓŤi’E…C‚ƒJƒ‹ƒVƒEƒ€ŒŒÇC’áƒiƒgƒŠƒEƒ€ŒŒÇCt•s‘SCŠĚ•s‘SC’áŽ_‘fŒŒÇjC③”sŒŒÇ/Š´őÇC④Á‰ťŠÇ•ÂÇC⑤ˆăŒ´ŤiŽOŠÂŒnR‚¤‚–ňEƒxƒ“ƒ]ƒWƒAƒ[ƒsƒ“ER‹Ű–ňEƒRƒ‹ƒ`ƒRƒXƒeƒƒCƒhENSAIDs ‚Č‚Ç‚Ě–ňÜŤC‰ťŠw—Ă–@C•úŽËüŽĄ—Áj‚đœŠOf’f‚ˇ‚éB
  • •›ě—p‚̑Ήž‚Ć‚ľ‚āC①ƒIƒsƒIƒCƒh‚ĚŒ¸—ʁC②•›ě—p‚ɑ΂ˇ‚é‘ÎÇ—Ă–@‚Ě‹­‰ťC③ƒIƒsƒIƒCƒhƒXƒCƒbƒ`ƒ“ƒOC④“Š—^Œo˜H‚Ě•ĎXC‚đŒŸ“˘‚ˇ‚éB
  • ①‚ĚƒIƒsƒIƒCƒh‚ĚŒ¸—Ę‚ÉŠÖ‚ľ‚ẮCáu’Ɋɘa‚ޗǍD‚Ĺ•›ě—p‚ŞŒy“x‚Š‚ç’†“™“x‚Ěę‡‚́C20`50“‚ĚŒ¸—Ę‚đŒŸ“˘‚ˇ‚éB‚ť‚ęˆČŠO‚Ěę‡‚́C’É‚Ý‚ĚŒ´ˆö‚ɑ΂ˇ‚鉝Šw—Ă–@E•úŽËüŽĄ—ÁC_ŒoƒuƒƒbƒNC”ńƒIƒsƒIƒCƒh’Á’É–ň‚â’Á’ɕ⏕–ň‚Ě•š—p‚É‚ć‚čCŒ¸—Ę‚Ş‰Â”\‚ŠŒŸ“˘‚ˇ‚éB
  • ②‚Ě•›ě—p‚ɑ΂ˇ‚é‘ÎÇ—Ă–@‚Ě‹­‰ť‚Ć‚ľ‚ẮCˆČ‰ş‚̂悤‚ɁCŒÂX‚̏Ǐó‚ɑΉž‚ˇ‚éB
  • ˆŤSEšq“fiŒoŒűƒ‚ƒ‹ƒqƒl•ž—pŽŇ‚Ě15`30“‚Őś‚ś‚éj‚́CƒƒgƒNƒƒvƒ‰ƒ~ƒhCƒnƒƒyƒŠƒh[ƒ‹CƒvƒƒNƒƒ‹ƒyƒ‰ƒWƒ“CƒWƒƒ“ƒqƒhƒŠƒi[ƒgCƒIƒ“ƒ_ƒ“ƒZƒgƒƒ“‚Č‚Ç‚Ş„§‚ł‚ę‚éBƒ‚ƒ‹ƒqƒl‚̔牺“Š—^‚Ö‚Ě•ĎX‚ĹˆŤSEšq“f‚ŞŒ¸­‚ˇ‚éę‡‚Ş‚ ‚éB
  • •Ö”éiŒoŒűƒ‚ƒ‹ƒqƒl•ž—pŽŇ‚Ě40`70“‚Őś‚ś‚éj‚́C‘ăŽÓŤŽžŠłi“œ”A•aC‚ƒJƒ‹ƒVƒEƒ€ŒŒÇC’áƒiƒgƒŠƒEƒ€ŒŒÇC”A“ŏǁCbó‘B‹@”\’ቺÇjC’E…C‚—îCŠˆ“Ž—ʂ̒ቺCH•¨‘@ˆŰŰŽć‚̒ቺC—˜”A–ň‚Č‚Ç‚Ě–ňÜ‚Ĺ‘ˆŤ‚ˇ‚éBƒZƒ“ƒiCƒrƒTƒRƒWƒ‹Cƒ‰ƒNƒcƒ[ƒX‚Ě“Š—^‚ސ„§‚ł‚ę‚éB
  • –°‹CiŒoŒűƒ‚ƒ‹ƒqƒl•ž—pŽŇ‚Ě20`60“‚Őś‚śC—p—ĘˆË‘śŤ‚Ĺ‚ ‚éj‚́C”牺“Š—^‚Ö‚Ě•ĎX‚âƒIƒsƒIƒCƒhƒXƒCƒbƒ`ƒ“ƒO‚ʼnü‘P‚ˇ‚éę‡‚Ş‚ ‚éB
  • Œy“x‚Ě”F’máŠQiƒIƒsƒIƒCƒh‚ĚŠJŽnŽžE‘—ĘŽž‚ɐś‚ś‚₡‚­C—p—ĘˆË‘śŤ‚Ĺ‚ ‚éj‚́CƒnƒƒyƒŠƒh[ƒ‹‚ŞŽĄ—Ă–ň‚Ć‚ľ‚Đ„§‚ł‚ę‚é‚ŞCƒIƒsƒIƒCƒhƒXƒCƒbƒ`ƒ“ƒO‚ʼnü‘P‚ˇ‚é‰Â”\Ť‚Ş‚ ‚éB
‚TD“ˏo’ɁFEAPC ‚ĚƒRƒ“ƒZƒ“ƒTƒXƒŒƒ|[ƒgiCancer, 2002j
  • European Association for Palliative CareiEAPCj‚̐ę–ĺ‰Ćě‹Ć•”‰ď‚ŞěŹ‚ľ‚˝ƒRƒ“ƒZƒ“ƒTƒXƒŒƒ|[ƒg‚Ĺ‚ ‚éB
  • “ˏo’ɂ̓IƒsƒIƒCƒh‚đŠÜ‚Ţ’Á’É–ň‚đŽg—p‚ľ‚Ä‚ŕ40`80“‚̍‚•p“x‚ɏoŒť‚ˇ‚éB
  • “ˏo’ɂł́C’É‚Ý‚Ě‹­‚łC•p“xCŽ‘ąŽžŠÔCŤŽżC‘ˆŤˆöŽq‚âŒy‰őˆöŽq‚𐳊m‚É•]‰ż‚ˇ‚é•K—v‚Ş‚ ‚éB“ˏo’É‚ĚŽĄ—Âɂ́C”wŒi‚É‚ ‚é’É‚Ý‚Ěó‘Ԃɉž‚ś‚Ä•Ş—Ţ‚ˇ‚é}4 ‚Ě•]‰żƒAƒ‹ƒSƒŠƒYƒ€‚Ş—L—p‚Ĺ‚ ‚éB
  • “ˏo’É‚ĚŽĄ—Âł́C①ƒIƒsƒIƒCƒh‚Ě—Ę‚â“Š—^ƒXƒPƒWƒ…[ƒ‹‚ĚŒŠ’ź‚ľC②’Á’ɕ⏕–ň‚Ě•š—pC③’čŠú“Š—^‚Ě‘—Ę‚â“Š—^ŠÔŠu‚Ě’ZkC④ƒŒƒXƒLƒ…[–ň‚Ě’˛ŽC⑤Šˆ“Ž•ű–@‚ĚŒŠ’ź‚ľ‚đŒŸ“˘‚ˇ‚éB
  • Œ´ˆö‚ɑ΂ˇ‚鎥—Ă‚Ć‚ľ‚āCƒzƒ‹ƒ‚ƒ“—Ă–@C‰ťŠw—Ă–@C•úŽËüŽĄ—ÁCŠO‰ČŽĄ—ÁCƒRƒ‹ƒZƒbƒg‚đŒŸ“˘‚ˇ‚éB
  • _ŒoáŠQŤáu’É‚Ě–ň•¨—Ă–@‚ɂ́C}5 ‚ĚŽĄ—ĂƒAƒ‹ƒSƒŠƒYƒ€‚Ş’ńĽ‚ł‚ę‚Ä‚˘‚éB’ɂ݂̐ŤŽż‚Ĺ‚Í“Á’č‚Ě–ňÜ‚ĚŒř‰Ę‚Í—\‘Ş‚Ĺ‚Ť‚Č‚˘‚ą‚Ć‚ŞŽŚ´‚ł‚ę‚Ä‚˘‚é‚ŞCƒAƒ‹ƒSƒŠƒYƒ€‚Ĺ‚Í•Ö‹X“I‚ɁCuŽÜ”M’Ɂviburning painj‚ɂ͍R‚¤‚–ňCu“dŒ‚’Ɂvilancinating painj‚ɂ͍R‚Ż‚˘‚ę‚ń–ň‚ĆŽŚ‚ł‚ę‚Ä‚˘‚éB‚ť‚Ě‘źC•a‘Ô‚â•›ě—p‚É‚ć‚čCNSAIDsCƒAƒZƒgƒAƒ~ƒmƒtƒFƒ“CƒRƒ‹ƒ`ƒRƒXƒeƒƒCƒhCƒIƒsƒIƒCƒh‚đŽg—p‚ľCƒrƒXƒzƒXƒzƒl[ƒgCƒPƒ^ƒ~ƒ“CR•sŽ–Ź–ň‚Č‚Ç‚đ‘g‚ݍ‡‚í‚š‚éB
  • ŒoŒű“Š—^‚Ěę‡CŒř‰Ę‚ŞĹ‘ĺ‚É‚Č‚é‚Ě‚Í“Š—^ŒăŠT‚Ë60 •Ş‚Ĺ‚ ‚é‚˝‚߁C“Ë”­“I‚É”­Ç‚ľŽ‘ą‚ľ‚Č‚˘’É‚Ý‚ĚŽĄ—Ă‚É‚Í•s“K‚Ĺ‚ ‚éB”牺“Š—^‚́CĂ–Ź“ŕ“Š—^‚ć‚čŒř‰Ę”­Œť‚Ş’x‚˘B

}4@“ˏo’É‚Ě•]‰żƒAƒ‹ƒSƒŠƒYƒ€

kEAPC ƒKƒCƒhƒ‰ƒCƒ“‚ć‚čˆę•”‰ü•Ďl

}5@_ŒoáŠQŤáu’É‚ĚŽĄ—ĂƒAƒ‹ƒSƒŠƒYƒ€

kEAPC ƒKƒCƒhƒ‰ƒCƒ“‚ć‚čˆę•”‰ü•Ďl

‚UD‚Ş‚ńáu’É‚É‚¨‚Ż‚郂ƒ‹ƒqƒl‚Ć‘ă‘ÖƒIƒsƒIƒCƒhFEAPC ‚̐„§iBJC, 2001j
  • European Association for Palliative CareiEAPCj‚ŞěŹ‚ľ‚˝Cƒ‚ƒ‹ƒqƒl‚ÉŠÖ‚ˇ‚鐄§‚Ĺ‚ ‚éimAnFŽż‚̂悢1 ‚ÂˆČă‚Ě–łěˆ×‰ť”äŠrŽŽŒą‚ÉŠî‚Ă‚­BmBnF‚ć‚­ƒfƒUƒCƒ“‚ł‚ę‚˝—Տ°Œ¤‹†‚ÉŠî‚Ă‚­BmCnFę–ĺ‰ĆˆĎˆő‰ď‚Ě•ń‚âˆÓŒŠC‚Ü‚˝‚̓GƒLƒXƒp[ƒg‚Ě—Ő°ŒoŒą‚ÉŠî‚Ă‚­jB
  • ’†“™“x‚Š‚çd“x‚Ě‚Ş‚ńáu’ɂɑ΂ˇ‚é‘ćˆę‘I‘đ‚̓‚ƒ‹ƒqƒl‚Ĺ‚ ‚čmCnCĹ“K‚Č“Š—^Œo˜H‚ÍŒoŒű‚ŁC™•úŤťÜiˆŰŽ—pj‚Ć‘Ź•úŤťÜiƒŒƒXƒLƒ…[–ňj‚Ě2 Ží—Ţ‚Ş•K—v‚Ĺ‚ ‚émCnB
  • Ĺ‚ŕŠČ•Ö‚ČŽŠ“K—Ę‚Ě’˛Ž–@‚́C4 ŽžŠÔ–ˆ‚Ƀ‚ƒ‹ƒqƒl‘Ź•úŤťÜ‚đŒoŒű“Š—^‚ľCáu’ÉŽž‚É‚ŕ“Ż—Ę‚đŒoŒű“Š—^‚ˇ‚é•ű–@‚Ĺ‚ ‚éBƒŒƒXƒLƒ…[–ň‚Í1 ŽžŠÔ‚ ‚Ż‚Ä•K—vŽž‰˝“x‚Ĺ‚ŕŒoŒű“Š—^‚ľC–ˆ“úC•K—v—ʂ𒲐Ž‚ľ‚Ä‚˘‚­mCnBAQ‘O‚É2 ”{—ĘŒoŒű“Š—^‚ˇ‚é‚̂́C–éŠÔ‚Ě“Ëo’É‚đ–h‚ŽŠČ•Ö‚Ĺ—LŒř‚Č•ű–@‚Ĺ‚ ‚émCnB
  • ™•úŤťÜ•ž—pŽž‚Ě‘O‚É’É‚Ý‚Ş‘ˆŤ‚ˇ‚éę‡‚́C™•úŤťÜ‚đ‘—Ę‚ˇ‚éBŽíX‚Ěƒ‚ƒ‹ƒqƒl™•úŤťÜ‚Ş‚ ‚é‚ŞCŽ‘ąŽžŠÔ‚â’Á’ÉŒř‰Ę‚É—D—ň‚̍ˇ‚Í‚Č‚˘mAnB™•úŤťÜ‚ĹˆŔ’č‚ľ‚˝’Á’ÉŒř‰Ę‚Ş“ž‚ç‚ę‚Ä‚˘‚Ä‚ŕC“ˏo’ɂɑ΂ľ‚ăŒƒXƒLƒ…[–ň‚Ş•K—v‚Ĺ‚ ‚émAnB
  • ŒoŒű“Š—^‚ލ˘“ď‚Čę‡‚́C‘ă‘ÖŒo˜H‚Ć‚ľ‚Ĕ牺“Š—^‚É•ĎX‚ˇ‚éB‹Ř“÷“ŕ“Š—^‚͐„§‚ł‚ę‚Č‚˘mCnBĂ–Ź“ŕ“Š—^‚ސ„§‚ł‚ę‚é‚̂́CĂ–ŹƒJƒe[ƒeƒ‹‚Ş—Ż’u‚ł‚ę‚Ä‚˘‚éę‡C‘SgŤ•‚Žî‚Ş‚ ‚éę‡CŽ‘ą”牺’‚É‚ć‚č”­ÔE’ɂ݁E”^ᇂސś‚ś‚˝ę‡C‹ĂŒĹˆŮí‚Ş‚ ‚éę‡C––˝zŠÂ•s‘S‚Ěę‡‚Ĺ‚ ‚émCnBŒűo”S–Œ‰şCă‰şC‹z“ü‚Ĺ‚Ěƒ‚ƒ‹ƒqƒl“Š—^‚͐„§‚ł‚ę‚Č‚˘mBnB
  • ŒoŒű“Š—^‚Ɣ牺“Š—^‚Ě’Á’ɗ͉ż‚Ě”ä‚́C1F2`1F3 ‚Ĺ‚ ‚éiƒ‚ƒ‹ƒqƒlŒoŒű“Š—^20`30 mg ‚ރ‚ƒ‹ƒqƒl”牺“Š—^10 mg ‚É‘Š“–‚ˇ‚éjmCnBŒoŒű“Š—^‚ƐÖŹ“ŕ“Š—^‚Ě’Á’ɗ͉ż‚Ě”ä‚ŕC1F2`1F3 ‚Ĺ‚ ‚émAnB
  • ŒoŒűƒ‚ƒ‹ƒqƒlŽg—pŽž‚É•›ě—p‚Ě‚˝‚ߏ\•Ş‚Č’Á’ÉŒř‰Ę‚Ş“ž‚ç‚ę‚Č‚˘ę‡‚́CƒIƒsƒIƒCƒh‚Ě•ĎX‚â“Š—^Œo˜H‚Ě•ĎX‚đŒŸ“˘‚ˇ‚émBnBƒIƒLƒVƒRƒhƒ“‚ÍŒoŒűƒ‚ƒ‹ƒqƒl‚Ě‘ă‘Ö–ň‚Ć‚ľ‚Ä—L—p‚Ĺ‚ ‚émAnBƒtƒFƒ“ƒ^ƒjƒ‹“\•tÜ‚́C•K—v—Ę‚ŞˆŔ’č‚ľ‚Ä‚˘‚éę‡‚ɂ́Cƒ‚ƒ‹ƒqƒl‚Ě‘ă‘Ö–ň‚Ć‚ľ‚Ä—L—p‚Ĺ‚ ‚émBnB
  • ‚ą‚ę‚烂ƒ‹ƒqƒl‘ă‘Ö–ň‚Ě“KŘ‚ČŽg—p‚É‚ŕ‚Š‚Š‚í‚炸•›ě—p‚Ş‹­‚­’Á’ÉŒř‰Ę‚Ş“ž‚ç‚ę‚Č‚˘ę‡‚́C_ŒoƒuƒƒbƒN‚Č‚Ç‚đŒŸ“˘‚ˇ‚émBnB
‚VD‚Ş‚ńáu’É‚Ěƒ}ƒlƒWƒƒ“ƒgFESMO ‚Ě—Ő°“I„§iAnn Oncol, 2007j
  • European Society for Medical Oncology GuidelinesiESMOjworking group ‚ŞěŹ‚ľ‚˝‚Ş‚ńáu’É‚ÉŠÖ‚ˇ‚鐄§•ń‚Ĺ‚ ‚éB
  • •p@“xFis‚Ş‚ńŠłŽŇ‚Ě80“ˆČă‚ŁCŽĺ‚ÉŽîᇂ̒źÚZ‚É‚ć‚é’ɂ݂𐜂ś‚éB’É‚Ý‚Í‚Ş‚ń‚̐is“x‚ĚŽw•W‚É‚ŕ‚Č‚é‚Ě‚Ĺd—v‚Ĺ‚ ‚éB‚Ş‚ńŠłŽŇ‚Ě’É‚Ý‚Ě20“‚Í‚Ş‚ńŽĄ—Ă‚É‹Nˆö‚ˇ‚é‚ŕ‚Ě‚Ĺ‚ ‚éB
  • ‘—ĘƒXƒPƒWƒ…[ƒ‹Fáu’ÉŽž‚ɁC1 “ú—Ę‚Ě10“‚Ü‚Ĺ‚Ě—Ę‚đƒŒƒXƒLƒ…[–ň‚Ć‚ľ‚ÄŽg—p‚ˇ‚éB1 “ú4 ‰ńˆČă•K—v‚Č‚çC’莞™•úŤťÜ‚Ě‘—Ę‚đŒŸ“˘‚ˇ‚éB
  • •›ě—p‚Ě‘ÎˆF’Á’ɕ⏕–ňC_ŒoƒuƒƒbƒNC•úŽËüŽĄ—Ă‚đ•š—p‚ľ‚ăIƒsƒIƒCƒh‚đŒ¸—Ę‚ľCƒIƒsƒIƒCƒhƒXƒCƒbƒ`ƒ“ƒOE“Š—^Œo˜H‚Ě•ĎX‚âC§“f–ň‚Č‚Ç‚Ě‘ÎÇ—Ă–@‚đs‚¤BƒIƒsƒIƒCƒh‰ß—Ę‚É‚ć‚é•›ě—pÇó‚ޏdÇ‰ť‚ľ‚˝ę‡‚̓iƒƒLƒ\ƒ“‚đŽg—p‚ˇ‚éB
  • •úŽËüŽĄ—ÁF“Á‚ɍœ“]ˆÚ’ɁE_Œoˆł”—E”]“]ˆÚ‚É‚ć‚é’É‚Ý‚É—LŒř‚Ĺ‚ ‚éB
  • ŠO‰ČŽĄ—ÁF“Á‚ɍœÜŽž‚âŠÇo‘ŸŠí‚Ě•ÂÇŽž‚Ě’É‚Ý‚É—LŒř‚Ĺ‚ ‚éB
  • “Ť‚Ě’É‚Ý‚ĚŽĄ—ÁF_ŒoáŠQŤáu’ɂ̓IƒsƒIƒCƒh‚ĚŒř‰Ę‚Ş•s\•Ş‚Čę‡‚Ş‘˝‚­C’Á’ɕ⏕–ň‚Ě•š—p‚Ş•K—v‚Ĺ‚ ‚éBƒIƒsƒIƒCƒhE”ńƒIƒsƒIƒCƒh’Á’É–ň‚ɁCR‚¤‚–ňCR¸_•a–ňER‚Ż‚˘‚ę‚ń–ň‚đ‘g‚ݍ‡‚í‚š‚éB_Œoˆł”—‚ɂ̓Rƒ‹ƒ`ƒRƒXƒeƒƒCƒh‚đCœ“]ˆÚ’ɂɂ̓rƒXƒzƒXƒzƒl[ƒg‚đŽg—p‚ˇ‚éB’É‚Ý‚ŞŠÉ˜a‚ł‚ę‚Č‚˘ŠłŽŇ‚ɂ́CƒPƒ^ƒ~ƒ“‚â_ŒoƒuƒƒbƒN‚Č‚Ç‚Ş—LŒř‚ČŽž‚Ş‚ ‚čCI––Šú‚É‚Í’ÁĂ‚Ş•K—v‚Čę‡‚Ş‚ ‚éB
‚WD”x‚Ş‚ń‚ĚŠÉ˜aƒPƒAFƒGƒrƒfƒ“ƒX‚ÉŠî‚Ă‚˘‚˝ACCP‚Ě—Ő°ƒKƒCƒhƒ‰ƒCƒ“iChest, 2007j
  • American College of Chest PhysiciansiACCPjěŹ‚Ě•śŒŁƒŒƒrƒ…[‚É‚ć‚鐄§‚ŁC”x‚Ş‚ńŠłŽŇ‚đ‘ÎŰ‚Ć‚ľ‚Ä‚˘‚éiƒGƒrƒfƒ“ƒX‚ĚŽż‚É‚ć‚čC‹­‚˘„§m1A`1CnCŽă‚˘„§m2A`2Cn‚Ě6 ’iŠK‚É•Ş—Ţ‚ł‚ę‚Ä‚˘‚éjB
  • Œy“x‚Š‚ç’†“™“x‚̒ɂ݂ɂ́C‹ÖŠő‚Ĺ‚Č‚Ż‚ę‚΃AƒZƒgƒAƒ~ƒmƒtƒFƒ“‚Ü‚˝‚ÍNSAIDs ‚đŠJŽn‚ľCd“x‚Čę‡E‘ˆŤ‚ˇ‚éę‡‚̓IƒsƒIƒCƒh‚đŠJŽn‚ˇ‚ém1BnB’Á’É–ň‚Ě‚Ý‚Ĺ’Á’ɍ˘“ď‚Čę‡CŽOŠÂŒnR‚¤‚–ňER‚Ż‚˘‚ę‚ń–ň‚Č‚Ç‚Ě’Á’ɕ⏕–ň‚Ě•š—p‚Ĺ’Á’ÉŒř‰Ę‚Şă‚Ş‚ém1CnB
  • ŠČ•Ö‚ĹˆŔ‰ż‚Č‚Ě‚ĹŒoŒű“Š—^‚đ—Dć‚ˇ‚é‚ŞCŒoŒű˘“ď‚Čę‡‚͍żÜE“\•tÜ‚đŽg—p ‚ˇ‚éB‹Ř“÷“ŕ“Š—^‚Í’É‚Ý‚Ş‚ ‚č‹zŽű‚Ş•sˆŔ’č‚Ȃ̂Ő„§‚ł‚ę‚Č‚˘m1CnB
  • •Ö”é‚͈ę”Ę“I‚Č•›ě—p‚Ĺ‚ ‚čC—\‘Ş‚ľ‚Ä—\–h“I‚ɉşÜ‚đŽg—p‚ľC’čŠú“I‚É•]‰ż‚ˇ‚ém1BnB
  • ‰Â”\‚ČŒŔ‚č‰^“Ž‚đ‘Ł‚ľCQ‚˝‚Ť‚č‚đ”đ‚Ż‚ém1BnB
  • ‹Ř‹Ů’Ł‚ÉŠÖ˜A‚ˇ‚é’É‚Ý‚Ěę‡‚́C”畆ŽhŒƒi‰ˇŠŚŽhŒƒjCčI‹„CS—“IƒTƒ|[ƒg‚Ě•š—p‚ސ„§‚ł‚ę‚é‚ŞC‚ą‚ę‚ç‚Í–ň•¨—Ă–@‚ÉŽć‚Á‚Ä‘ă‚í‚é‚ŕ‚Ě‚Ĺ‚Í‚Č‚˘m1CnB
  • áu’Ɋɘa–Ú“I‚Ĺ•úŽËüŽĄ—Â≝Šw—Ă–@‚đs‚¤‚ą‚Ć‚đŒŸ“˘‚ˇ‚ém1BnB•W€“I‚Č–ň•¨—Ă–@‚Ĺ’Á’ɍ˘“ď‚Čę‡C–ƒŒ‰Č‚âŠÉ˜aƒPƒA‚̐ę–ĺ‰Ć‚É‘Š’k‚ˇ‚ém1CnB
  • œ“]ˆÚ’ɂɑ΂ľ‚ẮC’Á’É–Ú“I‚Ě•úŽËüŽĄ—Ă‚đs‚˘CƒrƒXƒzƒXƒzƒl[ƒg‚đ•š—p‚ˇ‚ém1AnB’Á’ɍ˘“ď‚Čę‡‚́C•úŽËüˆă–ň•iiƒXƒgƒƒ“ƒ`ƒEƒ€j‚ĚŽg—p‚đŒŸ“˘‚ˇ‚ém1BnBŒĹ’čp‚Ě“K‰ž‚́C’ˇŠÇœ‚â‰×d‚Ş‚Š‚Š‚鍜‚Ě“]ˆÚ‚ŁC4 TˆČă‚̐ś‘ś‚ŞŒŠž‚Ü‚ę‘Sgó‘ԂޗǍD‚Čę‡‚Ĺ‚ ‚ém1CnB
  • Ň‘ˆł”—‚ĚŠm’čf’f‚ɂ́C’PƒX üCœƒVƒ“ƒ`ƒOƒ‰ƒtƒBCCT ‚Ĺ‚Í‚Č‚­‘SŇ‘‚ĚT1 ‹­’˛MRI ‚đŽB‚é‚ą‚Ć‚Ş„§‚ł‚ę‚ém1CnB

iŹŒ´O”VC—é–ؐłŠ°C“cŒű“Ţ’ĂŽqC“c’†rsC“c’†ŒjŽqj

 ƒKƒCƒhƒ‰ƒCƒ“ƒv[ƒ‹EƒŠƒXƒg

1j National Comprehensive Cancer NetworkiVersion 1. 2012jFNCCN Clinical Practice Guidelines in Oncology, Adult cancer pain.iNCCN ƒKƒCƒhƒ‰ƒCƒ“C2012j

2j Use of opioid analgesics in the treatment of cancer painFevidence-based recommendations from the EAPC. Lancet Oncol 2012G13Fe58-68iEAPC ƒKƒCƒhƒ‰ƒCƒ“C2012j

3j Management of cancer painFESMO Clinical Practice Guidelines. Ann Oncol 2012G23iSuppl 7jFvii139-54iESMO ƒKƒCƒhƒ‰ƒCƒ“C2012j

4j Strategies to manage the adverse effects of oral morphineFAn evidence-based report. J Clin Oncol 2001G19F2542-54iEAPC ƒKƒCƒhƒ‰ƒCƒ“C2001aj

5j EpisodicibreakthroughjpainFconsensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002G94F832-9iEAPC ƒKƒCƒhƒ‰ƒCƒ“C2002j

6j Morphine and alternative opioids in cancer painGthe EAPC recommendations. Br J Cancer 2001G84F587-93iEAPC ƒKƒCƒhƒ‰ƒCƒ“C2001bj

7j Management of cancer painFESMO clinical recommendations. Ann Oncol 2007G18iSuppl 2jFii92-4iESMO ƒKƒCƒhƒ‰ƒCƒ“C2007j

8j Palliative care in lung cancerFACCP evidence-based clinical practice guidelinesi2nd editionj. Chest 2007G132iSuppl 3jFS368-403iACCP ƒKƒCƒhƒ‰ƒCƒ“C2007j

9j Acute pain managementFScientific evidence. Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine, 2nd ed, 2005

10j SIAARTI recommendations on the assessment and treatment of chronic cancer pain. Minerva Anestesiol 2003G69F697-729

11j Practice guidelineFSummary version of the Standards, Options and Recommendations for the use of analgesia for the treatment of nociceptive pain in adults with canceriupdate 2002j. Br J Cancer 2003G89iSuppl 1jFS67-72

12j Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of lifeFa clinical practice guideline from the American College of Physicians. Ann Intern Med 2008G148F141-6

13j Pain measurement tools and methods in clinical research in palliative careF recommendations of an Expert Working Group of the European Association of Palliative Care. J Pain Symptom Manage 2002G23F239-55

14j Evidence-based standards for cancer pain management. J Clin Oncol 2008G 26F3879-85